1. NEW YORK, Jan. 27, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), ("Hoth" or the "Company"), a biopharmaceutical company, today announced the addition of Mario Lacouture, M.D. to the Company's Scientific Advisory Board. 

    While serving on the Board, Dr, Lacouture will oversee the development of HT-001, a topical therapeutic designed for the treatment of rash and skin disorders associated with initial and repeat courses of epidermal growth factor receptor (EGFR) inhibitor therapy. 

    Mr. Robb Knie, CEO of Hoth Therapeutics, commented, "Hoth is extremely pleased to welcome Dr. Lacouture to our Scientific Advisory Board.  Dr. Lacouture is a leader and pioneer in the treatment of skin toxicities during cancer therapy and his expertise will be invaluable towards the progression of our HT-001 therapeutic.  We look forward to leveraging his wealth of experience as we plan our clinical program for HT-001."

    Dr. Lacouture is an Attending Physician and the Director of the Oncodermatology Program in the Dermatology Service, Department of Medicine, at Memorial Sloan Kettering Cancer Center and a Professor in the Department of Dermatology, Weill Cornell Medicine in New York City. He completed his postdoctoral work at Brigham and Women's Hospital in Boston, MA, an internship in General Surgery at Cleveland Clinic and residency in dermatology at The University of Chicago, IL. He received his M.D. degree from Javeriana University in Bogota, Colombia, where he grew up.  Dr. Lacouture pioneered the discipline of Oncodermatology, which studies and treats dermatologic conditions in cancer patients, and those that arise as a consequence of chemotherapy and/or radiotherapy or stem cell transplants. Dr. Lacouture is currently the Principal Investigator for "The CHANCE Trial", A Longitudinal Study of Chemotherapy-Induced Hair Changes and Alopecia, Skin Aging and Nail Changes in Women with Non-Metastatic Breast Cancer and a NIH funded study to identify the mechanisms of immune-related cutaneous adverse events. In addition, Dr Lacouture is the principal investigator for various therapeutic trials in oncodermatology. Dr. Lacouture is a well-known lecturer in the US and abroad on dermatologic conditions as a result of cancer therapies. He founded a clinical program that encompasses patient care, education, and research on dermatologic care in cancer patients and survivors. He is the founder of the Oncodermatology and Immunotherapy Study Group of the Multinational Association of Supportive Care in Cancer and is on the advisory board of Cancer.Net. In 2012, CancerCare named Dr Lacouture as Physician of the Year for his contributions to the education of people living with cancer, and he has been rated as a Top Doctor by New York Magazine since 2012. In 2021 he was awarded the Everett C. Fox Memorial Lectureship by the American Academy of Dermatology for his innovative work in oncodermatology. Dr Lacouture has published over 260 articles in peer-reviewed journals and is the author of Dr Lacouture's Skin Care Guide for People Living With Cancer and Editor of the textbook Dermatologic Principles and Practice in Oncology.

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different therapeutic prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com.

    Forward-Looking Statement

    This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

    Investor Contact:

    LR Advisors LLC

    Email: 

    www.hoththerapeutics.com

    Phone: (678) 570-6791

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-announces-the-appointment-of-mario-e-lacouture-md-to-oversee-dermatology-therapeutic-program-for-cancer-patients-as-part-of-hoth-scientific-advisory-board-301215803.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  2. NEW YORK, Jan. 20, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced new in vitro data demonstrating the therapeutic potential of HT-003 to block acne pathogenic gene expression in human keratinocytes, the major cell type of the epidermis and the outermost of the layers of the skin.

    Dr. Jonathan Zippin, M.D., Ph.D., FAAD, Associate Professor of Dermatology at Weill Cornell Medicine and Hoth Senior Scientific Advisor, is lead on the study. "Thanks to Dr. Zippin and his team, we have gained significant insight for the therapeutic potential of HT-003 for the treatment of acne," stated Stefanie Johns, Chief Scientific Officer of Hoth Therapeutics

    Toll-like receptor 2 (TLR2) is one of the most critical pathways for acne pathophysiology. The data generated from this series of in vitro experiments shows that TLR2 is significantly inhibited by HT-003, including in the presence of TLR2 agonists. Baseline expression of TLR2 and a critical transcription factor for skin inflammation (NF-KB) are inhibited by HT-003.

    "The ability of HT-003 to potently inhibit TLR2 signaling pathway suggests that this drug will not only be effective for acne but may also help a broad range of patients suffering from disease driven by overactive inflammatory responses to bacteria," stated Dr. Zippin.

    Dr. Zippin will continue to investigate the therapeutic mechanism of action of HT-003 through in vitro dose-response analyses and in animal models.

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit  https://ir.hoththerapeutics.com/.

    Forward-Looking Statement

    This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

    Investor Contact:

    LR Advisors LLC

    Email:  

    www.hoththerapeutics.com

    Phone: (678) 570-6791  

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-announces-positive-initial-mechanism-of-action-data-for-ht-003-in-pursuit-for-acne-treatment-indication-301211360.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  3. NEW YORK, Jan. 13, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced the Pre-IND meeting requested on 22 December 2020 for HT-001 with the U.S. Food and Drug Administration (FDA) Division of Dermatology and Dental Products has been granted to receive written responses only from FDA that are targeted for delivery on February 22, 2021.

    HT-001 is a topical formulation under development for the treatment of rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor (EGFR) inhibitor therapy for patients undergoing treatment for cancer.

    The Pre-IND meeting topics include the acceptability of the overall proposed drug development program for HT-001 including requirements for nonclinical, clinical pharmacology, clinical, chemistry, and manufacturing controls. The proposed clinical trial designs for the first clinical studies (phase 2) in the HT-001 program are also included in the Pre-IND meeting topics to receive FDA feedback.

    "We are looking forward to receiving feedback from FDA to continue advancing the HT-001 development program towards the clinic as efficiently as possible," stated Robb Knie, Chairman and CEO of Hoth Therapeutics. "Receiving feedback from FDA in February positions us well to achieve our planned IND-enabling development activities on time with the eventual goal of initiating the first HT-001 clinical trial in patients."

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne and other immunological disorders.   Hoth has also recently entered into two different agreements to further the development of two different therapeutic prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com.

    Forward-Looking Statement

    This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

    Investor Contact:

    LR Advisors LLC

    Email: 

    www.hoththerapeutics.com

    Phone: (678) 570-6791

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/fda-grants-hoth-therapeutics-pre-ind-meeting-regarding-proposed-drug-development-plan-for-ht-001-treatment-for-cancer-patients-301207307.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  4. NEW YORK, Jan. 11, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced an agreement with Charles River Laboratories to initiate preclinical studies of HT-001, a topical formulation designed for the treatment of patients with rash and skin disorders associated with initial and repeat EGFR inhibitor cancer treatment.

    Hoth_Therapeutics_Logo

    Together with Charles River Laboratories, Hoth has outlined six preclinical studies, the first bioanalytical method development studies beginning in Q1 2021. The initial studies will develop the required bioanalytical methods to perform GLP toxicology studies required by the U.S. Food and Drug Administration (FDA) to initiate clinical studies for HT-001. Hoth recently submitted

    NEW YORK, Jan. 11, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced an agreement with Charles River Laboratories to initiate preclinical studies of HT-001, a topical formulation designed for the treatment of patients with rash and skin disorders associated with initial and repeat EGFR inhibitor cancer treatment.

    Hoth_Therapeutics_Logo

    Together with Charles River Laboratories, Hoth has outlined six preclinical studies, the first bioanalytical method development studies beginning in Q1 2021. The initial studies will develop the required bioanalytical methods to perform GLP toxicology studies required by the U.S. Food and Drug Administration (FDA) to initiate clinical studies for HT-001. Hoth recently submitted a request for a Pre-Investigational New Drug (IND) meeting to the FDA to discuss the proposed drug development program of HT-001 which is also anticipated to occur during the first quarter of 2021. At the Pre-IND Meeting, Hoth will discuss the required preclinical safety and toxicology studies and the full development plan of HT-001. After the Meeting, Hoth will then initiate the GLP toxicology studies with Charles River Laboratories.

    "We are pleased to have reached an agreement to initiate our studies in collaboration with Charles River Laboratories," said Robb Knie, CEO of Hoth Therapeutics. "Charles River is the gold standard for toxicology studies in the industry. Execution of these critical preclinical studies takes us one step closer to the clinic. We believe our topical treatment addresses a significant unmet need as a supportive care treatment for the millions currently suffering from dermatological adverse effects of EGFR inhibitor cancer treatment."

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different therapeutic prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com.

    Forward-Looking Statement

    This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

    Investor Contact:

    LR Advisors LLC

    Email: 

    www.hoththerapeutics.com

    Phone: (678) 570-6791

    Cision View original content:http://www.prnewswire.com/news-releases/hoth-therapeutics-to-initiate-ind-enabling-studies-of-ht-001-treatment-for-cancer-patients-301205202.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  5. NEW YORK, Jan. 5, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced that it has entered into a definitive securities purchase agreement in connection with a private placement to institutional investors.  Upon the closing of the financing, the Company expects to receive gross proceeds of approximately $5.0 million, not including any proceeds that may be received upon exercise of warrants. The closing of the financing is subject to customary closing conditions. 

    The Benchmark Company, LLC is acting as the exclusive placement agent for the financing. 

    Under the securities purchase agreement, the investors have agreed to purchase 2,475,248 million shares of the Company's Common Stock ("Common Stock") and accompanying warrants to purchase up to an aggregate of approximately 1,237,624 million shares of Common Stock, at a purchase price of $2.02 per share and accompanying warrant to purchase 0.5 of a share of Common Stock, which is at-the-market under Nasdaq rules. The warrants will be exercisable for a period of five years following the date of issuance and will have an exercise price of $2.25 per share, subject to proportional adjustments in the event of stock splits or combinations or similar events.  The closing is expected to occur on January 7, 2021, subject to customary closing conditions. 

    The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

    This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state.

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different therapeutic prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com.

    Forward-Looking Statement

    This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

    Investor Contact:

    LR Advisors LLC

    Email: 

    www.hoththerapeutics.com

    Phone: (678) 570-6791

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-announces-private-placement-of-equity-priced-at-the-market-under-nasdaq-rules-301201029.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  6. NEW YORK, Jan. 4, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has entered into a Non-Exclusive Commercial Evaluation License Agreement with the U.S. Army Medical Research and Development Command (USAMRDC) for a new molecular entity (NME) developed by the Walter Reed Army Institute of Research with a novel antibacterial mechanism of action that targets multiple bacterial pathogens. 

    While this NME (to be developed under the identifier "HT-006") has the potential to treat many different types of bacterial infections, Hoth will initially target treatment of serious bacterial infections of the lung, such as hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP).  Both HAP and VAP are considered life-threatening diseases for which current treatment options are limited or not effective against multi-drug resistance bacteria. As such, Hoth intends to pursue streamlined development opportunities under the U.S. Food and Drug Administration's (FDA) program for "antibacterial therapies for patients with an unmet medical need for the treatment of serious bacterial diseases." This streamlined program allows for the use of nonclinical animal studies to reduce clinical studies required for approval.

    Preclinical studies investigating the minimal inhibitory concentration of HT-006 for various multi-drug resistant bacterial species are planned to start in Q1 2021.

    Licensing through the USAMRDC provides a unique opportunity to collaborate with U.S. Army laboratory resources and experts during development of the technology, including the Walter Reed Army Institute of Research and The U.S. Army Aeromedical Research Laboratory. Hoth intends to collaborate with USAMRDC experts and utilize the laboratory resources during development of HT-006.

    "Hoth is proud to be partnering with the U.S. Army Medical Research and Development Command on such an extensive and innovative endeavor," stated Dr. Stefanie Johns Chief Scientific Officer of Hoth Therapeutics. "We are excited about the potential impact that novel antibiotic treatments with HT-006 can have on the millions of patients that are afflicted with pneumonia."

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different therapeutic prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com.

    Forward-Looking Statement

    This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

    Investor Contact:

    LR Advisors LLC

    Email:  

    www.hoththerapeutics.com

    Phone: (678) 570-6791

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-announces-licensing-agreement-and-collaboration-with-us-army-medical-research-and-development-command-usamrdc-for-treating-multi-drug-resistant-bacterial-lung-infections-301199938.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  7. NEW YORK, Dec. 31, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced that it has signed a production agreement for both GLP and GMP materials associated with HT-001  with Tergus Pharma for its novel cancer treatment drug, HT-001.

    This announcement follows the recent news that Hoth has requested a Pre-Investigational New Drug (IND) meeting to the U.S. Food and Drug Administration (FDA) to discuss a proposed drug development program for the novel treatment. 

    HT-001 is a topical formulation designed for the treatment of patients with mild to moderate rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor (EGFR) inhibitor therapy.   EGFR inhibitors are used for treatment of cancers with EGFR up-regulation (such as non-small cell lung cancer, pancreatic cancer, breast cancer, and colon cancer). EGFR inhibitors are often associated with dose-limiting skin toxicities that can result in interruption of treatment.  HT-001 is targeted to treat these EGFR-induced skin disorders to allow patients to achieve the best potential outcomes of EGFR therapy.

    "Hoth management is pleased with the advancement of our HT-001 treatment throughout the developmental process," said Robb Knie, CEO of Hoth Therapeutics. "Patients struggling with dermatological ailments have been known to halt, and even discontinue potentially life-saving oncology treatments.  Our hope that is our topical therapeutic will provide care to those in need."

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different therapeutic prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com .

    Forward-Looking Statement

    This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

    Investor Contact:

    LR Advisors LLC

    Email: 

    www.hoththerapeutics.com

    Phone: (678) 570-6791

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-announces-production-of-ht-001-for-cancer-treatment-301199561.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  8. NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced the request for a Pre-Investigational New Drug (IND) meeting to the U.S. Food and Drug Administration (FDA) to discuss the proposed drug development program for HT-001, a topical drug formation under development for the treatment of rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy. EGFR inhibitors are critical therapeutic agents for the treatment of non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer, squamous-cell carcinoma of the head and neck, and breast cancer.

    NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced the request for a Pre-Investigational New Drug (IND) meeting to the U.S. Food and Drug Administration (FDA) to discuss the proposed drug development program for HT-001, a topical drug formation under development for the treatment of rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy. EGFR inhibitors are critical therapeutic agents for the treatment of non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer, squamous-cell carcinoma of the head and neck, and breast cancer.

    Cancer patients receiving EGFR inhibitor therapy often require repeat courses to achieve effective cancer treatment, and >50% of patients have significant dermatological side effects within the first 2 weeks of treatment that persist even after stopping EGFR therapy. These skin toxicities can severely impact patient quality of life and can result in reduction of EGFR inhibitor dose or interruption of treatment. HT-001 is targeted to treat these EGFR-induced skin disorders to allow patients to achieve the best potential outcomes of EGFR therapy, as there are currently no approved drugs to specifically treat EGFR inhibitor-induced skin disorders.

    In July 2019 Hoth Therapeutics entered into a Sponsored Research Agreement with the George Washington University (GW) to explore preclinical pharmacology studies with topically administered HT-001.

    Currently in the preclinical stage of development of HT-001, Hoth Therapeutics anticipates a meeting with the FDA to be scheduled during the first quarter of 2021. HT-001 is being positioned for submission via the 505(b)(2) development pathway, in which Hoth Therapeutics intends to rely on information not obtained through right of reference in order to reduce the nonclinical and clinical program and expedite time to NDA submission. During the pre-IND meeting with the FDA, Hoth Therapeutics plans to discuss the overall proposed drug development program for HT-001 including requirements for nonclinical, clinical pharmacology, clinical, and chemistry, manufacturing, controls. Hoth also plans to present clinical trial designs for the IND-opening, phase 2a dose ranging study as well as a proposed follow-up phase 2b safety and efficacy dose extension study; both studies will be conducted in cancer patients receiving EGFR inhibitor therapy.

    "Palliative care treatment for cancer patients continues to be an underserved segment of the market that our HT-001 product has an opportunity to provide patients with a better quality of life during their cancer treatment," stated Robb Knie, Chairman and CEO of Hoth Therapeutics. "We look forward to working closely with the FDA on our Phase 2a and Phase 2b trial designs and advancing HT-001 through the research and development process."

    About Hoth Therapeutics, Inc. 

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different therapeutic prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com .

    Forward-Looking Statement 

    This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

    Investor Contact: 

    LR Advisors LLC 

    Email: 

    www.hoththerapeutics.com

    Phone: (678) 570-6791

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-submits-request-for-a-pre-investigational-new-drug-pre-ind-meeting-for-ht-001-treatment-for-cancer-patients-301197951.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  9. NEW YORK, Dec. 21, 2020 /PRNewswire/ -- Hoth (NASDAQ:HOTH) has a partnership agreement with Zylö Therapeutics Inc.,to co-develop a new topical treatment for patients with Cutaneous Lupus Erythematosus (CLE), a chronic autoimmune disease that affects the skin and is associated with a significant burden on patient quality of life. Therapeutic options for CLE are limited to steroids (topical and oral), topical calcineurin inhibitors, and other immunomodulating therapies that could have adverse effects during long-term use. Zylö Therapeutics has developed a patented topical delivery system using xerogel-derived nanoparticles called Z-pods™. Hoth has an exclusive license to develop HT-005, a drug that targets the endocannabinoid pathway, encapsulated…

    NEW YORK, Dec. 21, 2020 /PRNewswire/ -- Hoth (NASDAQ:HOTH) has a partnership agreement with Zylö Therapeutics Inc.,to co-develop a new topical treatment for patients with Cutaneous Lupus Erythematosus (CLE), a chronic autoimmune disease that affects the skin and is associated with a significant burden on patient quality of life. Therapeutic options for CLE are limited to steroids (topical and oral), topical calcineurin inhibitors, and other immunomodulating therapies that could have adverse effects during long-term use. Zylö Therapeutics has developed a patented topical delivery system using xerogel-derived nanoparticles called Z-pods™. Hoth has an exclusive license to develop HT-005, a drug that targets the endocannabinoid pathway, encapsulated in the Z-pods™ to enhance absorption into the skin. To investigate proof-of concept efficacy of HT-005 loaded Z-pods™, Zylö Therapeutics conducted a study in MRL/MpJ-Faslpr/J mice, an established animal model that shows symptoms similar to systemic lupus erythematosus (SLE) in humans. Results from the study demonstrated that the novel HT-005 loaded Z-pods™ were effective to reduce skin plaques associated with CLE, with statistical significance demonstrated in the overall average skin score as well as individual skin scores on the head and scapula.

    Study Title: Topical treatment of cutaneous lesions in the MRL-Lpr mouse model of SLE

    • 8 week old MRL/MpJ-Faslpr/J mice were randomly placed into a dosing group according to the Table below when an animal developed a skin plaque score of 1.
    • Mice were treated for 10 weeks with either HT-005 alone or HT-005 encapsulated in Z-pods™ or not treated (control) HT-005 Z-Pods™

     

     

     

     

    HT-005 Z-Pods™  

    Includes a novel topical delivery matrix (Z-Pods™) loaded with an endogenous ligand with suspected immune-modulating action. Z-Pods™ use patented xerogel-derived nanoparticles for sustained and controlled topical delivery of active pharmaceutical ingredients.

    Representative Images of Cutaneous Lesions from Control Mice and Mice Treated with Encapsulated HT-005 | Group 1 (No Treatment) - Mouse #27: Start, Middle, End

     

    Representative Images of Cutaneous Lesions from Control Mice and Mice Treated with Encapsulated HT-005 | Group 2 (HT-005) - Mouse #53: Start,  Middle, End

     

    Representative Images of Cutaneous Lesions from Control Mice and Mice Treated with Encapsulated HT-005 | Group 3 (Encapsulated HT-005) - Mouse #60: Start,  Middle, End

    Partnership

    The study was conducted at The Jackson Laboratory

    Profile

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's mission is to develop novel therapies that improve patient quality of life. Hoth has exclusive worldwide rights to the BioLexa Platform.

    Company Contact

    HOTH THERAPEUTICS

    One Rockefeller Plaza, Suite 1039

    New York, New York 10020

    LR Advisors LLC

     

    www.hoththerapeutics.com

    Phone: (678) 570-6791

    Safe Harbor Statement: This document contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words "could", "believe", "anticipate", "intend", "estimate", "expect", "may", "continue", "predict", "potential" and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of Hoth Therapeutics, Inc. ("Hoth" or "the Company") to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company's technology platforms, retaining and expanding the Company's customer base, fluctuations in consumer spending on the Company's products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward- looking information contained in this document, whether as a result of new information, future events or otherwise, after the date of this document or to reflect the occurrence of unanticipated events except as required by law.

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/endocannabinoid-pathway-targeted-drug-demonstrates-proof-of-concept-efficacy-in-a-cutaneous-lupus-erythematosus-mouse-model-301196588.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  10. NEW YORK, Dec. 10, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that is has received Human Research Ethics Committee (HREC) clearance to commence the first cohort of the Phase 1b clinical trial of BioLexa Lotion for the treatment of mild to moderate atopic dermatitis in Australia. 

    The Company expects to dose the first subject during early 2021 and report top-line data from the first cohort of the trial in the first quarter of 2021, followed by initiation of dosing in patients with mild to moderate atopic dermatitis in the second quarter. Following the successful completion of the Phase 1b trial, the Company intends to conduct a Phase 2 trial with adult and adolescent patients to continue clinical investigation of the efficacy of BioLexa Lotion for treatment of mild to moderate atopic dermatitis.

    BioLexa Phase 1b Trial Design:

    • Randomized, double-blind, parallel-design, placebo-controlled study conducted in two parts. Part 1 will be conducted in healthy subjects. After review of the Part 1 safety data, the study will proceed with Part 2 that includes adult patients with mild to moderate atopic dermatitis.
    • The primary goal of the study is to evaluate the safety and characterize pharmacokinetics of topical BioLexa Lotion.
    • Participants will be treated twice daily with topical application directly on skin for 14 days
    • Preliminary efficacy will also be investigated in the Part 2 atopic dermatitis patient cohort, including change in atopic dermatitis extent of involvement and severity using EASI, SCORAD, IGA as well as patient-centric quality of life assessments.

    "Receiving ethical clearance is a critical milestone towards initiating our Phase 1b clinical trial in Australia," stated Robb Knie, Chairman and CEO of Hoth Therapeutics. "Beyond the cost efficiencies of conducting a trial in Australia, we strategically chose Australia for our Phase 1b trial due to the rigorous guidelines of the HREC, which will support the submission of our full data set upon successful completion of this Phase 1b and our upcoming Phase 2 trial to the FDA. Management, our Board and scientific advisors believe that Hoth's atopic dermatitis solution, BioLexa, represents a significant global opportunity and we look forward to advancing the treatment through the clinic."

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different therapeutic prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com.

    Forward-Looking Statement

    This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

    Investor Contact:

    LR Advisors LLC

    Email:  

    www.hoththerapeutics.com

    Phone: (678) 570-6791  

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-receives-approval-to-commence-phase-1b-clinical-trial-of-biolexa-for-the-treatment-of-atopic-dermatitis-in-humans-301190549.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  11. NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. today announced that it will participate in the 2020 Fall TechConnect Virtual Innovation Conferences' Virtual Defense TechConnect Innovation Summit. The conference will be held November 17-19, 2020.

    Importantly, the Company was also selected as a 2020 TechConnect Defense Innovation Awardee.  The annual TechConnect Defense Innovation Awards recognizes the top 15% of submitted Challenge technologies as ranked by the Selection Committee.

    Voltron's COVID-19 vaccine, HaloVax, is being developed using the novel Self Assembling Vaccine technology exclusively licensed from the Massachusetts General Hospital's Vaccine and Immunotherapy Center, provides a novel approach to attacking…

    NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. today announced that it will participate in the 2020 Fall TechConnect Virtual Innovation Conferences' Virtual Defense TechConnect Innovation Summit. The conference will be held November 17-19, 2020.

    Importantly, the Company was also selected as a 2020 TechConnect Defense Innovation Awardee.  The annual TechConnect Defense Innovation Awards recognizes the top 15% of submitted Challenge technologies as ranked by the Selection Committee.

    Voltron's COVID-19 vaccine, HaloVax, is being developed using the novel Self Assembling Vaccine technology exclusively licensed from the Massachusetts General Hospital's Vaccine and Immunotherapy Center, provides a novel approach to attacking the virus, and an important alternative to first generation vaccines in development.

    Entering its seventh year, the annual Defense TechConnect (DTC) Summit, co-located with the Fall SBIR/STTR Innovation Summit, brings together defense, private industry, federal agency, and academic leadership to accelerate state-of-the-art technology solutions for the warfighter and national security.

    The DTC supports innovation imperatives in the new National Defense Strategy (NDS) and is a unique platform to reach thousands of public and private leaders focused on innovation and technology to support the warfighter. At last year's Defense Innovation Summit, close to 1,000+ one-on-one meetings took place between small businesses and SBIR Federal Program Managers, 200+ booths and tabletop displays in the Exhibit Hall representing private sector companies and non-traditional innovators, and more than 30 breakout sessions focused on defense innovation areas of interest including but not limited to energy, cyber, biomedical, and command, control, communications, computers/intelligence, surveillance, and reconnaissance (C4ISR).

    The DTC Summit is proud to once again host the Defense Innovation Technology Acceleration Challenges (DITAC), connecting emerging technologies with DOD component commands, officers, and acquisition experts. The annual DTC is one of the most well-attended defense innovation conferences of the year.

    To learn more about the Virtual Defense TechConnect Summit and Expo, one of the most well-attended defense events of the year, please visit: https://events.techconnect.org/DTCFall/.

    About Voltron Therapeutics, Inc.

    Voltron Therapeutics, Inc., a Delaware corporation, was founded in 2017 to lead and accelerate the development of the Vaccine and Immunotherapy Center (VIC), and the Massachusetts General Hospital's novel Self Assembling Vaccine technology in a variety of indications, including in Oncology and emerging Infectious Diseases. Voltron holds an exclusive worldwide license to this technology. With the work of our world class team of researchers and physicians, this technology has shown in certain pre-clinical studies initial proof of concept in two infectious diseases (Lassa Fever and Q Fever) as well as two oncology indications (Ovarian and HPV Related Cancers). For more information, please visit www.voltrontx.com.

    About HaloVax™, LLC

    HaloVax, LLC is a special purpose subsidiary of Voltron Therapeutics, Inc. in joint venture with Hoth Therapeutics, Inc. (NASDAQ:HOTH) The mission of HaloVax is to develop a novel, Self-Assembling Vaccine against COVID-19, utilizing technology licensed by Voltron Therapeutics, Inc. from the Vaccine and Immunotherapy Center at the Massachusetts General Hospital. The vaccine is being designed from a validated platform to provide customized T cell immunity against COVID-19, as well as be able to adapt rapidly to potential genetic drift of the virus. For more information, please visit www.HaloVax.com

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements

    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the VaxCelerate Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Voltron's current expectations and various assumptions. Voltron believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Voltron may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and any Voltron filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Voltron's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Voltron cannot guarantee future results, events, levels of activity, performance or achievements. Voltron does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Investor Contacts:

    Matt Duffy

    President

    Voltron Therapeutics, Inc.

    646-335-5923

    Jason Assad

    Investor Relations

    Voltron Therapeutics, Inc.

    678-570-6791



    Primary Logo

    View Full Article Hide Full Article
  12. NEW YORK, Nov. 3, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced positive, statistically significant proof-of-concept preclinical data on its therapeutic HT-005 for the treatment of Cutaneous Lupus Erythematosus (CLE), a chronic autoimmune skin disease. 

    The study conducted by Jackson Laboratory in partnership with Zylö Therapeutics using a CLE mouse model demonstrated a significant reduction in skin plaque severity after treatment with HT-005-loaded topical Z-pods™ compared to untreated control mice.  The skin severity scoring was based on a semi-quantitative measurement scale of erythema, thickness, scaling, and alopecia measured on the scapula, head, and overall composite score. The study was conducted over the period of 10 weeks and significant reduction of plaque severity in the overall composite score was observed within 3 weeks of treatment and maintained through the entire 10 week treatment cycle, supporting that the therapeutic response is sustained.

    "Our final preclinical proof-of-concept data set provides us with optimism in our topical drug candidate for a high unmet need indication, CLE," stated, Robb Knie, Chairman and CEO of Hoth Therapeutics. "We look forward to working with our partner, Zylö Therapeutics, on the next phase of development of this promising therapeutic."

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com.

    Forward-Looking Statement

    This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

    Investor Contact:

    LR Advisors LLC

    Email:  

    www.hoththerapeutics.com

    Phone: (678) 570-6791  

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-announces-positive-statistically-significant-proof-of-concept-preclinical-data-on-its-therapeutic-for-cutaneous-lupus-erythematosus-cle-a-chronic-autoimmune-skin-disease-301165697.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  13. NEW YORK, Nov. 2, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced key upcoming milestones towards the commercial development of the novel COVID-19 products currently being developed. Hoth Therapeutics has cast a wide net to contribute to the fight against COVID-19 that includes: HT-002 peptide therapeutic targeted to treat symptoms associated with COVID-19, the On-the-Go SARS-CoV-2 Testing Device, and VaxCelerate SARS-CoV-2 vaccine.

    Hoth_Therapeutics_Logo

    HT-002
    HT-002 is a novel peptide therapeutic targeted for the treatment of illness associated with SARS-CoV-2 infection (COVID-19 disease).

    SARS-CoV-2 live virus inhibition test data is expected to be available in December 2020, which would characterize the…

    NEW YORK, Nov. 2, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced key upcoming milestones towards the commercial development of the novel COVID-19 products currently being developed. Hoth Therapeutics has cast a wide net to contribute to the fight against COVID-19 that includes: HT-002 peptide therapeutic targeted to treat symptoms associated with COVID-19, the On-the-Go SARS-CoV-2 Testing Device, and VaxCelerate SARS-CoV-2 vaccine.

    Hoth_Therapeutics_Logo

    HT-002

    HT-002 is a novel peptide therapeutic targeted for the treatment of illness associated with SARS-CoV-2 infection (COVID-19 disease).

    SARS-CoV-2 live virus inhibition test data is expected to be available in December 2020, which would characterize the therapeutic potential of the HT-002 peptide in an in vitro model. Pending results of the study, Hoth Therapeutics intends to pursue formulation development, preclinical safety testing, and meetings with the US Food and Drug Administration ("FDA") in 2021 for HT-002.

    On-the-Go SARS-CoV-2 Testing Device

    The On-the-Go SARS-CoV-2 Testing Device System is the first of its kind technology under development as a point-of-care/patient-use device as an aid in the diagnosis of COVID-19 infection. The system uses a nanohole array (NHA)-based plasmonic system that is being designed for high sensitivity and selectivity detection of SARS-CoV-2 virus with rapid reporting of results.

    The On-the-Go SARS-CoV-2 Testing Device is currently in the research phase of development. Proof-of-concept data supporting sensitive detection of SARS-CoV-2 virus by prototype devices is expected by the end of 2020, with further studies characterizing specificity of the device contemplated in 2021. The initial research level data is expected to be used to support a pre-Emergency Use Authorization (EUA) meeting with the US Food and Drug Administration in 2021, which will be focused on the verification and validation requirements to obtain EUA for a non-laboratory use device.

    "COVID-19 disease remains a critical unmet medical need in the US and there still exists a significant gap for effective vaccines, safe and efficacious therapeutics, and rapid, accurate diagnostic tests that can be performed by patients at home. We are pushing an aggressive development timeline for each of the COVID-19 products to help fill this gap," stated, Stefanie Johns, PhD, Chief Scientific Officer of Hoth Therapeutics.  "We look forward to sharing our progress on these COVID-19 products as we stay focused on the development tasks at hand towards commercialization."

    VaxCelerate SARS-CoV-2 Vaccine

    The SARS-CoV-2 vaccine is being developed using VaxCelerate, a self-assembling vaccine platform licensed from the Vaccine and Immunotherapy Center at Massachusetts General Hospital by HaloVax, LLC. VaxCelerate offers two unique elements to combat SARS-CoV-2: a fixed immune adjuvant and variable immune targeting, the combination which is designed to illicit a robust, protective immune response.

    Proof-of-concept mouse model data has recently been generated with the SARS-CoV-2 vaccine candidate that supports an immune response is achieved after inoculation. Additional studies are planned to optimize the vaccine formulation and collect additional preclinical data in a humanized-mouse model to position the vaccine candidate for initiating human clinical trials.

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different therapeutic prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com.

    Forward-Looking Statement

    This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

    Investor Contact:

    LR Advisors LLC

    Email:  

    www.hoththerapeutics.com

    Phone: (678) 570-6791  

    Cision View original content:http://www.prnewswire.com/news-releases/hoth-therapeutics-provides-update-for-novel-covid-19-therapeutic-on-the-go-sars-cov-2-testing-device-and-vaccine-301164942.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  14. NEW YORK, Oct. 20, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced that through its commercial licensing agreement with the University of Maryland, Baltimore (UMB) the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 10,793,525 related to novel 13-Cis-RAMBA retinamides optimized to target key signaling pathways implicated in a variety of cancers.  This patent is also the first of its kind, expiring on October 5, 2036.

    Numerous cancer types, including breast, prostate, bladder, and pancreatic cancers, share a similar oncogenic lineage through hyperactivation of a biochemical signaling cascade that promotes cancer initiation, progression, and metastases. This cancerous signal "hijacking" is controlled by two proteins, MAPK-interacting kinases 1 and 2 (or MNK 1/2); therefore, restoring control of the signaling pathway promotes programmed cell death (apoptosis) and inhibits cell growth. Researchers at UMB discovered novel 13-cis-retinoic acid metabolism blocking agent (RAMBAs) retinamides that are targeted to interrupt the MNK1/2-driven signaling pathway as potential therapeutics for various cancers. The potential therapeutic utility of these novel RAMBAs was shown in tumor xenograft animal models for both breast and prostate cancer. 

    Last year, Hoth Therapeutics announced that it had entered into a Commercial Licensing Agreement with University of Maryland, Baltimore for the development of  HT-003, a related but chemically different RAMBA, being developed for the treatment of acne and psoriasis. 

    "With this patent, Hoth Therapeutics continues to bolster its diverse IP portfolio, which now contains multiple patents related to both oncology treatments and dermatological disorders," stated, Robb Knie, Chairman and CEO of Hoth Therapeutics.  "We look forward to progressing towards additional breakthroughs throughout our entire biopharmaceutical pipeline in the near future."

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com.

    Forward-Looking Statement

    This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

    Investor Contact:

    LR Advisors LLC

    Email:  

    www.hoththerapeutics.com

    Phone: (678) 570-6791  

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-announces-uspto-grant-of-patent-for-targeted-13-cis-ramba-retinamides-for-development-as-a-novel-cancer-therapeutic-301155861.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  15. NEW YORK, Sept. 24, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced completing testing to examine the ability of HT-003 to block acne pathogenic gene expression in human keratinocytes, the major cell type of the epidermis and the outermost of the layers of the skin.

    Dr. Jonathan Zippin, M.D., Ph.D., FAAD, Associate Professor of Dermatology at Weill Cornell Medicine and Hoth Senior Scientific Advisor, led the first phase of the study. "Thanks to Dr. Zippin and his team, we have gained insight and gathered significant data with regards to the significance of HT-003 in blocking acne pathogenic gene expression," stated Robb Knie, CEO of Hoth Therapeutics. "We will continue to monitor the data at lower doses and move onto the testing of rodent skin and carcinogenesis."

    Initial data from the first phase of the research reports that one of the most critical genes for acne pathophysiology, toll-like receptor 2 (TLR2), is significantly inhibited by HT-003.  In addition, HT-003 at doses as high as 50 µM led to no observable toxicity.  During the next phase of the research, Dr. Zippin will identify the minimal effective dose required to block TLR2 signaling in response to a broad range of bacteria derived agonists to further elucidate the pathway. 

    "The ability of HT-003 to potently inhibit TLR2 expression suggests that this drug will not only be effective for acne but may also help a broad range of patients suffering from disease driven by over active inflammatory responses to bacteria," stated Dr. Zippin.

    Once HT-003 biomarkers have been identified using thein vitro human keratinocytes models, testing will move onto into live rodents.

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit https://ir.hoththerapeutics.com/.

    Forward-Looking Statement

    This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

    Investor Contact:

    LR Advisors LLC

    Email:  

    www.hoththerapeutics.com

    Phone: (678) 570-6791  

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-announces-its-ht-003-shows-positive-initial-data-inhibiting-toll-like-receptor-2-tlr2-301137358.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
    • Presentation Times and Weblinks Released for Over 150 Presenting Companies
    • Day 1: Wednesday, September 23, 2020
    • ALL INSTITUTIONAL AND RETAIL INVESTORS ARE WELCOME

    NEW YORK, NY / ACCESSWIRE / September 22, 2020 / Sidoti & Company, LLC has released the presentation schedule, with weblink click-throughs, for Wednesday, September 23, 2020, the first day of its two-day Fall 2020 Virtual Investor Conference. The presentation schedule and related links for day two of the virtual event, Thursday, September 24, 2020, will be published shortly after the conclusion of Wednesday's session or can be found at www.sidoticonference.com/events (click Schedule).

    Virtual Agenda - Wednesday, September 23rd - All Times EDT

    Click on Company Name to Open Link to Zoom Meeting

    • Presentation Times and Weblinks Released for Over 150 Presenting Companies
    • Day 1: Wednesday, September 23, 2020
    • ALL INSTITUTIONAL AND RETAIL INVESTORS ARE WELCOME

    NEW YORK, NY / ACCESSWIRE / September 22, 2020 / Sidoti & Company, LLC has released the presentation schedule, with weblink click-throughs, for Wednesday, September 23, 2020, the first day of its two-day Fall 2020 Virtual Investor Conference. The presentation schedule and related links for day two of the virtual event, Thursday, September 24, 2020, will be published shortly after the conclusion of Wednesday's session or can be found at www.sidoticonference.com/events (click Schedule).

    Virtual Agenda - Wednesday, September 23rd - All Times EDT

    Click on Company Name to Open Link to Zoom Meeting

    8:30-9:00

    LICT Corporation (LICT)

    ****

    Tonix Pharmaceuticals Holding Corp. (TNXP)

    Acme United Corporation (ACU)

    ****

    The ODP Corporation [Office Depot] (ODP)

    Yatra Online Inc (YTRA)

    9:15-9:45

    Huron Consulting Group (HURN)

    Vishay Precision Group (VPG)

    ****

    Hooker Furniture Corporation (HOFT)

    ****

    Unifi (UFI)

    ****

    10:00-10:30

    AudioCodes (AUDC)

    Brady Corporation (BRC)

    ****

    ****

    Forrester (FORR)

    Neenah Inc (NP)

    Lincoln Educational Services (LINC)

    10:45-11:15

    A10 Networks (ATEN)

    CSW Industrials, Inc. (CSWI)

    LeMaitre Vascular (LMAT)

    ICF (ICFI)

    ****

    SWM Intl (SWM)

    ****

    11:30-12:00

    Benchmark Electronics, Inc. (BHE)

    Arcosa, Inc. (ACA)

    Winnebago Industries (WGO)

    Systemax Inc. (SYX)

    Carriage Services, Inc. (CSV)

    Quaker Houghton (KWR)

    LightPath Technologies, Inc. (LPTH)

    12:15-12:45

    G5 Entertainment AB (GENTF)

    Titan International, Inc. (TWI)

    RadNet, Inc. (RDNT)

    Tetra Tech, Inc. (TTEK)

    BBSI (BBSI)

    Minerals Technologies Inc. (MTX)

    Powell Industries, Inc. (POWL)

    1:00-1:30

    PC Connection, Inc. (CNXN)

    ExOne (XONE)

    Transcat, Inc. (TRNS)

    Universal Electronics (UEIC)

    Farmer Mac (AGM)

    Haynes International, Inc. (HAYN)

    AZZ Inc (AZZ)

    1:45-2:15

    Onto Innovation (ONTO)

    ****

    Dyadic International Inc (DYAI)

    Primoris Services Corporation (PRIM)

    Pitney Bowes (PBI)

    Heska Corporation (HSKA)

    Universal Technical Institute (UTI)

    2:30-3:00

    Immersion Corporation (IMMR)

    Mistras Group (MG)

    Hoth Therapeutics, Inc. (HOTH)

    TrueBlue (TBI)

    Viad Corp (VVI)

    Kadant Inc. (KAI)

    Balchem Corporation (BCPC)

    3:15-3:45

    Intelligent Systems (INS)

    CTS Corporation (CTS)

    Infusystem, Inc. (INFU)

    FAT Brands Inc. (FAT)

    Resources Connection (RGP)

    ABM Industries (ABM)

    Avista Corporation (AVA)

    4:00-4:30

    QAD (QADA)

    DMC Global Inc. (BOOM)

    Black Hills Corporation (BKH)

    The Alkaline Water Company (WTER)

    ServiceSource International, Inc. (SREV)

    Ranpak Holdings Corp (PACK)

    Alexander & Baldwin (ALEX)

    1x1s Only

    TTEC Holdings Inc. (TTEC)

    EnPro Industries (NPO)

    Modine Mfg. Company (MOD)

    La-Z-Boy Inc (LZB)

    Strategic Education, Inc. (STRA)

    Havertys (HVT)

    Perdoceo Education Corp. (PRDO)

    Federal Signal (FSS)

    Insteel Industries (IIIN)

    **Additional Companies Hosting 1x1s Both Days: EZCORP (EZPW) | Gorman-Rupp (GRC) | Heritage Insurance (HRTG) | Herman Miller (MLHR) | HNI Corp (HNI)**

    About Sidoti

    For over two decades, Sidoti has been a premier provider of independent securities research focused specifically on small- and micro-cap companies and the institutions that invest their securities, with most of our coverage in the $100 million - $3 billion market cap range. Our approach affords companies and institutional clients a combination of high-quality research, a small-and micro- cap focused nationwide sales effort, broad access to corporate management teams, and extensive trading support. We serve 500+ institutional clients in the U.S., Canada and the U.K., including many leading managers of portfolios with $200 million to $2 billion of AUM. Sidoti promotes meaningful interaction between issuers and investors in the small- and micro-cap space through our conferences www.sidoticonference.com and the hundreds of non-deal roadshows we host each year.

    Contact

    Sidoti Events Team
    212-453-7031

    SOURCE: Sidoti & Company, LLC



    View source version on accesswire.com:
    https://www.accesswire.com/607330/Sidoti-Virtual-Investor-Conference

    View Full Article Hide Full Article
  16. NEW YORK, Sept. 21, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced  that it has entered into a Sponsored Research Agreement ("SRA") with the George Washington University ("GW") relating to the development of an in vitro diagnostic device that has the potential for testing by patients anywhere to allow public health professionals to immediately detect SARS-CoV-2 via a mobile device as an aid in the diagnosis of the COVID-19 infection.

    The device, which is based upon intellectual property rights licensed by Hoth from GW, is a nanohole array ("NHA") based plasmonic system being designed for high sensitivity and specificity for detecting the SARS-CoV-2 virus. The device uses a thin sheet of gold coated with virus-specific proteins that can bind with the SARS-CoV-2 virus. Once the SARS-CoV-2 virus binds, the wavelength of light bouncing off the surface changes, creating a different color of light.  This change in light color can be detected by a smartphone camera and an app with algorithms designed to detect the SARS-CoV-2 virus. The test has the potential to provide results within minutes and the results can then be sent to healthcare professionals or public health databases using the app on the patient's mobile device.   

    The objective of the SRA is to design and assess the analytical performance of the NHA-based system to directly detect the SARS-CoV-2 virus and distinguish that binding from other human coronaviruses.

    "Hoth is pleased to once again be working alongside some of the most renowned experts in the fields of engineering and public health research at GW," stated, Robb Knie, Chairman and CEO of Hoth Therapeutics.  "Narrowing down the time in which a COVID-19 test is administered and when results are provided remains a significant issue for our society. A device that can provide immediate COVID-19 test results would have a dramatic impact on our economy returning to normal once again. We are committed to doing what we can to fast-track the development of this device, which could potentially have a monumental impact in slowing and or stopping the spread of COVID-19 when its presence is detected."

    "Our research team is very pleased that Hoth Therapeutics has decided to partner with GW to develop this important SARS-CoV-2 virus detection system," said Dr. Mona Zaghloul, a GW professor of electrical and computer engineering and the principal investigator of the research team that created the diagnostic device. "Our device has great potential to help in the fight against COVID-19, and we are proud to be able to contribute to stopping the spread of the disease."

    "What we need is a home-based test that is both inexpensive and simple to use that could quickly identify asymptomatic people shedding high levels of virus," said Jeanne Jordan, PhD, a professor of epidemiology at GW Milken Institute School of Public Health. "Such a test could be a game changer for identifying those at greatest risk of transmitting the virus to others. A home-based test could pave the way toward a safe reopening of schools and the economy."

    "There is a significant unmet need for rapid COVID-19 in vitro diagnostic devices that can be used at home or in other non-lab settings by patients," stated Stefanie Johns, Chief Scientific Officer of Hoth Therapeutics. "The availability of a rapid COVID-19 test that can be used by patients in any location, and have results immediately shared with healthcare providers, would be a dramatic advancement for the battle against COVID-19 and improve access to COVID-19 testing for Americans. We plan to start discussions with the US Food and Drug Administration about the development plans for this novel technology in early 2021 to position the device for an emergency use authorization request."

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit  https://ir.hoththerapeutics.com/.

    Forward-Looking Statement

    This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

    Investor Contact:

    LR Advisors LLC

    Email:  

    www.hoththerapeutics.com

    Phone: (678) 570-6791  

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-enters-into-sponsored-research-agreement-for-on-the-go-covid-19-testing-device-301134318.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  17. NEW YORK, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. today announced that it has executed a manufacturing agreement for its vaccine portfolio with a global pharmaceutical contract development and manufacturing organization. The agreement partners Voltron with a multi-national company known for enabling companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. 

    Today's news comes on the heels of the Company's announcement of the successful completion of its first small animal safety and immunogenicity study assessing the effect of novel vaccine Halovax™ against COVID-19. The vaccine construct was completed with positive response…

    NEW YORK, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. today announced that it has executed a manufacturing agreement for its vaccine portfolio with a global pharmaceutical contract development and manufacturing organization. The agreement partners Voltron with a multi-national company known for enabling companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. 

    Today's news comes on the heels of the Company's announcement of the successful completion of its first small animal safety and immunogenicity study assessing the effect of novel vaccine Halovax™ against COVID-19. The vaccine construct was completed with positive response to selected COVID-19 peptides in conjunction with the self-assembling vaccine prototype. The study demonstrates that selection algorithm for immunogenic peptides is functioning appropriately.

    HaloVax is being developed in conjunction with Hoth Therapeutics, Inc. (NASDAQ:HOTH).

    The company's vaccines are built on a base of a heat shock protein (HSP70) that activates the cellular portion of the immune system; this is different from most other vaccine efforts, which have used adjuvants such as alum. The second portion of the vaccine consists of peptides derived from the target of the vaccine – which can be a virus or a cancer patient's tumor.  These are bound to the heat shock protein via Avidin and Biotin. This enables rapid iteration and up-to-date data informed changes in the peptide sequences to enable swift production of the vaccine.

    "We are pleased to have executed a manufacturing agreement with an international contract manufacturer for our vaccine portfolio. This initiative builds atop our recent operational momentum, including our recently announced successful preclinical testing of our COVID-19 vaccine candidate. We are now actively moving toward starting clinical trials in humans with the goal of bringing to market proven and effective vaccines to help treat a range of conditions, including various cancers and COVID-19," said Pat Gallagher, Chief Executive Officer, Voltron Therapeutics, Inc.

    About Voltron Therapeutics, Inc.

    Voltron Therapeutics, Inc., a Delaware corporation, was founded in 2017 to lead and accelerate the development of the Vaccine and Immunotherapy Center (VIC), and the Massachusetts General Hospital's novel Self Assembling Vaccine technology in a variety of indications, including in Oncology and emerging Infectious Diseases. Voltron holds an exclusive worldwide license to this technology. With the work of our world class team of researchers and physicians, this technology has shown in certain pre-clinical studies initial proof of concept in two infectious diseases (Lassa Fever and Q Fever) as well as two oncology indications (Ovarian and HPV Related Cancers). For more information please visit www.voltrontx.com.

    About HaloVax™, LLC

    HaloVax, LLC is a special purpose subsidiary of Voltron Therapeutics, Inc. in joint venture with Hoth Therapeutics, Inc. (NASDAQ:HOTH) The mission of HaloVax is to develop a novel, Self-Assembling Vaccine against COVID-19, utilizing technology licensed by Voltron Therapeutics, Inc. from the Vaccine and Immunotherapy Center at the Massachusetts General Hospital. The vaccine is being designed from a validated platform to provide customized T cell immunity against COVID-19, as well as be able to adapt rapidly to potential genetic drift of the virus. For more information, please visit www.HaloVax.com

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements

    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the VaxCelerate Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Voltron's current expectations and various assumptions. Voltron believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Voltron may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and any Voltron filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Voltron's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Voltron cannot guarantee future results, events, levels of activity, performance or achievements. Voltron does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Investor Contacts:

    Matt Duffy

    President

    Voltron Therapeutics, Inc.

    646-335-5923

    Jason Assad

    Investor Relations

    Voltron Therapeutics, Inc.

    678-570-6791

    Primary Logo

    View Full Article Hide Full Article
  18. NEW YORK, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. announced today the successful completion of its previously announced first small animal safety and immunogenicity study assessing the effect of novel Covid-19 vaccine HaloVax™. The vaccine construct was administered with positive response to the selected COVID-19 peptides in the self-assembling vaccine. Preliminary results of this study demonstrate initial proof of concept for the algorithm that was used to select immunogenic peptides.

    The Company previously announced it had initiated preclinical animal testing of the first construct of its HaloVax Self-Assembling Vaccine (SAV) against COVID-19, while intending to take two different vaccines, with differing sets…

    NEW YORK, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. announced today the successful completion of its previously announced first small animal safety and immunogenicity study assessing the effect of novel Covid-19 vaccine HaloVax™. The vaccine construct was administered with positive response to the selected COVID-19 peptides in the self-assembling vaccine. Preliminary results of this study demonstrate initial proof of concept for the algorithm that was used to select immunogenic peptides.

    The Company previously announced it had initiated preclinical animal testing of the first construct of its HaloVax Self-Assembling Vaccine (SAV) against COVID-19, while intending to take two different vaccines, with differing sets of targets forward, in order to identify the best balance of immune responses for prevention of this pandemic pathogen. The experience with the first construct will inform our design of the second vaccine construct.  HaloVax is being developed in conjunction with Hoth Therapeutics, Inc. (NASDAQ:HOTH).

    The vaccine is built on a base of a heat shock protein (HSP70) that activates the cellular portion of the immune system; this is different from most other vaccine efforts, which have used adjuvants such as alum. The second portion of the vaccine consists of peptides derived from the COVID-19 virus, which are bound to the heat shock protein via Avidin and Biotin. This enables rapid iteration and up-to-date data informed changes in the peptide sequences to enable swift production and accommodate potential changes or mutations in the pathogen itself. The selected immunogenic peptides complete the customized COVID-19 vaccine.

    Dr. Mark Poznansky, Director, Vaccine and Immunotherapy Center, Massachusetts General Hospital (MGH) stated, "The heat shock protein that is the immune activating component of our vaccine has previously shown efficacy in facilitating a productive immune response, while minimizing mechanisms known to induce adverse reactions to a vaccine. Our goal has always been to rapidly develop and test a vaccine that could help the population at large, and especially individuals who are at increased risk for the most serious complications of COVID-19 infection. With today's announcement of successful preclinical animal testing, we believe we continue to make material progress towards the potential success of our new COVID-19 vaccine."

    The vaccine is currently in development by HaloVax, LLC a biopharmaceutical company and special purpose subsidiary of Voltron Therapeutics, Inc. The company was established to advance an application of VaxCelerate, the SAV platform licensed from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH) specifically for the rapid development of vaccines against emerging pathogens including COVID-19 and specific types of cancer. The VaxCelerate platform was developed to improve patient outcomes by activating and targeting the immune system to identify and destroy the infectious agent. Voltron Therapeutics, Inc. has acquired an exclusive worldwide license to this technology from MGH.

    "Our team continues to work tirelessly to advance HaloVax as we continue the development and, potentially, deployment of a vaccine that will not only prevent disease, but will offer safe administration with a strong immune response," said Pat Gallagher, Chief Executive Officer, Voltron Therapeutics, Inc. "Our confidence is heightened by the recent completion of first small animal safety and immunogenicity study. "We are optimistic that given the kind of safety profile we are targeting in the development of HaloVax, this successful preclinical testing will rapidly lead to a final vaccine construct and human trials, which will bring us closer to a safe and effective vaccine to help prevent COVID-19 disease."

    About Voltron Therapeutics, Inc.

    Voltron Therapeutics, Inc., a Delaware corporation, was founded in 2017 to lead and accelerate the development of the Vaccine and Immunotherapy Center (VIC), and the Massachusetts General Hospital's novel Self Assembling Vaccine technology in a variety of indications, including in Oncology and emerging Infectious Diseases. Voltron holds an exclusive worldwide license to this technology. With the work of our world class team of researchers and physicians, this technology has shown in certain pre-clinical studies initial proof of concept in two infectious diseases (Lassa Fever and Q Fever) as well as two oncology indications (Ovarian and HPV Related Cancers). For more information please visit www.voltrontx.com.

    About HaloVax™, LLC

    HaloVax, LLC is a special purpose subsidiary of Voltron Therapeutics, Inc. in joint venture with Hoth Therapeutics, Inc. (NASDAQ:HOTH) The mission of HaloVax is to develop a novel, Self-Assembling Vaccine against COVID-19, utilizing technology licensed by Voltron Therapeutics, Inc. from the Vaccine and Immunotherapy Center at the Massachusetts General Hospital. The vaccine is being designed from a validated platform to provide customized T cell immunity against COVID-19, as well as be able to adapt rapidly to potential genetic drift of the virus. For more information, please visit www.HaloVax.com

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements

    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the VaxCelerate Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Voltron's current expectations and various assumptions. Voltron believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Voltron may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and any Voltron filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Voltron's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Voltron cannot guarantee future results, events, levels of activity, performance or achievements. Voltron does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Investor Contacts:

    Matt Duffy

    President

    Voltron Therapeutics, Inc.

    646-335-5923

    Jason Assad

    Investor Relations

    Voltron Therapeutics, Inc.

    678-570-6791

    Primary Logo

    View Full Article Hide Full Article
  19. NEW YORK, Sept. 1 , 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced  Dr. Stefanie Johns, who has agreed to join Hoth and serve as its Chief Scientific Officer, is scheduled to appear as a featured guest on One America News Network Tuesday, September 1, 2020 at 3:00pm ET.

    Interested parties can find One America News Network on the following national providers: AT&T U-verse – 208 (SD) and 1208 (HD), CenturyLink PRISM – 208 (SD) and 1208 (HD), DirecTV – 347, GCI – 64 (SD) and 703 (HD), and Verizon FiOS – 116 (SD) and 616 (HD).  Dr. Johns will talk about Hoth's recent announcement that it has licensed a real time, breath- based COVID-19 Mobile Testing Device.

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit https://ir.hoththerapeutics.com/.

    Forward-Looking Statement

    This press release includes forward-looking statements based upon Hoth's current expectationswhich may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

     

    Investor Contact:

    LR Advisors LLC

    Email:   

    www.hoththerapeutics.com

    Phone: (678) 570-6791 

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-chief-scientific-officer-dr-stefanie-johns-to-appear-on-one-america-news-network-on-tuesday-september-1-2020-301121590.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  20. NEW YORK, Aug. 31, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company, today announces the appointment of Stefanie Johns, Ph.D., to the position of Chief Scientific Officer, effective September 2020. In her role, Dr. Johns will further advance Hoth's pipeline through both preclinical and clinical stages. 

    "It's our pleasure and privilege to have Dr. Johns join us, as she brings a rare combination of clinical and medical affairs proficiency from her previous work," said Robb Knie, Chairman and CEO of Hoth. "She will be a vital resource for our inventors, Scientific Advisory Board, and the entire Hoth team as we continue to build momentum toward executing our corporate vision of bringing novel treatments to the patients who need them."

    Dr. Johns has worked in the biopharmaceutical and medical device industries for over 8 years, with development experience across drug, biologic, medical devices, and in vitro diagnostic device products in US and global markets. Prior to joining Hoth, Dr. Johns served as Director of Regulatory Affairs at Enable Injections, Inc., where she led the global regulatory strategy for the subcutaneous drug delivery device platforms. As a consultant at Camargo Pharmaceutical Services, Dr. Johns provided strategic regulatory and development guidance on over 30 505(b)(2) drug and drug-device combination product programs spanning the Dermatology, Cardiovascular and Renal, Gastroenterology, Pulmonary, Neurology, Oncology, Anesthesiology/Pain, Psychiatry, Urology/Gynecology, and Rare Disease Divisions at FDA. Dr. Johns was also a contributing scientist in the development of the Hoth BioLexa Platform technology, scheduled to enter clinical trials in Q4 2020, and has served on the Hoth Scientific Advisory Board since March 2019, providing strategic regulatory guidance across the pipeline portfolio. Dr. Johns received her Ph.D. in protein biochemistry from the University of Cincinnati and a B.S. in Biological Sciences from Wright State University.   

    "Hoth Therapeutics has developed a diverse pipeline with innovative therapeutic potential and I look forward to using my industry experience to help drive advancement of the existing programs and continue expanding the pipeline portfolio. I am honored to serve as Chief Scientific Officer and contribute to Hoth's mission to develop a new generation of therapies," said Dr. Stefanie Johns.

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com.

    Forward-Looking Statement

    Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including statements regarding the proposed offering, timing and the use of proceeds. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this press release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company's filings with the Securities and Exchange Commission. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

    Investor Contact:

    LR Advisors LLC

    Email:  

    www.hoththerapeutics.com

    Phone: (678) 570-6791  

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-appoints-stefanie-johns-phd-as-chief-scientific-officer-301120700.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  21. NEW YORK, Aug. 28, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced that Chief Executive Officer, Robb Knie, is scheduled to present at the following investor conferences in September:

    The LD 500 Virtual Investor Conference

    September 3, 2020 at 12:20 p.m. ET

    Registration: https://www.webcaster4.com/Webcast/Page/2019/36780 

    H.C. Wainwright & Co. 22nd Annual Global Investment Conference 2020

    September 16, 2020 at 1:30 p.m. ET

    Registration: https://www.meetmax.com/sched/event_61861/investor_login.html?attendee_role_id=INVESTOR  

    Sidoti & Company 2020 Fall Virtual Investor Conference

    September 23, 2020 at 2:30 p.m. ET

    Registration: https://sidoti.meetmax.com/sched/event_63793/conference_register.html?attendee_role_id=SIDOTI_INVESTOR 

    Management will be available for 1x1 meetings with investors throughout each event. Please contact your conference representative to schedule a meeting. To stay up to date on upcoming events please check our calendar regularly: https://ir.hoththerapeutics.com/events/category/events/

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please click here.

    Investor Contact:

    LR Advisors LLC

    Email:  

    www.hoththerapeutics.com

    Phone: (678) 570-6791  

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-announces-participation-at-upcoming-investor-conferences-in-september-301120459.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  22. Featuring

    • Michael V. Callahan, MD, MSPH, DTM&H (U.K), Massachusetts General Hospital (MGH) Infectious Disease and Director, Clinical Translation and Mass-Casualty Therapeutics at the Vaccine and Immunotherapy Center (VIC)
    • Mark Poznansky, MD, PhD, Director of the VIC at MGH
    • Patrick Reeves, PhD, Team Leader at the VIC

    NEW YORK, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Laidlaw Venture Partners, the venture capital arm of Laidlaw & Company (UK) Ltd., today announced that on Monday, August 24, 2020, it held a panel discussion titled "Cutting Edge Perspectives on the Latest Developments in COVID-19 Vaccine Development Strategy."

    An online replay of the presentation is available here: Click Here

    Panel discussion topics included (times during the recording…

    Featuring

    • Michael V. Callahan, MD, MSPH, DTM&H (U.K), Massachusetts General Hospital (MGH) Infectious Disease and Director, Clinical Translation and Mass-Casualty Therapeutics at the Vaccine and Immunotherapy Center (VIC)
    • Mark Poznansky, MD, PhD, Director of the VIC at MGH
    • Patrick Reeves, PhD, Team Leader at the VIC

    NEW YORK, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Laidlaw Venture Partners, the venture capital arm of Laidlaw & Company (UK) Ltd., today announced that on Monday, August 24, 2020, it held a panel discussion titled "Cutting Edge Perspectives on the Latest Developments in COVID-19 Vaccine Development Strategy."

    An online replay of the presentation is available here: Click Here

    Panel discussion topics included (times during the recording):

    • COVID-19 Vaccine Focus of Operation Warp Speed – are our bases covered? (4:45)
    • Have S-Protein neutralizing antibodies in recovered patients or in convalescent plasma trials proven to be protective, to date? (14:25)
    • Importance of T-cells in Vaccine Generated Immunity to COVID-19.  (19:30)
    • Should we be concerned with potential ADE (Antibody-mediated Disease Enhancement)?  (25:15)
    • The HaloVax™ Self Assembling Vaccine – a novel approach to pandemic preparedness.  (33:00)

    "This panel of world leaders in immunology and vaccine technology brings unique perspective on critical issues facing vaccine developers.  Our novel approach with HaloVax, our self-assembling vaccine against COVID-19 attempts to capitalize on these vital insights," said Patrick Gallagher, CEO of Voltron Therapeutics, Inc.  HaloVax is being developed in conjunction with Hoth Therapeutics, Inc. (NASDAQ:HOTH).

    "As we continue to build our portfolio companies it is imperative that we tap global experts for their years of knowledge and service in this space," said Matthew Eitner, Chief Executive Officer, Laidlaw & Company (UK) Ltd. "We are thrilled to have Michael V. Callahan, MD, MSPH, DTM&H (U.K), Mark Poznansky, MD, PhD, and Patrick Reeves, PhD join this important panel, sharing their expertise and experience."

    About Voltron Therapeutics, Inc.

    Voltron Therapeutics, Inc., a Delaware corporation, was founded in 2017 to lead and accelerate the development of the Vaccine and Immunotherapy Center (VIC), and the Massachusetts General Hospital's novel Self Assembling Vaccine technology in a variety of indications, including in Oncology and emerging Infectious Diseases. Voltron holds an exclusive worldwide license to this technology. With the work of our world class team of researchers and physicians, this technology has shown in certain pre-clinical studies initial proof of concept in two infectious diseases (Lassa Fever and Q Fever) as well as two oncology indications (Ovarian and HPV Related). For more information please visit www.voltrontx.com.

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. To learn more, please visit www.hoththerapeutics.com.

    About Laidlaw & Company 

    Laidlaw & Company is a full-service investment banking and brokerage firm offering personalized investment advice and skillful execution to private institutions, public institutions, and high net worth individual investors.

    Laidlaw & Company (U.K.) Ltd., a broker-dealer registered with FINRA in the United States, clears on a fully disclosed basis through INTL FCStone Financial Inc., a member of the Securities Investor Protection Corporation (SIPC). Laidlaw & Company International Limited, an affiliate of Laidlaw & Company, is authorized by the Financial Conduct Authority (FCA) in the United Kingdom.

    Laidlaw Wealth Management is an affiliate of, and Laidlaw Venture Partners is a DBA, of Laidlaw & Company.

    For more information, please visit: https://laidlawltd.com/

    Contact:

    Matt Duffy, Managing Partner

    646-335-5923

    Media:

    Jason Assad

    LR Advisors LLC.

    678-570-6791

     

    Primary Logo

    View Full Article Hide Full Article
  23. NEW YORK, Aug. 19, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today is providing shareholders with a update on its COVID-19 initiatives including vaccine and real-time, breath-based mobile testing device as well as its dermatological therapy pipeline.  

    Mr. Robb Knie, Chief Executive Officer of Hoth, commented, "By leveraging our platform, expertise and strategic relationships, we have made significant progress in advancing our robust therapeutics pipeline. Additionally, we've been able to invest in strategic, undervalued assets – all amidst the ongoing global pandemic. Since inception, we have acquired the rights to assets that addresses global issues, via our partnership for a COVID-19 vaccine, novel peptides and medical device. While continuing to evaluate these assets, we recently submitted for ethics board approval in Australia for our lead therapy candidate, BioLexa, for Atopic Dermatitis, to launch our clinical study in humans during the second half of this year. Going forward, we have several initiatives that we believe will help enhance shareholder value."

    Dermatological Therapeutics Pipeline:

    The BioLexa Platform, Hoth's leading therapy candidate, is a proprietary antimicrobial therapy designed for the treatment of atopic dermatitis or eczema, through a non-corticosteroid approach. Recently, Hoth submitted its planned clinical study for approval of BioLexa treatment of Atopic Dermatitis to the Bellberry Human Research Ethics Committee in Australia. Hoth anticipates to begin the study during the second half of 2020.

    Hoth has executed a licensing agreement with Isoprene Pharmaceuticals, Inc. to acquire the rights to VNLG-152, a novel retinamides (Retinoic acid metabolism blocking agents, or RAMBAs) for the treatment of dermatological diseases. Hoth is exploring whether VNLG-152 is capable of blocking this inflammatory response. Immediately after identifying an effective dose of VNLG-152, the researchers will conduct studies on mouse skin to determine if this drug is effective in blocking acne-like inflammation. As the Weill Cornell lab reopens later this month Hoth is working closely with the Weill Cornell lab to finalize the results of its preclinical work.

    The Company entered into a further research agreement with the George Washington University (GW) to explore the potential use of WEG-232 for topical and/or systemic therapy to counter the dermatological related side-effects of Erlotinib therapy in cancer patients. Erlotinib is a drug that is used to combat various cancers and has been known to cause varying degrees of skin rashes, lesions, hair loss and nail changes to patient. A recent animal research study suggested the topical application of WEG-232 could be very effective in suppressing erlotinib induced-facial rash/hair loss with approximate 71% reduction. Hoth has partnered with Tergus to produce GMP materials in hopes of a Pre-IND consultation with the FDA before year end.

    Gene Therapy

    After COVID-19 delays the Company has begun the initiation of a preclinical study for the treatment of asthma and allergic inflammation in collaboration with North Carolina State University (NC State). The study has begun the delivery and distribution of nebulized particles which will enable the therapeutic oligonucleotide (oligo), short DNA and RNA molecules that have a wide range of applications in gene testing. Hoth has appointed Dr. Glenn Cruse to its Scientific Advisory Board and will oversee the Company's gene therapy program's advancements. Hoth also entered into a licensing agreement with North Carolina State University (NC State) to study NC State's Exon Skipping Approach for Treating Allergic Diseases. This Exon Skipping Approach was developed by Dr. Glenn Cruse, Principal Investigator and Assistant Professor in the Department of Molecular Biomedical Sciences at the NC State College of Veterinary Medicine. During Dr. Cruse's research, a new approach for the technique of antisense oligonucleotide-mediated exon skipping to specifically target and down-regulate IgE receptor expression in mast cells was identified. These findings set a breakthrough for allergic diseases as they are driven by the activation of mast cells and the release of mediators in response to IgE-directed antigens.

    COVID-19 Initiatives:

    Hoth also recently licensed the intellectual property rights relating to the development of a medical device that has the potential to allow public health professionals to immediately diagnose COVID-19 infection via breath sample and track through a mobile device from the George Washington University ('GW').  Hoth is working to share further data about the device and determine how few virus particles can be detected using the device to help counteract spread and allow for quicker and more efficient testing and tracing.  The laboratory team at GW will consist not only of virologists but of engineers and engineering postdoctoral students, all of whom have to be trained to handle deactivated pathogens to help speed the development of this program. 

    VaxCelerate is a self-assembling vaccine (SAV) platform designed to protect patients at risk of COVID-19 infection believed to offer unique advantages over other compounds in combination therapy. In infectious applications, it allows rapid development against viruses and other pathogens. Preclinical animal testing of the first construct of VaxCelerate against COVID-19 has commenced. Hoth believes, along with its joint venture partner HaloVax, to have results of this animal study and additional next steps in early Q4 2020.

    Additionally, Hoth has licensed the technology and intellectual property for a novel peptide therapeutic to prevent spike protein binding, which may be a leading cause of COVID-19, and potentially slow its transmission. Dr. Michael Peters at VCU has begun further pre-clinical testing through a Scientific Research Agreement that Hoth executed with VCU.

    Hoth filed its Form 10-Q with the Securities and Exchange Commission for the period ended June 30, 2020 on August 13, 2020.

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com.

    Forward-Looking Statement

    Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including statements regarding the proposed offering, timing and the use of proceeds. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this press release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company's filings with the Securities and Exchange Commission. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

    Investor Contact:

    LR Advisors LLC

    Email:  

    www.hoththerapeutics.com

    Phone: (678) 570-6791 

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-provides-shareholder-update-on-covid-19-initiatives-and-dermatological-therapy-pipeline-301114759.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  24. NEW YORK, Aug. 13, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has submitted for ethics approval in Australia for its planned Clinical study of its therapeutic BioLexa for Atopic Dermatitis. The ethics submission was made to the Bellberry Human Research Ethics Committee in Australia.

    Hoth's proposed study will be a Randomised, Double-Blind, Vehicle Controlled, Sequential Group Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Application of Topical BioLexa in Healthy Subjects and Patients with Mild to Moderate Atopic Dermatitis.

    Mr. Robb Knie, Chief Executive Officer of Hoth, stated, "Thanks to the hard work of our team and CRO partner Novotech, this ethics submission is yet another important step in the Company's clinical development program." 

    BioLexa is a proprietary antimicrobial therapy designed for the treatment of atopic dermatitis. The therapeutic offers a non-corticosteroid approach in treating atopic dermatitis. 

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com

    Forward-Looking Statement

    Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including statements regarding the proposed offering, timing and the use of proceeds. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this press release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company's filings with the Securities and Exchange Commission. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

    Investor Contact:

    Email: 

    www.hoththerapeutics.com 

    Phone: (678) 570-6791  LR Advisors LLC

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutic-announces-that-it-has-submitted-its-request-to-australia-ethics-board-to-begin-clinical-trial-of-biolexa-for-atopic-dermatitis-301111852.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  25. NEW YORK, Aug. 10, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced licensing the intellectual property rights relating to the development of a medical device that has the potential to allow public health professionals to immediately diagnose COVID-19 infection via breath sample and track through a mobile device from the George Washington University ('GW').

    Dr. Mona E. Zaghloul, a professor of Electrical and Computer Engineering at GW School of Engineering and Applied Science, and her former doctoral student Yangyang Zhao, developed the design of the device, based on prior work of other former students, in collaboration with the National Institute of Standards and Technology to detect and distinguish different species of gas. The device is based on nanotechnology Nanoholes using Plasmonics principles. The surface of the device is covered in a thin sheet of gold that can bind with other molecules, like those of a gas. Once the binding occurs, the wavelength of light bouncing off the surface changes, creating a different color of light. Different gases would cause different shifts in light. The results can be available quickly, and artificial intelligence programs can then classify the molecules that are bound to the surface of the device. The results, including the different classes of the molecules, can then be sent to the cloud by a mobile device, allowing the ability to track the data. 

    Dr. Jeanne A. Jordan, PhD, a professor in Epidemiology at the GW Milken Institute School of Public Health, was instrumental in recognizing the potential diagnostic capabilities of the technology. As the COVID-19 pandemic spread, she suggested alterations to the device.  The researchers believe that the modified apparatus, which is as small as a strand of hair, can be coated with a solution designed to bind specifically to the SARS-CoV-2 virus that causes COVID-19.  This design would allow the virus to bind to the surface, thereby allowing for the detection of an optical change that could immediately be sensed by phone cameras when an infected person's specimen is applied.

    The research by Dr. Zaghloul and Dr. Jordan was funded by a COVID-19 Technology Maturation Grant from GW's Technology Commercialization Office to accelerate the development of this medical device. The device would allow communities to build trackable real-time databases of infection. People can upload information directly to the cloud.

    "These are devices that a public health professional could go out with into the field to administer point-of-care testing, either at a walk-up center or directly in the community," Dr. Jordan said. "They're extremely rapid—the turnaround time to having test results is within minutes, and you do the testing right there instead of having to send your sample to a large commercial laboratory with a massive backlog. That would allow these professionals to say immediately if someone needs to be quarantined, and to get the names of their contacts so they can start contact tracing."

    Mr. Robb Knie, Chief Executive Officer of Hoth, stated, "The immediate diagnosis and ongoing tracking of COVID-19 is a critical initiative towards mitigating the ongoing spread of COVID-19.  This device which is under development would allow users to conduct widespread testing and provide instantaneous results through the administration of a breath sample and tracking through a mobile device. Securing the rights to this paradigm shifting technology in the fight against the global COVID-19 pandemic is a significant opportunity for Hoth and its shareholders.  We look forward to working with the team at GW to accelerate the development of this breakthrough technology."

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com.

    Forward-Looking Statement

    Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including statements regarding the proposed offering, timing and the use of proceeds. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this press release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company's filings with the Securities and Exchange Commission. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

    Investor Contact:

    Email:  

    www.hoththerapeutics.com 

    Phone: (678) 570-6791  LR Advisors LLC

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-licenses-intellectual-property-to-develop-real-time-breath-based-covid-19-mobile-testing-device-301108911.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  26. NEW YORK, July 31, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has executed a licensing agreement with Isoprene Pharmaceuticals, Inc. to acquire the rights to VNLG-152, a novel retinamides (Retinoic acid metabolism blocking agents, or RAMBAs) for the treatment of dermatological diseases. Isoprene is a cancer therapeutic company that is a University of Maryland, Baltimore New Venture Initiative start-up.

    This agreement, which formalizes the previously announced Letter of Intent between the two companies, will also grant Hoth royalty payments from Isoprene for any use of its VNLG-152 including Oncology.

    Researchers at the University of Maryland Baltimore discovered novel retinamide RAMBAs and validated their therapeutic utility in animal models of breast and prostate cancer. RAMBAs inhibit the cellular enzyme that metabolizes all-trans retinoic acid (ATRA), which actively directs cells to mature in a controlled manner to ensure normal growth.

    In addition to enhancing the beneficial effects of ATRA, the mechanism of action for these RAMBAs has been shown to involve degradation of Mnk 1/2 and suppression of the oncogenic eIF4E pathway. For potential use in treating dermatological conditions, UMB researchers obtained promising early results demonstrating that lead retinamide RAMBAs have equal or superior effects over approved retinoids (ATRA and 13-CRA) to inhibit proliferation of normal human adult keratinocytes and sebocytes, and antikeratinizing effects in reconstructed human epidermis. Initial toxicity profiles for a panel of RAMBAs [Njar et al., 2006] also showed good indications for safe therapeutic use.

    These novel RAMBAs block the normal metabolism of endogenous ATRA in cells, increasing the beneficial effects of ATRA. They provide a unique approach to achieve the therapeutic benefit of retinoid therapy while potentially circumventing the adverse events associated with it, a very important property for application to dermatology therapy. ATRA deficiencies are associated with dermatological diseases (acne and psoriasis), and retinoid derivatives have been one of the mainstay therapies for acne. Liarozole is in clinical use for the treatment of psoriasis and ichthyosis. Dermatological retinoid deficiencies are characterized by hyperkeratinization and desquamation and include diseases such as acne, eczema, psoriasis, cold sores, wounds, burns, sunburn, ichthyosis, skin cancer, and Kaposi's Sarcoma, all of which are plausible targets for retinamide RAMBA therapy.

    Mr. Robb Knie, Chief Executive Officer of Hoth, commented, "Hoth is pleased to finalize this licensing agreement of a novel therapy that has shown such promise in targeting such a wide array of dermatological afflictions.  This latest license agreement reinforces Hoth's commitment to developing novel therapies for multiple skin diseases."

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com.

    Forward-Looking Statement

    Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including statements regarding the proposed offering, timing and the use of proceeds. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this press release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company's filings with the Securities and Exchange Commission. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

    Investor Contact:

    Phone: (646) 756-2997

    Email:  

    www.hoththerapeutics.com

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-executes-licensing-agreement-of-vnlg-152-for-treatment-of-dermatological-diseases-301103754.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  27. Over 100 Presenting Companies Have Already Registered

    NEW YORK, NY / ACCESSWIRE / July 30, 2020 / Sidoti, among the preeminent providers of independent securities research to small- and micro-cap companies with about 200 names under coverage, is pleased to announce that its Fall 2020 Virtual Investor Conference is now open for presenting companies and investor attendees. Our Biannual Investor Conference has become a leading forum for small-cap companies to interface with investors specifically interested in the small-cap equities. At our last Biannual Investor Conference, we had:

    • 132 presenters
    • 743 registered investors
    • 1,137 one-on-one meetings
    • Approximately 9 one-on-one meetings per company on average

    This year's Fall conference will be held virtually…

    Over 100 Presenting Companies Have Already Registered

    NEW YORK, NY / ACCESSWIRE / July 30, 2020 / Sidoti, among the preeminent providers of independent securities research to small- and micro-cap companies with about 200 names under coverage, is pleased to announce that its Fall 2020 Virtual Investor Conference is now open for presenting companies and investor attendees. Our Biannual Investor Conference has become a leading forum for small-cap companies to interface with investors specifically interested in the small-cap equities. At our last Biannual Investor Conference, we had:

    • 132 presenters
    • 743 registered investors
    • 1,137 one-on-one meetings
    • Approximately 9 one-on-one meetings per company on average

    This year's Fall conference will be held virtually over two days, September 23-24, 2020. In June, we hosted our first virtual event specifically targeted to micro-cap companies and the feedback we received was excellent. The on-line nature of the conference enabled us to draw from a much more geographically disbursed audience than at a typical "on-site" event. We expect that companies presenting in the Fall will realize these same benefits, as a greater number of our 500+ institutional investor clients should be able to "attend," as should our growing list of family office, high net worth, hedge fund and registered investment advisor attendees. Already, the response to our September event has been robust. Over 100 companies have registered to present, as shown in the list below. If you are interested in learning more about our event and/or registering (as presenter or investor), please visit www.sidoticonference.com or contact our Events Team, at email or number below. We look forward to seeing you virtually in September!

    About Sidoti

    For over two decades, Sidoti has been a premier provider of independent securities research focused specifically on small- and micro-cap companies and the institutions that invest their securities, with most of our coverage in the $100 million - $3 billion market cap range. Our approach affords companies and institutional investor clients a combination of high-quality research, a small- and micro- cap focused nationwide sales effort, broad access to corporate management teams, and extensive trading support. We serve 500+ institutional clients in the U.S., Canada, and the U.K., including many leading managers of portfolios with $200 million to $2 billion of assets under management. Sidoti promotes meaningful interaction between issuers and investors in the small and micro-cap space through our conferences (www.sidoticonference.com) and the hundreds of non-deal roadshows we host each year.

    Contact:

    Sidoti Events Team
    212-453-7031

    SOURCE: Sidoti & Company, LLC



    View source version on accesswire.com:
    https://www.accesswire.com/599472/Registration-for-Sidotis-2020-Fall-Virtual-Investor-Conference-is-Now-Open

    View Full Article Hide Full Article
  28. NEW YORK , July 09, 2020 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. (the Company) announced today it has retained Buenaventura Advisors, LLC to explore strategic alternatives for HaloVax, a biopharmaceutical company and special purpose subsidiary of Voltron Therapeutics, Inc.  HaloVax was formed to develop a novel, self-assembling vaccine against COVID-19 utilizing technology licensed from the Vaccine and Immunotherapy Center at Harvard's Massachusetts General Hospital. The vaccine is being developed in conjunction with Hoth Therapeutics, Inc (NASDAQ:HOTH).

    The HaloVax product development technology is in initial animal testing and it is now seeking strategic opportunities to provide the resources necessary to accelerate development…

    NEW YORK , July 09, 2020 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. (the Company) announced today it has retained Buenaventura Advisors, LLC to explore strategic alternatives for HaloVax, a biopharmaceutical company and special purpose subsidiary of Voltron Therapeutics, Inc.  HaloVax was formed to develop a novel, self-assembling vaccine against COVID-19 utilizing technology licensed from the Vaccine and Immunotherapy Center at Harvard's Massachusetts General Hospital. The vaccine is being developed in conjunction with Hoth Therapeutics, Inc (NASDAQ:HOTH).

    The HaloVax product development technology is in initial animal testing and it is now seeking strategic opportunities to provide the resources necessary to accelerate development of the vaccine and maximize shareholder value. Buenaventura will counsel the Company on the exploration of strategic alternatives including licensing, co-development opportunities and possible outright sale.

    The vaccine has been developed using unique proprietary technology to create a differentiated immune response to the COVID-19 virus. 

    "The team at Voltron and MGH has made tremendous progress in designing, manufacturing and initiating testing on our novel COVID-19 vaccine" stated Pat Gallagher, CEO of Voltron Therapeutics.  "Given the importance of our approach to the COVID pandemic, we would like to devote the resources required to move the vaccine into human testing as rapidly and safely as possible."

    About Voltron Therapeutics, Inc.

    Voltron Therapeutics, Inc., a Delaware corporation, was founded in 2017 to lead and accelerate the development of the Vaccine and Immunotherapy Center (VIC), and the Massachusetts General Hospital's novel Self Assembling Vaccine technology in a variety of indications, including in Oncology and emerging Infectious Diseases. Voltron holds an exclusive worldwide license to this technology.  With the work of our world class team of researchers and physicians, this technology has shown in certain pre-clinical studies initial proof of concept in two infectious diseases (Lassa Fever and Q Fever) as well as two oncology indications (Ovarian and HPV Related).  For more information please visit www.voltrontx.com.

    About HaloVax™, LLC

    HaloVax, LLC is a special purpose subsidiary of Voltron Therapeutics, Inc.  The mission of HaloVax is to develop a novel, Self-Assembling Vaccine against COVID-19, utilizing technology licensed by Voltron Therapeutics, Inc. from the Vaccine and Immunotherapeutics Center at the Massachusetts General Hospital.  The vaccine is being designed from a validated platform to provide customized cellular immunity against COVID-19, as well as be able to adapt rapidly to potential genetic drift of the virus.  For more information, please visit www.HaloVax.com. 

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements

    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the VaxCelerate Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Voltron's current expectations and various assumptions. Voltron believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Voltron may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and any Voltron filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Voltron's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Voltron cannot guarantee future results, events, levels of activity, performance or achievements. Voltron does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Media Contact:

    Matt Pennacchio

    516-851-4766

    Investor Contact:



    Matt Duffy, President

    646-335-5923

    Primary Logo

    View Full Article Hide Full Article
  29. NEW YORK, July 08, 2020 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. announced today it has initiated preclinical animal testing of the first construct of its HaloVax Self-Assembling Vaccine (SAV) against COVID-19. Voltron will take two different vaccines, with differing sets of targets into preclinical testing, in order to identify the best balance of immune responses for prevention of this pandemic pathogen. HaloVax is being developed in conjunction with Hoth Therapeutics, Inc. (NASDAQ:HOTH).

    The vaccine is built on a base of a heat shock protein (HSP70) that activates the cellular portion of the immune system; this is different from most other vaccine efforts, which have used adjuvants such as alum. The second portion of the vaccine…

    NEW YORK, July 08, 2020 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. announced today it has initiated preclinical animal testing of the first construct of its HaloVax Self-Assembling Vaccine (SAV) against COVID-19. Voltron will take two different vaccines, with differing sets of targets into preclinical testing, in order to identify the best balance of immune responses for prevention of this pandemic pathogen. HaloVax is being developed in conjunction with Hoth Therapeutics, Inc. (NASDAQ:HOTH).

    The vaccine is built on a base of a heat shock protein (HSP70) that activates the cellular portion of the immune system; this is different from most other vaccine efforts, which have used adjuvants such as alum. The second portion of the vaccine consists of peptides derived from the COVID-19 virus, which are bound to the heat shock protein via Avidin and Biotin. This enables rapid iteration and up-to-date data informed changes in the peptide sequences to enable swift production and accommodate potential changes in the pathogen itself. The selected immunogenic peptides complete the customized COVID-19 vaccine.

    Dr. Mark Poznansky, Director, Vaccine and Immunotherapy Center, MGH said, "The heat shock protein that is the immune activating component of our vaccine has shown efficacy in facilitating a productive immune response while minimizing mechanisms known to induce adverse reactions to a vaccine. Our goal is to rapidly develop and test a vaccine that could help the population at large, and especially individuals who are at increased risk for the most serious complications of COVID-19 infection. Preclinical testing begins here and the fact that prior animal testing of our vaccine platform in the context of other infections has been successful increases the probability of success with our new COVID-19 vaccine."

    The vaccine is currently in development by HaloVax, LLC a biopharmaceutical company and special purpose subsidiary of Voltron Therapeutics, Inc. The company was established to advance an application of VaxCelerate, the SAV platform licensed from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH) specifically for the rapid development of vaccines against emerging pathogens including COVID-19 and specific types of cancer. The VaxCelerate platform was developed to improve patient outcomes by activating and targeting the immune system to identify and destroy the infectious agent. Voltron Therapeutics, Inc. has acquired an exclusive worldwide license to this technology from MGH.

    "Our team has worked tirelessly to bring HaloVax into preclinical testing, as we continue the development and, potentially, deployment of a vaccine that will not only prevent disease, but will offer safe administration with a strong immune response," said Pat Gallagher, Chief Executive Officer, Voltron Therapeutics, Inc. "We are quite optimistic that given the kind of safety profile we are targeting in the development of HaloVax, that successful preclinical testing will rapidly lead to clinical trials in humans and bring us closer to a proven and effective vaccine to help treat COVID-19 infection."

    About Voltron Therapeutics, Inc.

    Voltron Therapeutics, Inc., a Delaware corporation, was founded in 2017 to lead and accelerate the development of the Vaccine and Immunotherapy Center (VIC), and the Massachusetts General Hospital's novel Self Assembling Vaccine technology in a variety of indications, including in Oncology and emerging Infectious Diseases. Voltron holds an exclusive worldwide license to this technology. With the work of our world class team of researchers and physicians, this technology has shown in certain pre-clinical studies initial proof of concept in two infectious diseases (Lassa Fever and Q Fever) as well as two oncology indications (Ovarian and HPV Related Cancers). For more information please visit www.voltrontx.com.

    About HaloVax™, LLC

    HaloVax, LLC is a special purpose subsidiary of Voltron Therapeutics, Inc. in joint venture with Hoth Therapeutics, Inc. (NASDAQ:HOTH) The mission of HaloVax is to develop a novel, Self-Assembling Vaccine against COVID-19, utilizing technology licensed by Voltron Therapeutics, Inc. from the Vaccine and Immunotherapy Center at the Massachusetts General Hospital. The vaccine is being designed from a validated platform to provide customized T cell immunity against COVID-19, as well as be able to adapt rapidly to potential genetic drift of the virus. For more information, please visit www.HaloVax.com

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements

    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the VaxCelerate Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Voltron's current expectations and various assumptions. Voltron believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Voltron may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and any Voltron filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Voltron's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Voltron cannot guarantee future results, events, levels of activity, performance or achievements. Voltron does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Media Contact:

    Matt Pennacchio

    516-851-4766

    Investor Contacts:

    Matt Duffy

    President

    Voltron Therapeutics, Inc.

    646-335-5923

    Jason Assad

    Voltron Therapeutics, Inc.

    Investor Relations

    678-570-6791

    Primary Logo

    View Full Article Hide Full Article
  30. NEW YORK, June 30, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced entering into a sponsored research agreement with Virginia Commonwealth University (VCU) for a potential COVID-19 treatment.

    Research will operate under the direction of Dr. Michael Peters to develop and optimize peptide biomimetics in order to achieve high binding rates of peptide to the RBD of SARS-Cov-2 spike protein at the nanomolar level with demonstrated negligible toxicity through combined computational and experimental efforts. Specifically, point mutations will be conducted in-silico in order to seek to improve the stability and binding properties of these decoy peptides. These optimized, in-silico peptides will be synthesized and experimentally characterized through structure determination, binding to the spike protein, and finally cell challenge assays with SARS-Cov-2.  Hoth Therapeutics has exclusive license to this novel peptide COVID-19 therapeutic.

    "VCU, through the leadership of Dr. Michael Peters, has made significant strides in the research of the COVID-19 disease," said Mr. Robb Knie, CEO of Hoth Therapeutics.  "We look forward to working with VCU in accelerating progress on the development of this intellectual property and in establishing novel treatments to combat the pandemic."

    Currently, Dr. Peters is utilizing supercomputers as part of the COVID-19 High Performance Computing (HPC) Consortium through the Extreme Science and Engineering Discovery Environment (XSEDE), a virtual system that scientists can use to interactively share computing resources. The consortium is a private-public partnership that includes the White House Office of Science and Technology Policy and major tech corporations.

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com.

    Forward-Looking Statement

    Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including statements regarding the proposed offering, timing and the use of proceeds. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this press release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company's filings with the Securities and Exchange Commission. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

    Investor Contact:

    Phone: (646) 756-2997

    Email:  

    www.hoththerapeutics.com

    KCSA Strategic Communications

    Valter Pinto, Managing Director

    (212) 896-1254

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-announces-sponsored-research-agreement-with-vcu-for-potential-covid-19-treatment-301085873.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  31. NEW YORK, June 16, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company, today announced that it has expanded its sponsored research agreement with the George Washington University (GW) to explore the potential use of WEG232 for topical and/or systemic therapy to counter the dermatological related side-effects of chemotherapy and immunotherapy in cancer patients.

    The company has increased its commitment to further the science behind this therapeutic with Dr. William Wegliki's lab at GW.  Hoth intends to request a Pre-IND meeting with the FDA by year-end. 

    Hoth continues to develop topical WEG232 formulation for treatment of mild to moderate (grades 1-3) rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor (EGFR) inhibitor therapy. A recent research study suggested the topical application of WEG232 could be very effective in suppressing erlotinib induced-facial rash/hair loss with approximate 71% reduction. It concluded that WEG232 may be used as an effective intervention to prevent EGFR-TKI-induced cutaneous toxicity. 

    Future studies will include:

    • Determining the optimal treatment or pretreatment time of application and the weekly number of applications, eg. 2 or 3/week, of WEG232 to prevent the occurrence of the anticipated skin rash/hair loss.
    • Determine at the facial skin level if differentially effective topical applications correlate with the extent of suppressed SP-mediated neurogenic inflammation.
    • Determine any impact the topical WEG232 application may have on the indicators of systemic neurogenic inflammation and oxidative stress.

    "We are pleased to broaden our relationship with the George Washington University as we continue to make great strides in bringing a much needed therapeutic to patients struggling with the many side effects of chemo and immunotherapy," stated Mr. Robb Knie, CEO of Hoth Therapeutics. 

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com.

    Forward-Looking Statement

    Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including statements regarding the proposed offering, timing and the use of proceeds. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this press release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company's filings with the Securities and Exchange Commission. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

    Investor Contact:

    Phone: (646) 756-2997

    Email: 

    www.hoththerapeutics.com

    KCSA Strategic Communications

    Valter Pinto, Managing Director

    (212) 896-1254

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-enters-into-expanded-sponsored-research-agreement-with-the-george-washington-university-for-dermatology-treatment-candidate-weg232-301077812.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  32. NEW YORK, June 15, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Scientific Advisory Board member and inventor of novel peptide COVID-19 therapeutic, Michael H. Peters, Ph.D., Professor, Department of Chemical and Life Science Engineering at VCU, College of Engineering, has published a white paper detailing his mappings of the COVID-19 virus and its spike protein.

    Hoth has licensed technology and intellectual property exclusively from VCU for a novel peptide therapeutic to prevent spike protein binding, which may be a leading cause of COVID-19, and slow its transmission.

    The spike in protein plays an important role in attaching to human cells and infecting the body. Researchers at VCU have developed at novel peptide that binds with extremely high affinity to SD1 segment of the SARS-CoV-2 spike protein mimicking its attachment to ACE2. This high binding affinity helps block the spike protein from attaching to the ACE2 surface receptor, thus limiting the transmission of the virus.

    The SARS-Cov-2 virion responsible for the current world-wide pandemic COVID-19 has a characteristic Spike protein (S) on its surface that embellishes both a prefusion state and fusion state. The prefusion Spike protein (S) is a large trimeric protein where each protomer may be in a so-called Up state or Down state, depending on the configuration of its receptor binding domain (RBD). The Up state is believed to allow binding of the virion to ACE-2 receptors on human epithelial cells, whereas the Down state is believed to be relatively inactive or reduced in its binding behavior. 

    Currently, Peters is utilizing supercomputers as part of COVID-19 High Performance Computing (HPC) Consortium through the Extreme Science and Engineering Discovery Environment (XSEDE), a virtual system that scientists can use to interactively share computing resources. The consortium is a private-public partnership that includes the White House Office of Science and Technology Policy and major tech corporations.

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com.

    Forward-Looking Statement

    Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including statements regarding the proposed offering, timing and the use of proceeds. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this press release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company's filings with the Securities and Exchange Commission. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

    Investor Contact:

    Phone: (646) 756-2997

    Email:  

    www.hoththerapeutics.com

    KCSA Strategic Communications

    Valter Pinto, Managing Director

    (212) 896-1254

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-scientific-advisory-board-member-and-inventor-of-licensed-novel-peptide-covid-19-therapeutic-dr-michael-peters-publishes-white-paper-301076621.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  33. NEW YORK, June 8, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for US Patent Application Number: 15/528,317 related to "13-Cis-RAMBA Retinamides that Degrade MNKs for Treating Cancer".

    The Notice of Allowance concludes the substantive examination of the US Patent Application by the USPTO and will result in the issuance of a US patent after remaining administrative processes are completed.  Hoth Therapeutics continues to strengthen the company's intellectual property portfolio surrounding new generation therapies treating various diseases.

    "We are pleased to receive allowance of additional claims from the USPTO, which marks a critical step in bolstering our intellectual property portfolio protecting novel therapeutics designed to target dermatological disorders," stated Mr. Robb Knie, CEO of Hoth Therapeutics.  "This patent regarding several methods will be critical as we move compounds to treat in vivo anti-cancer activity and in vitro for treating dermatology conditions forward."

    Researchers at UMB discovered novel retinamide RAMBAs and validated their therapeutic utility in animal models of breast and prostate cancer. RAMBAs inhibit the cellular enzyme that metabolizes all-trans retinoic acid (ATRA), which actively directs cells to mature in a controlled manner to ensure normal growth. In addition to enhancing the beneficial effects of ATRA, the mechanism of action for these RAMBAs has been shown to involve degradation of Mnk 1/2 and suppression of the oncogenic eIF4E pathway. For potential use in treating dermatological conditions, UMB researchers obtained promising early results demonstrating that lead retinamide RAMBAs have equal or superior effects over approved retinoids (ATRA and 13-CRA) to inhibit proliferation of normal human adult keratinocytes and sebocytes, and antikeratinizing effects in reconstructed human epidermis. Initial toxicity profiles for a panel of RAMBAs [Njar et al., 2006] also showed good indications for safe therapeutic use.

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com.

    Forward-Looking Statement

    Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including statements regarding the proposed offering, timing and the use of proceeds. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this press release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company's filings with the Securities and Exchange Commission. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

    Investor Contact:

    Phone: (646) 756-2997

    Email:  

    www.hoththerapeutics.com

    KCSA Strategic Communications

    Valter Pinto, Managing Director

    (212) 896-1254

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-receives-notice-of-allowance-for-us-patent-regarding-methods-for-treating-cancer-and-dermatology-conditions-301071788.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  34. NEW YORK, June 3, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today provided an update on its pipeline of therapeutics including six compounds in various stages of clinical development, targeting atopic dermatitis, lupus as well as a COVID-19 vaccine and peptide therapeutic.

    "Hoth has assembled a unique and portfolio of therapeutics, that is each addressing significant unmet market needs globally," stated Mr. Robb Knie, CEO of Hoth Therapeutics.  "We have partnered with some of the most renowned doctor, clinics, and scientific institutions as we strive to bring these innovative therapeutic solutions through the clinic.  We have several significant milestones upcoming throughout the rest of 2020 into next year including our human study for BioLexa, targeting the treatment of eczema in adolescents.  Management remains committed to developing, and bringing these novel treatments to market and improving the lives of those that require them."

    BioLexa Platform (Dermatological)

    The BioLexa Platform is a proprietary antimicrobial therapy designed for the treatment of atopic dermatitis or eczema through a non-corticosteroid approach.  In January 2020, Hoth concluded its "In-life 28-day animal study."  The BioLexa Platform has recorded positive results from its pilot project in 2019 and most recently obtained strong data from initial animal testing.  Additionally the Company is preparing to begin its first trial in humans later this year.

    VNLG-152 (Dermatological)

    Earlier this year, Hoth acquired the full licensing rights of VNLG-152 novel retinamides (Retinoic acid metabolism blocking agents, or RAMBAs) for the treatment of dermatological diseases. The Company previously announced that pre-clinical work is underway at Weill Cornell Medicine to examine the efficacy of RAMBAs in blocking acne pathogenic gene expression and carcinogenesis in mice.  Currently, Hoth is exploring whether VNLG-152 is capable of blocking this inflammatory response. Immediately after identifying an effective dose of VNLG-152, the researchers will conduct studies on mouse skin to determine if this drug is effective in blocking acne-like inflammation.  As the Weill Cornell lab reopens later this month Hoth has intentions to finalize the results of its preclinical work.

    WEG-232 (Dermatological)

    Last year Hoth entered into a research agreement with the George Washington University (GW) to explore the potential use of WEG-232 for topical and/or systemic therapy to counter the dermatological related side-effects of Erlotinib therapy in cancer patients. Erlotinib is a drug that is used to combat various cancers and has been known to cause varying degrees of skin rashes, lesions, hair loss and nail changes to patient.  A recent research study suggested the topical application of WEG-232 could be very effective in suppressing erlotinib induced-facial rash/hair loss with approximate 71% reduction. It concluded that WEG-232 may be used as an effective intervention to prevent EGFR-TKI-induced cutaneous toxicity.  Hoth recently engaged Tergus Pharma as CMO as it looks forward to filing a pre-IND with the FDA this year to receive guidance and begin its human trial.

    VaxCelerate (COVID-19)

    VaxCelerate is a self-assembling vaccine (SAV) platform designed to protect patients at risk of Coronavirus (COVID-19) infection. VaxCelerate is believed to offer unique advantages over other compounds in combination therapy. In infectious applications, it allows rapid development against viruses and other pathogens. The vaccine focuses on both DNA and internal / external mutated proteins providing the immune system with more potential targets to attack.  VaxCelerate is currently in animal trials and Hoth will share those results as the testing completes.

    Novel Peptide Therapeutic (COVID-19)

    The Company recently licensed technology and intellectual property exclusively from Virginia Commonwealth University ("VCU") for a novel peptide therapeutic to prevent spike protein binding, a potential leading cause of COVID-19.  This treatment could be a breakthrough in slowing the transmission of the virus. Current research is being led by inventor, Michael H. Peters, Ph.D., Professor, Department of Chemical and Life Science Engineering at VCU, College of Engineering.  The work is being aided, in part, by powerful supercomputers as part of the COVID-19 High Performance Computing Consortium through a virtual system that scientists can use to interactively share computing resources known as the Extreme Science and Engineering Discovery Environment.  Hoth hopes to have an update as to further collaboration with VCU in the month ahead.

    AEA-loaded Z-pods™ (Lupus)

    Developed in partnership with Zylö Therapeutics, Hoth's AEA-loaded Z-pods™ are currently being tested for approval in the treatment of Cutaneous Lupus Erythematosus (CLE).  The preclinical results were announced in earlier this year and demonstrated that topical administration with AEA-loaded nanoparticles significantly prevents the development of CLE in an established animal model of lupus. Hoth is currently working with Zylö to plan and coordinate the next phase of development and will update shareholder as soon as more information is available.

    Exon Skipping Approach (Allergic Disease)

    During November of 2019, Hoth entered into a licensing agreement with North Carolina State University (NC State) to study NC State's Exon Skipping Approach for treating allergic diseases. This Exon Skipping Approach was developed by Dr. Glenn Cruse, Principal Investigator and Assistant Professor in the Department of Molecular Biomedical Sciences at the NC State College of Veterinary Medicine. During Dr. Cruse's research, a new approach for the technique of antisense oligonucleotide-mediated exon skipping to specifically target and down-regulate IgE receptor expression in mast cells was identified. The preclinical studies were initiated in February 2020 and NC State is ready to move to the next stage of the study once laboratories open.

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com

    Forward-Looking Statement

    Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including statements regarding the proposed offering, timing and the use of proceeds. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this press release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company's filings with the Securities and Exchange Commission. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

    Investor Contact:
    Phone: (646) 756-2997
    Email:   
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto, Managing Director
    (212) 896-1254
     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-provides-shareholder-update-on-therapeutics-pipeline-301069716.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  35. NEW YORK, May 28, 2020 (GLOBE NEWSWIRE) -- The Benchmark Company announced the closing on March 27th of an Underwritten Public Offering for Hoth Therapeutics, Inc. (NASDAQ:HOTH) of 1,818,182 shares of common stock at a public offering price of $2.75 per share for gross proceeds of $5.0 million.  In addition, the Company has granted the underwriters an option to purchase up to an additional 272,727 shares of common stock to cover over-allotments.

    HOTH intends to use the net proceeds from the offering for general corporate purposes and to advance the development of its therapeutic candidates. 

    The Benchmark Company acted as sole book-running manager of the offering.

    This press release shall not constitute an offer to sell or the solicitation…

    NEW YORK, May 28, 2020 (GLOBE NEWSWIRE) -- The Benchmark Company announced the closing on March 27th of an Underwritten Public Offering for Hoth Therapeutics, Inc. (NASDAQ:HOTH) of 1,818,182 shares of common stock at a public offering price of $2.75 per share for gross proceeds of $5.0 million.  In addition, the Company has granted the underwriters an option to purchase up to an additional 272,727 shares of common stock to cover over-allotments.

    HOTH intends to use the net proceeds from the offering for general corporate purposes and to advance the development of its therapeutic candidates. 

    The Benchmark Company acted as sole book-running manager of the offering.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne.  Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19.  To learn more, please visit www.hoththerapeutics.com

    About The Benchmark Company

    The Benchmark Company is a full-service investment banking firm offering a suite of corporate finance, advisory and institutional brokerage services.  We were founded in 1988 and are headquartered in New York City with offices in San Francisco, Boston, and Milwaukee.  Our focus is on fostering the long-term success of our corporate clients through raising capital, providing strategic advisory services, generating insightful research and developing institutional sponsorship by leveraging the firm's sales, trading and equity research capabilities.  https://www.benchmarkcompany.com.

    A registration statement on Form S-3 (including a preliminary prospectus describing the terms of the offering) relating to these securities has been filed with the Securities and Exchange Commission (SEC) and has become effective. The offering will be made only by means of a prospectus supplement and accompanying prospectus. A copy of the final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and may be obtained, when available, for free on the SEC's website located at http://www.sec.gov. When available, electronic copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained by contacting The Benchmark Company, Attn: Prospectus Department, 150 E. 58th Street, 17th floor, New York, NY 10155 or by calling 212-312-6700 or by emailing .

    For further information please contact:

    Elise Stern
    Managing Director, Institutional Equities & Corporate Services
    150 East 58th Street 17th Floor | New York, New York 10155
    D: 212-312-6747  | 

    Member FINRA/SIPC

    Primary Logo

    View Full Article Hide Full Article
  36. NEW YORK, May 22, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced that Michael H. Peters, Ph.D., has joined the company's Scientific Advisory Board. Dr. Peters is the inventor of Hoth's newly licensed Novel Peptide COVID-19 Therapeutic, to prevent spike protein binding, which may be a leading cause of COVID-19, and could potentially slow its transmission.  Dr. Peters is also a recent recipient of COVID-19 Rapid Research Funding sponsored by the Office of the Vice President for Research and Innovation and the C. Kenneth and Dianne Wright Center for Clinical and Translational Research.

    Mr. Robb Knie, CEO of Hoth Therapeutics, commented, "On behalf of the entire team at Hoth, we are pleased to welcome Michael Peters to our Scientific Advisory Board. His acute insight and research experience will be an invaluable asset to us." 

    Dr. Peters currently serves as a member of the Developmental Therapeutics research program at VCU Massey Cancer Center and professor in the Department of Chemical and Life Science Engineering at the VCU College of Engineering. 

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements

    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the joint venture and the preclinical development of the novel peptide technology for COVID-19 and the potential development of products related to COVID-19 and other information that is not historical information. When used herein, words such as "anticipate," "being," "will," "plan," "may," "continue," and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2019, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Investor Contact:
    Phone: (646) 756-2997
    Email:  
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto, Managing Director
    (212) 896-1254

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-announces-the-appointment-of-michael-peters-phd-to-scientific-advisory-board-301064111.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  37. NEW YORK, May 21, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ:HOTH), a biopharmaceutical company, today announced the pricing of an underwritten public offering of 1,818,182 shares of common stock at a public offering price of $2.75 per share, before underwriting discounts and commissions. In addition, Hoth has granted the underwriters a 45-day option to purchase up to an additional 272,727 shares of common stock at the public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by Hoth. Gross proceeds from the offering will be approximately $5.0 million. The offering is expected to close on or about May 27, 2020, subject to the satisfaction of customary…

    NEW YORK, May 21, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ:HOTH), a biopharmaceutical company, today announced the pricing of an underwritten public offering of 1,818,182 shares of common stock at a public offering price of $2.75 per share, before underwriting discounts and commissions. In addition, Hoth has granted the underwriters a 45-day option to purchase up to an additional 272,727 shares of common stock at the public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by Hoth. Gross proceeds from the offering will be approximately $5.0 million. The offering is expected to close on or about May 27, 2020, subject to the satisfaction of customary closing conditions. 

    The Benchmark Company is acting as sole book-running manager for the offering.

    A registration statement on Form S-3 (including a preliminary prospectus describing the terms of the offering) relating to these securities has been filed with the Securities and Exchange Commission (SEC) and has become effective. The offering will be made only by means of a prospectus supplement and accompanying prospectus. A copy of the final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and may be obtained, when available, for free on the SEC's website located at http://www.sec.gov. When available, electronic copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained by contacting The Benchmark Company, Attn: Prospectus Department, 150 E. 58th Street, 17th floor, New York, NY 10155 or by calling 212-312-6700 or by emailing .

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com.

    Forward-Looking Statement

    Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including statements regarding the proposed offering, timing and the use of proceeds. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this press release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company's filings with the Securities and Exchange Commission. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

    Investor Contact:
    Phone: (646) 756-2997
    Email:  
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto, Managing Director
    (212) 896-1254

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-announces-pricing-of-public-offering-of-shares-of-common-stock-301064105.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  38. NEW YORK, May 21, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. ("Hoth" or the "Company") (NASDAQ:HOTH), a biopharmaceutical company, today announced that it intends to offer shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 45-day option to purchase up to an additional 15 percent (15%) of the number of shares of common stock sold in the offering solely to cover over-allotments, if any. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

    The Benchmark Company is acting as sole book-running manager for the offering.

    The offering is being conducted pursuant to a shelf registration statement that was previously filed with, and declared effective by, the U.S. Securities and Exchange Commission ("SEC"). Prospective investors should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that Hoth has filed with the SEC for more complete information about Hoth and the offering. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available free of charge on the website of the SEC at www.sec.gov. When available, electronic copies of the preliminary prospectus supplement and the accompanying prospectus may also be obtained from The Benchmark Company, Attn: Prospectus Department, 150 E. 58th Street, 17th floor, New York, NY 10155 or by calling 212-312-6700 or by emailing  

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com.

    Forward-Looking Statement

    Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including statements regarding the proposed offering, timing and the use of proceeds. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this press release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company's filings with the Securities and Exchange Commission. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

    Investor Contact:
    Phone: (646) 756-2997
    Email:   
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto, Managing Director
    (212) 896-1254

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-announces-proposed-public-offering-of-common-stock-301063925.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  39. NEW YORK, May 20, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced licensing technology and intellectual property exclusively from Virginia Commonwealth University ("VCU") for a novel peptide therapeutic to prevent spike protein binding, which may be a leading cause of COVID-19, and slow its transmission.

    The research is being led by inventor Michael H. Peters, Ph.D., Professor, Department of Chemical and Life Science Engineering at VCU, College of Engineering, and is being aided, in part, by powerful supercomputers as part of the COVID-19 High Performance Computing Consortium through a virtual system that scientists can use to interactively share computing resources known as the Extreme Science and Engineering Discovery Environment. The consortium is a private-public partnership that includes the White House Office of Science and Technology Policy and major technology corporations.

    SARS-CoV-2 or COVID-19 attaches to and enters cells through the binding of its perfusion Spike Protein to the cell surface receptor Angiotensin Converting Enzyme 2 (ACE2). ACE2 is a protein found on the surface of lung alveolar cells, cells of the small intestine, and arteriole cells making it highly dispersed throughout the body. Because of the wide-spread dispersion of ACE2 within the body, there are numerous opportunities for SARS-CoV-2 to infiltrate the body.

    The spike in protein plays an important role in attaching to human cells and infecting the body. Researchers at VCU have developed at novel peptide that binds with extremely high affinity to SD1 segment of the SARS-CoV-2 spike protein mimicking its attachment to ACE2. This high binding affinity helps block the spike protein from attaching to the ACE2 surface receptor, thus limiting the transmission of the virus. Further development of the novel peptide can also allow a novel target for the SARS-CoV-2.

    Dr. Peters commented, "The spike protein of the novel corona virus SARS-Cov-2 associated with the current COVID-19 pandemic uses a specific receptor on human epithelial cells, called ACE2, for its fusion and infection process.  This therapeutic development effort exploits the unusually strong and unique binding of the SARS-Cov-2 spike protein to ACE2 to develop safe and effective peptide 'decoys' that have the potential to preferentially bind to the spike protein and prevent fusion and infection."

    "Computer modeling of SARS-CoV-2's spike protein is an important step in finding ways to prevent the virus from binding to ACE2 receptors and allowing the virus to replicate," said Ivelina Metcheva, Ph.D., Senior Executive Director of VCU's Innovation Gateway. "We are very excited to assist Dr. Peter's collaboration with Hoth Therapeutics to develop potentially life-saving therapy for COVID-19."

    "My team and Board have continued to see remarkable technologies that could have potential breakthroughs in the fight against COVID-19," said Robb Knie, CEO of Hoth Therapeutics. "Dr. Peters and his team have been working diligently on analyzing data surrounding the theory of SARS-CoV-2's spike protein, its potential effect on COVID-19 and developing a therapeutic that would be effective in limiting transmission of the virus."

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has recently entered into a Joint Development Agreement to further the development of vaccine prospects to prevent, intercept or treat the Coronavirus (COVID-19) based upon VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH). To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements
    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the joint venture and the preclinical development of technology for COVID-19 and the potential development of products related to COVID-19 and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2019, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Investor Contact:
    Phone: (646) 756-2997
    Email:  
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto, Managing Director
    (212) 896-1254

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-licenses-novel-peptide-covid-19-therapeutic-301062389.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  40. NEW YORK, May 19, 2020 /PRNewswire/ -- Voltron Therapeutics, Inc. announces today a letter to the shareholders.

    Dear Voltron Therapeutics shareholders,

    We hope this letter finds you well during this remarkable time. We would also like to thank for your support of Voltron.

    The current COVID-19 pandemic is exactly the kind of situation that our VaxCelerate platform was created to address.  Recall that this is the technology to which we acquired a global, exclusive license from the Massachusetts General Hospital (MGH)/Harvard Medical School. We have moved ahead rapidly to advance the technology in order to help address this global threat.

    We would like to update you on our progress with both the COVID-19 vaccine, as well as on the parallel effort…

    NEW YORK, May 19, 2020 /PRNewswire/ -- Voltron Therapeutics, Inc. announces today a letter to the shareholders.

    Dear Voltron Therapeutics shareholders,

    We hope this letter finds you well during this remarkable time. We would also like to thank for your support of Voltron.

    The current COVID-19 pandemic is exactly the kind of situation that our VaxCelerate platform was created to address.  Recall that this is the technology to which we acquired a global, exclusive license from the Massachusetts General Hospital (MGH)/Harvard Medical School. We have moved ahead rapidly to advance the technology in order to help address this global threat.

    We would like to update you on our progress with both the COVID-19 vaccine, as well as on the parallel effort to develop VaxCelerate for oncology indications.

    HaloVax, COVID-19 Vaccine

    Our vaccine has a number of important advantages that other company's efforts do not share; most importantly in VaxCelerate we have an incredibly nimble and flexible platform that can quickly adapt to new mutations of the virus, where others may not.  Further, only VaxCelerate has been designed to be both flexible and avoid known safety issues with vaccines, such as Antibody Induced Enhanced Disease.

    We have taken several important steps in the development of our vaccine:

    • Voltron executed a Sponsored Research Agreement (SRA) with MGH to conduct preclinical research on two COVID-19 vaccine candidates
    • Formed a development partnership with Hoth Therapeutics (NASDAQ:HOTH) to advance the COVID technology, including an investment by Hoth
    • Selected the first of two vaccine candidates
    • Began manufacturing the peptides that will complete the first vaccine
    • Initiated the process at MGH to begin testing in a mouse vaccine model
    • Began the process of selecting the second vaccine candidate
    • Started the process of scaling up production of the largest component of the vaccine, Heat Shock Protein 70 (HSP70), which is common to all versions of VaxCelerate vaccines in both infectious disease and oncology
    • Initiated the process to secure government funding for future development of the vaccine, from sources including BARDA and the Department of Defense.
    • Our Scientific Co-Founder and advisor was featured in a number of news articles and interviewed numerous times for TV, radio, podcasts and other online reports, including MSNBC, Bloomberg, Yahoo Finance, and several others.  https://voltrontx.com/news/

    Our next key steps for the HaloVax vaccine include:

    1. Initiate animal testing of the first COVID-19 vaccine
    2. Select the second vaccine candidate and manufacture the required peptides
    3. Initiate animal testing on the second candidate
    4. Report initial animal data for both vaccines
    5. Begin testing in a second animal model for each vaccine, if required by the FDA
    6. Announce any external funding acquired

    Additionally, we have assembled a world class team, including:

    • Dr. Mark Poznansky, Director of the Vaccine and Immunotherapy Center (VIC) and Physician at Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical School. Scientific founder and Scientific Advisory Board member
    • Dr. Jeffrey A. Gelfand is an infectious disease specialist at MGH and inventor of this technology
    • Zachary Shriver, PhD, Visterra Inc., a globally recognized expert in manufacturing & protein design
    • Jeffrey Conroy, a Business Development expert with decades of experience and deep experience in pharmaceutical deal-making; currently CEO at Embody
    • Paul Korner, MD, a Clinical Development expert with numerous products progressed through the clinical/regulatory process at Sarepta and Axovant
    • George Steinfels, a Clinical Research Organization executive, formerly with Quintiles and Dupont Pharmaceuticals.

    Oncology Programs

    Fortunately, virtually all of our COVID efforts will simultaneously advance our Oncology programs.  This is because all VaxCelerate vaccines will have 90+% that is identical from one vaccine to the next – the HSP70 portion.  This allows us to make substantial progress with both our manufacturing and regulatory efforts in oncology through the work we are conducting for the COVID program. 

    We have selected Ovarian and other Human Papilloma Virus (HPV) related cancers as our initial targets.  We are moving these programs ahead in parallel with the ID efforts.

    We have taken several important steps ahead in development of the oncology vaccines:

    • We are executing a new Sponsored Research Agreement (SRA) with MGH to conduct preclinical research in two vaccine candidates
    • Started the process of scaling up production of the main component of the vaccine, Heat Shock Protein 70 (HSP70), which is common to all versions of VaxCelerate vaccines in both infectious disease and oncology

    Our next key steps for the cancer vaccine program include:

    1. Finalize the SRA with MGH
    2. Initiate animal testing in the first indication, likely Ovarian cancer
    3. Initiate animal testing in the second tumor type
    4. Report animal data for both indications

    Again, thank you for your support and please be well.

    Best Regards,

    Pat Gallagher, Chief Executive Officer
    Matthew Duffy, President
    James Ahern, Director
    Matthew Eitner, Director

    About Voltron Therapeutics, Inc.

    Voltron Therapeutics, Inc., a Delaware corporation, was founded in 2017 to lead and accelerate the development of the Vaccine and Immunotherapy Center (VIC), and the Massachusetts General Hospital's novel Self Assembling Vaccine technology in a variety of indications, including in Oncology and emerging Infectious Diseases. Voltron holds an exclusive worldwide license to this technology.  With the work of our world class team of researchers and physicians, this technology has shown in certain pre-clinical studies initial proof of concept in two infectious diseases (Lassa Fever and Q Fever) as well as two oncology indications (Ovarian and HPV Related).  For more information please visit www.voltrontx.com.

    Forward Looking Statements

    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the VaxCelerate Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Voltron's current expectations and various assumptions. Voltron believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Voltron may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and any Voltron filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Voltron's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Voltron cannot guarantee future results, events, levels of activity, performance or achievements. Voltron does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Investor Contact:

    Matt Duffy, President
    646-335-5923

    Media Contact:

    Matt Pennacchio
    516-851-4766

    Cision View original content:http://www.prnewswire.com/news-releases/voltron-therapeutics-publishes-letter-to-shareholders-301061841.html

    SOURCE Voltron Therapeutics, Inc.

    View Full Article Hide Full Article
  41. NEW YORK, May 18, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced today that the company has obtained exclusive worldwide licensing rights to the BioLexa Platform, a proprietary, patented antimicrobial therapy focused on treating atopic dermatitis. This agreement serves as an extension to the previously executed sublicense agreement for the compound with Chelexa Biosciences, Inc.

    According to the National Eczema Association, "Atopic dermatitis (also known as AD) is the most common type of eczema. In fact, more than 18 million American adults have atopic dermatitis — which often appears as a red, itchy rash normally on the cheeks, arms and legs. Atopic dermatitis typically begins in childhood, usually in the first six months of a baby's life. Even though it's a common form of eczema, it's also severe and long-lasting. When you or your child have atopic dermatitis, it may improve at times, but at others it may get worse. Often, atopic dermatitis disappears as a child grows older, though some children will have atopic dermatitis flares into adulthood." Atopic dermatitis exists with two other allergic conditions: asthma and hay fever (allergic rhinitis). People who have asthma and/or hay fever or who have family members who do, are more likely to develop AD.

    The global atopic dermatitis market is positioned for significant growth at approximately 24.1% CAGR during the projection period (2020-2027 source: Fact.MR) Millions of people are afflicted by this debilitating skin ailment. 

    "Management is pleased to fully own global licensing rights for the BioLexa Platform," said Robb Knie, CEO of Hoth Therapeutics.

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has recently entered into a Joint Development Agreement to further the development of vaccine prospects to prevent, intercept or treat the Coronavirus (COVID-19) based upon VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH). To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements
    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of BioLexa, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2018, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Investor Contact:
    Phone: (646) 756-2997
    Email:  
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto, Managing Director
    (212) 896-1254

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-procures-full-licensing-rights-for-biolexa-platform-atopic-dermatitis-treatment-301060632.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  42. NEW YORK, May 5, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced it has completed a strategic investment in Zylö Therapeutics, Inc ("Zylö").

    Mr. Robb Knie, Chief Executive Officer of Hoth, commented, "We are pleased to expand our partnership with Zylö and look forward to working together as our therapeutic for Lupus patients continues through the next phase of development. This small equity investment in Zylö is a further commitment to our belief in Zylö's science and team."

    Stated Scott Pancoast, CEO of Zylö Therapeutics, "Partnering with Hoth in 2019 was an important step in propelling our lupus program forward. This equity investment in Zylö stock represents an expansion of the partnership and is a win-win for the two companies." 

    According to estimates by the Lupus Foundation of America (LFA), 1.5 Million Americans currently suffer from lupus, with 16,000 new cases reported annually. Tragically, lupus strikes mostly women of child-bearing age. Worldwide, the LFA estimates that at least five million people may have some form of the disease. Of the people diagnosed, approximately two-thirds will develop CLE. The annual average cost to provide medical treatment for a person with lupus: $6,000 to $10,000, with some treatment costing several thousand dollars a month.

    About Zylö Therapeutics, Inc.
    Zylö, dedicated to bringing innovative technologies to multiple facets of medicine, has an innovative sustained-release drug-delivery system that was developed by Joel Friedman MD PhD, Adam Friedman MD FAAD, and Andrew Draganski PhD. The delivery system uses patented xerogel-derived nanoparticles, called Z-pods™, to deliver—in a sustained and controlled manner—notoriously hard-to-deliver therapeutic agents through topical administration. For more information, please visit; http://www.zylotherapeutics.com/

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has recently entered into a Joint Development Agreement to further the development of vaccine prospects to prevent, intercept or treat the Coronavirus (COVID-19) based upon VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH). To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements
    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of AEA-loaded Z-pods™, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2018, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Investor Contact:
    Phone: (646) 756-2997
    Email:  
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto, Managing Director
    (212) 896-1254

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-expands-partnership-with-zylo-therapeutics-inc-301053001.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  43. NEW YORK, April 24, 2020 /PRNewswire/ -- Voltron Therapeutics, Inc. announced today that it has selected the peptides required to complete the structure of HaloVax for development and progression into pre-clinical animal testing of the HaloVax Self-Assembling Vaccine (SAV). Voltron will take two different vaccines, with differing sets of targets into pre-clinical testing, in order to identify the best balance of immune responses for prevention of infection. This vaccine is designed to protect patients at risk of coronavirus (COVID-19) infection. Initiation of the first animal study for the vaccine candidates is expected to begin in May 2020.

    The vaccine candidates are built on a base of a heat shock protein (HSP70) that activates the cellular…

    NEW YORK, April 24, 2020 /PRNewswire/ -- Voltron Therapeutics, Inc. announced today that it has selected the peptides required to complete the structure of HaloVax for development and progression into pre-clinical animal testing of the HaloVax Self-Assembling Vaccine (SAV). Voltron will take two different vaccines, with differing sets of targets into pre-clinical testing, in order to identify the best balance of immune responses for prevention of infection. This vaccine is designed to protect patients at risk of coronavirus (COVID-19) infection. Initiation of the first animal study for the vaccine candidates is expected to begin in May 2020.

    The vaccine candidates are built on a base of a heat shock protein (HSP70) that activates the cellular portion of the immune system; this is different from most other vaccine efforts, which used adjuvants like alum. The second portion of the vaccine consists of peptides from the COVID-19 virus, which are bound at high affinity to the heat shock protein via Avidin and Biotin. The selected immunogenic peptides complete the customized COVID-19 vaccine.

    "The bacterial heat shock protein portion of the vaccine is extremely potent at presenting vaccine antigens to immune cells, resulting in both antibody and cell-mediated immunity. The Avidin portion of the vaccine we designed enables rapid iteration and change in the antigen to enable swift production and accommodate potential changes in the pathogen, or new evolving pathogens," according to Dr. Jeffrey Gelfand, coinventor of the vaccine.

    The vaccine is currently in development in partnership with HaloVax, LLC a biopharmaceutical company and special purpose subsidiary of Voltron Therapeutics, Inc., and Hoth Therapeutics, Inc (NASDAQ:HOTH). The partnership was established to advance an application of VaxCelerate, the SAV platform licensed from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH) specifically for the rapid development of vaccines against emerging pathogens and specific types of cancer, in this case COVID-19. The VaxCelerate platform was developed to improve patient outcomes by activating and targeting the immune system to identify and destroy the infectious agent. Voltron Therapeutics, Inc. has acquired an exclusive worldwide license to this technology.

    The selection of the first of two sets of testing candidates builds on the recent announcement of a Sponsored Research Agreement which Voltron Therapeutics entered into with the VIC at MGH. Voltron Therapeutics and VIC at MGH have a longstanding relationship for the development of vaccines to fight infectious diseases and cancer.

    "Our accelerated development program to deliver a safe and effective vaccine that can protect people from this terrible virus as quickly as possible is now one step closer to reaching clinical trials. We are very pleased to have identified the first of our two lead vaccine candidates from the constructs that we've been working on since March," said Pat Gallagher, Chief Executive Officer, Voltron Therapeutics, Inc. "We are optimistic about the continued success of our partnership with the VIC and all of our partners and subsidiaries that we are closing in on a new solution to help protect those potentially affected by COVID-19."

    Robb Knie, Chief Executive Officer, Hoth Therapeutics, Inc, continued, "The hard work of the Joint Development Committee of Hoth, Voltron and the VIC at Mass General  is making tremendous strides in a short time period to bring the HaloVax Self Assembling Vaccine closer to the clinic. I am appreciative of Dr. Poznansky and his team as they take the next steps in this most important program."

    Dr. Mark Poznansky, Director, Vaccine and Immunotherapy Center, MGH added, "The selection of candidates for animal testing is a critical step forward to reaching human clinical trials. Ultimately, taking two candidates forward, with differing expected effects on the immune system, expands the breadth of our study, which we think increases the probability that a successful vaccine emerges from our preclinical trials. The new potential candidate is designed to facilitate a productive immune response while minimizing mechanisms known to induce adverse reactions to a vaccine or even potentially enhance the negative effects of COVID-19 infection. This has been an extraordinary effort by the exceptional team at the VIC/Massachusetts General Hospital, Voltron and Hoth."

    About Voltron Therapeutics, Inc.
    Voltron Therapeutics, Inc., a Delaware corporation, was founded in 2017 to lead and accelerate the development of the Vaccine and Immunotherapy Center (VIC), and the Massachusetts General Hospital's novel Self Assembling Vaccine technology in a variety of indications, including in Oncology and emerging Infectious Diseases. Voltron holds an exclusive worldwide license to this technology. With the work of our world class team of researchers and physicians, this technology has shown in certain pre-clinical studies initial proof of concept in two infectious diseases (Lassa Fever and Q Fever) as well as two oncology indications (Ovarian and HPV Related). For more information please visit www.voltrontx.com.

    About HaloVax™, LLC
    HaloVax, LLC is a special purpose subsidiary of Voltron Therapeutics, Inc. The mission of HaloVax is to develop a novel, Self-Assembling Vaccine against COVID-19, utilizing technology licensed by Voltron Therapeutics, Inc. from the Vaccine and Immunotherapy Center at the Massachusetts General Hospital.  The vaccine is being designed from a validated platform to provide customized T cell immunity against COVID-19, as well as be able to adapt rapidly to potential genetic drift of the virus.  For more information, please visit www.HaloVax.com

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma, and acne. To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements
    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the VaxCelerate Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Voltron's current expectations and various assumptions. Voltron believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Voltron may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and any Voltron filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Voltron's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Voltron cannot guarantee future results, events, levels of activity, performance or achievements. Voltron does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Media Contact:

    Matt Pennacchio
    516-851-4766

    Investor Contact:

    Matt Duffy, President & Director
    646-335-5923

     

    Cision View original content:http://www.prnewswire.com/news-releases/voltron-therapeutics-inc-announces-selection-of-the-first-of-two-sets-of-virus-targeting-peptides-for-animal-testing-in-the-development-of-a-covid-19-vaccine-301046845.html

    SOURCE Voltron Therapeutics

    View Full Article Hide Full Article
  44. NEW YORK, April 24, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) announced today that Voltron Therapeutics, Inc has selected the peptides required to complete the structure of HaloVax for development and progression into pre-clinical animal testing of the HaloVax Self-Assembling Vaccine (SAV).  Voltron will take two different vaccines, with differing sets of targets into pre-clinical testing, in order to identify the best balance of immune responses for prevention of infection. This vaccine is designed to protect patients at risk of coronavirus (COVID-19) infection. Initiation of the first animal study for the vaccine candidates is expected to begin during May of 2020.

    The vaccine candidates are built on a base of a heat shock protein (HSP70) that activates the cellular portion of the immune system; this is different from most other vaccine efforts, which used adjuvants like alum. The second portion of the vaccine consists of peptides from the COVID-19 virus, which are bound at high affinity to the heat shock protein via Avidin and Biotin. The selected immunogenic peptides complete the customized COVID-19 vaccine.   "The bacterial heat shock protein portion of the vaccine is extremely potent at presenting vaccine antigens to immune cells, resulting in both antibody and cell-mediated immunity. The avidin portion of the vaccine we designed enables rapid iteration and change in the antigen to enable rapid production and accommodate potential changes in the pathogen, or new evolving pathogens", according to Dr. Jeffrey Gelfand, coinventor of the vaccine.

    The vaccine is currently in development in partnership with HaloVax, LLC a biopharmaceutical company and special purpose subsidiary of Voltron Therapeutics, Inc., and Hoth Therapeutics, Inc. The partnership was established to advance an application of VaxCelerate, the SAV platform licensed from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH) specifically for the rapid development of vaccines against emerging pathogens and specific types of cancer, in this case COVID-19. The VaxCelerate platform was developed to improve patient outcomes by activating and targeting the immune system to identify and destroy the infectious agent. Voltron Therapeutics, Inc. has acquired an exclusive worldwide license to this technology.

    The selection of testing candidates builds on the recent announcement of a Sponsored Research Agreement which Voltron Therapeutics entered into with the VIC at MGH. Voltron Therapeutics and VIC at MGH have a longstanding relationship for the development of vaccines to fight infectious diseases and cancer.

    "Our accelerated development program to deliver a safe and effective vaccine that can protect people from this terrible virus as quickly as possible is now one step closer to reaching clinical trials. We are very pleased to have identified the first of our two lead vaccine candidates from the constructs that we've been working on since March," said Pat Gallagher, Chief Executive Officer, Voltron Therapeutics. "We are optimistic about the continued success of our partnership with the VIC and all of our partners and subsidiaries that we are closing in on a new solution to help protect those potentially affected by COVID-19."

    Robb Knie, CEO of Hoth, continued: "The hard work of the Joint Development Committee of Hoth, Voltron and the VIC at Mass General is making tremendous strides in a short time period to bring the HaloVax Self Assembling Vaccine closer to the clinic.  I am appreciative of Dr. Poznansky and his team as they take the next steps in this most important program."

    Dr. Mark Poznansky, Director, Vaccine and Immunotherapy Center www.advancingcures.org, MGH added, "The selection of candidates for animal testing is a critical step forward to reaching human clinical trials.  Ultimately, taking two candidates forward, with differing expected effects on the immune system, expands the breadth of our study, which we think increase the probability that a successful vaccine emerges from our preclinical trials. The new potential candidate is designed to facilitate a productive immune response while minimizing mechanisms known to induce adverse reactions to a vaccine or even potentially enhance the negative effects of COVID-19 infection.  This has been an extraordinary effort by the exceptional team at the VIC/Massachusetts General Hospital, Voltron and Hoth."

    About Voltron Therapeutics, Inc.
    Voltron Therapeutics, Inc., a Delaware corporation, was founded in 2017 to lead and accelerate the development of the Vaccine and Immunotherapy Center (VIC), and the Massachusetts General Hospital's novel Self Assembling Vaccine technology in a variety of indications, including in Oncology and emerging Infectious Diseases. Voltron holds an exclusive worldwide license to this technology. With the work of our world class team of researchers and physicians, this technology has shown in certain pre-clinical studies initial proof of concept in two infectious diseases (Lassa Fever and Q Fever) as well as two oncology indications (Ovarian and HPV Related). For more information please visit www.voltrontx.com.

    About HaloVax™, LLC
    HaloVax, LLC is a special purpose subsidiary of Voltron Therapeutics, Inc. The mission of HaloVax is to develop a novel, Self-Assembling Vaccine against COVID-19, utilizing technology licensed by Voltron Therapeutics, Inc. from the Vaccine and Immunotherapy Center at the Massachusetts General Hospital.  The vaccine is being designed from a validated platform to provide customized T cell immunity against COVID-19, as well as be able to adapt rapidly to potential genetic drift of the virus.  For more information, please visit www.HaloVax.com

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has recently entered into a Joint Development Agreement to further the development of vaccine prospects to prevent, intercept or treat the Coronavirus (COVID-19) based upon VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH). To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements
    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the joint venture and the preclinical development of the SAV technology for COVID-19 and the potential development of products related to COVID-19 and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2019, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Contacts
    Investor Relations Contact:
    Phone: (646) 756-2997
    Email:   
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto, Managing Director
    (212) 896-1254

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-inc-voltron-therapeutics-inc--halovax-announce-selection-of-the-first-of-two-sets-of-virus-targeting-peptides-for-animal-testing-in-the-development-of-a-covid-19-vaccine-301046834.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  45. NEW YORK, April 23, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced hosting a shareholder update conference call with Dr. Mark Poznansky on Thursday, April 23, 2020 at 10:15 a.m. ET.  Dr. Poznansky will be providing shareholders with an overview and update on VaxCelerate, a potential vaccine for COVID-19, and answer pre-submitted questions at the conclusion of his prepared remarks. Investors are asked to submit their questions to .

    Hoth Therapeutics and HaloVax, LLC, a biopharmaceutical company and special purpose subsidiary of Voltron Therapeutics, Inc., recently announced an agreement to advance VaxCelerate, a self-assembling vaccine (SAV) platform licensed from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH), designed to protect patients at risk of Coronavirus (COVID-19) infection. Voltron Therapeutics, Inc. has acquired an exclusive license to this technology.

    Conference Call Information:

    Date:

    Thursday, April 23, 2020

    Time:

    10:15 a.m. Eastern Time

    Live Call:

    +1-877-705-6003 (U.S. Toll-Free) or +1-201-493-6725 (International)

    Webcast:

    Archived for 90 days, http://public.viavid.com/index.php?id=139467

    Dr. Poznansky currently serves as the Director of The Vaccine & Immunotherapy Center (VIC) at Massachusetts General Hospital. He is also an Associate Professor of Medicine at Harvard Medical School and Attending Physician in General and Transplant Infectious Diseases at Massachusetts General Hospital.

    "Hoth is honored to introduce Dr. Poznansky to its investors, particularly during this very busy time for him in this environment. Access to his insight and expertise on COVID-19, infectious disease, and potential treatments during this global pandemic is invaluable for all of us," stated Mr. Robb Knie, CEO of Hoth Therapeutics.  "This conference call is a unique opportunity not just for investors, but for anyone who is interested in learning more about VaxCelerate and the process behind a race for getting a vaccine through the clinic." 

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has recently entered into a Joint Development Agreement to further the development of vaccine prospects to prevent, intercept or treat the Coronavirus (COVID-19) based upon VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH). To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements
    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the joint venture and the preclinical development of the SAV technology for COVID-19 and the potential development of products related to COVID-19 and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2019, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Contacts
    Investor Relations Contact:
    Phone: (646) 756-2997
    Email:  
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto, Managing Director
    (212) 896-1254

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/reminder-hoth-therapeutics-to-host-shareholder-update-conference-call-with-dr-mark-poznansky-to-discuss-covid-19-vaccine-candidate-vaxcelerate-301046195.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  46. NEW YORK, April 22, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced hosting a shareholder update conference call with Dr. Mark Poznansky on Thursday, April 23, 2020 at 10:15 a.m. ET.  Dr. Poznansky will be providing shareholders with an overview and update on VaxCelerate, a potential vaccine for COVID-19, and answer pre-submitted questions at the conclusion of his prepared remarks. Investors are asked to submit their questions to  .

    Hoth Therapeutics and HaloVax, LLC, a biopharmaceutical company and special purpose subsidiary of Voltron Therapeutics, Inc., recently announced an agreement to advance VaxCelerate, a self-assembling vaccine (SAV) platform licensed from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH), designed to protect patients at risk of Coronavirus (COVID-19) infection. Voltron Therapeutics, Inc. has acquired an exclusive license to this technology.

    Conference Call Information:

    Date:

    Thursday, April 23, 2020

    Time:

    10:15 a.m. Eastern Time

    Live Call:

    +1-877-705-6003 (U.S. Toll-Free) or +1-201-493-6725 (International)

    Webcast:

    Archived for 90 days, http://public.viavid.com/index.php?id=139467

    Dr. Poznansky currently serves as the Director of The Vaccine & Immunotherapy Center (VIC) at Massachusetts General Hospital. He is also an Associate Professor of Medicine at Harvard Medical School and Attending Physician in General and Transplant Infectious Diseases at Massachusetts General Hospital.

    "Hoth is honored to introduce Dr. Poznansky to its investors, particularly during this very busy time for him in this environment. Access to his insight and expertise on COVID-19, infectious disease, and potential treatments during this global pandemic is invaluable for all of us," stated Mr. Robb Knie, CEO of Hoth Therapeutics.  "This conference call is a unique opportunity not just for investors, but for anyone who is interested in learning more about VaxCelerate and the process behind a race for getting a vaccine through the clinic." 

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has recently entered into a Joint Development Agreement to further the development of vaccine prospects to prevent, intercept or treat the Coronavirus (COVID-19) based upon VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH). To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements
    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the joint venture and the preclinical development of the SAV technology for COVID-19 and the potential development of products related to COVID-19 and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2019, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Contacts
    Investor Relations Contact:
    Phone: (646) 756-2997
    Email:  
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto, Managing Director
    (212) 896-1254

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-to-host-shareholder-update-conference-call-with-dr-mark-poznansky-to-discuss-covid-19-vaccine-candidate-vaxcelerate-301045202.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  47. NEW YORK, April 21, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced top line data from its Cutaneous Lupus Erythematosus (CLE) study, a chronic autoimmune skin disease, in partnership with Zylö Therapeutics, Inc. for topical administration of Anandamide (AEA)-loaded Z-pods™. 

    During the study, 50 female MRL/lpr mice that develop an autoimmune disease resembling systemic lupus erythematosus, a disease affecting over approximately 1.5 million Americans, were scored weekly for skin lesions beginning at 12 weeks of age. The mice were tested weekly for 10 weeks. The results show that mice treated with AEA-loaded particles experienced lesions that regressed in size and severity, while untreated…

    NEW YORK, April 21, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced top line data from its Cutaneous Lupus Erythematosus (CLE) study, a chronic autoimmune skin disease, in partnership with Zylö Therapeutics, Inc. for topical administration of Anandamide (AEA)-loaded Z-pods™. 

    During the study, 50 female MRL/lpr mice that develop an autoimmune disease resembling systemic lupus erythematosus, a disease affecting over approximately 1.5 million Americans, were scored weekly for skin lesions beginning at 12 weeks of age. The mice were tested weekly for 10 weeks. The results show that mice treated with AEA-loaded particles experienced lesions that regressed in size and severity, while untreated mice treated with AEA-neat experienced worsening lesions.

    When a mouse was first observed with a lesion, it was enrolled into the study and randomized to one of these three arms: (i) Test Article Arm: These animals were treated twice per week with interscapular topical application of AEA-loaded silica particles (avg. radius of 125nm) in coconut oil; (ii) Control Test Article Arm: These animals were treated twice per week with interscapular topical application of AEA in coconut oil; (iii) Negative Control Arm: These mice were not treated.   All mice were regularly scored using a validated modified CLASI tool, measuring erythema, thickness, scaling, and alopecia, to assess the effect of AEA on cutaneous disease.

    Mr. Robb Knie, Chief Executive Officer of Hoth, commented, "We are pleased to have concluded our preclinical study of CLE. Clearly, administering anandamide through the AEA-loaded Z-pods™ delivery system has significant lesion improvement in CLE patients. Together with the Zylö team, we will continue to move this treatment forward through to the clinic."

    Hoth owns an exclusive license to develop Anandamide-loaded Z-pods™ for the treatment of CLE in North America. Anandamide, generally referred to as AEA, is one of the cannabinoids that the human body makes naturally. The Company also possesses rights related to geographic expansion and to follow-on indications such as psoriasis and rheumatoid arthritis.

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has recently entered into a Joint Development Agreement to further the development of vaccine prospects to prevent, intercept or treat the Coronavirus (COVID-19) based upon VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH). To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements
    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of AEA-loaded Z-pods™, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2018, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Investor Contact:
    Phone: (646) 756-2997
    Email:  
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto, Managing Director
    (212) 896-1254

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-announces-top-line-preclinical-data-from-cutaneous-lupus-erythematosus-cle-study-301044299.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  48. NEW YORK, April 17, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced the addition of two independent members, Mr. Graig Springer and Mr. Wayne Linsley, to its Board of Directors. The Company also announced the resignation of current board member, Mr. Anthony Hayes.

    "Management is pleased to announce the addition of two experienced and successful leaders to our Board," said Mr. Robb Knie, Chief Executive Officer of Hoth Therapeutics. "I am confident that their experience in business management, financial reporting and capital markets will serve us well as we continue our growth and development.  We look forward to leveraging their insights and experience."

    Mr. Knie continued, "Anthony Hayes has been a trusted colleague and advisor for many years. On behalf of my fellow directors, the company's management team, and shareholders, I'd like to thank him for the significant contributions he made during his service on Hoth's Board, we wish him the best in his future endeavors."

    Graig Springer assisted with product development and governance at Invesco U.S., an investment management company, and from December 2013 to May 2019, he served in various capacities at OppenheimerFunds, Inc., an investment management company acquired by Invesco U.S., including distribution compliance and product development. In addition, Mr. Springer served on the Sub-Adviser Oversight Committee at OppenheimerFunds, Inc. Mr. Springer earned his Juris Doctor from Fordham University School of Law and concentrated in corporate law. Mr. Springer was elected to serve as Notes & Articles Editor for the Fordham Journal of Corporate and Financial Law and was the founding member and Chair of Fordham's Committee on Diversity in Business Law. Mr. Springer earned his Bachelors of Arts from Columbia College and majored in English and Comparative Literature. 

    Since 2011, Mr. Linsley has served as the Vice President of Operations of CFO Oncall, Inc., a company that provides financial management and CFO services, and since 2010 he has served as the Managing Member of Flagship Advisory & Management Group, LLC, a management consulting firm. In addition, since 2019, Mr. Linsley has served as the Chief Executive Officer and sole owner of Executive Outsource Group, Inc., a company that provides financial reporting services. Mr. Linsley has served in various other capacities including Alternate Channels Manager of Mettel; Director of Channel Sales of Impsat, USA; National Accounts Manager of Venali, Inc; and Director of Sales of Broadview Networks. Since January 2020, Mr. Linsley has served as a member of the board of directors of Uppercut Brands, Inc. Mr. Linsley received his Bachelor of Business Administration degree in accounting/business administration from Siena College.

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth recently entered into a Joint Development Agreement to further the development of vaccine prospects to prevent, intercept or treat the Coronavirus (COVID-19) based upon VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH).

    To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements
    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the joint venture and the preclinical development of the SAV technology for COVID-19 and the potential development of products related to COVID-19 and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2019, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Contacts
    Investor Relations Contact:
    Phone: (646) 756-2997
    Email:  
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto, Managing Director
    (212) 896-1254

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-announces-additions-to-its-board-of-directors-301042468.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  49. NEW YORK, April 15, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced that Dr. Mark Poznansky, Co-Creator of VaxCelerate, a self-assembling vaccine (SAV) platform, appeared as a guest on MSNBC's All In with Chris Hayes last night to discuss COVID-19 vaccines and can be viewed from the following link https://drive.google.com/file/d/1t75xOLeIoIqwHZC8BIhJrrRZl3f1Wqmt/view

    VaxCelerate was co-created by Dr. Mark Poznansky, MD, PhD, and Dr. Jeffrey Gelfand, MD, at Massachusetts General Hospital (MGH).  Dr. Poznansky is the Director of the Vaccine and Immunotherapy Center (VIC) and a Physician at Massachusetts General Hospital, as well as an Associate Professor of Medicine at Harvard Medical School. He serves as both scientific founder and scientific advisory board member of HaloVax, the joint venture entity that was recently formed, based upon Hoth's recent agreement with Voltron Therapeutics, Inc. to undertake preclinical studies for the development of vaccine prospects to prevent the Coronoavirus (COVID-19).

    VaxCelerate is a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) to aid at risk patients of being infected with COVID-19.  The VaxCelerate vaccine platform was developed as a means of rapidly generating and pre-clinically testing a new vaccine against specific pathogen targets. The technology which received Department of Defense (DoD) funding historically demonstrated proof of concept in Lassa Fever, an emerging infectious disease.  HaloVax intends to use these same SAV principles to assist in the development of a potential vaccine against the COVID-19 pandemic.

    Dr. Poznansky will help advise Halovax on the early clinical research and implementation of testing in the hospital setting.

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth recently entered into a Joint Development Agreement to further the development of vaccine prospects to prevent, intercept or treat the Coronavirus (COVID-19) based upon VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH).
    To learn more, please visit www.hoththerapeutics.com.

    About HaloVax™, LLC

    The mission of HaloVax is to develop a novel, Self-Assembling Vaccine against COVID-19, utilizing technology licensed by Voltron Therapeutics, Inc. from the Vaccine and Immunotherapeutics Center at the Massachusetts General Hospital.  The vaccine is being designed from a validated platform to provide customized cellular immunity against COVID-19, as well as be able to adapt rapidly to potential genetic drift of the virus.  For more information, please visit www.HaloVax.com.  

    About Voltron Therapeutics, Inc.
    Voltron Therapeutics, Inc., a Delaware corporation, was founded in 2017 to lead and accelerate the development of the Vaccine and Immunotherapy Center (VIC), and the Massachusetts General Hospital's novel Self Assembling Vaccine technology in a variety of indications, including in Oncology and emerging Infectious Diseases. Voltron holds an exclusive worldwide license to this technology.  With the work of our world class team of researchers and physicians, this technology has shown in certain pre-clinical studies initial proof of concept in two infectious diseases (Lassa Fever and Q Fever) as well as two oncology indications (Ovarian and HPV Related).  For more information please visit www.voltrontx.com

    Forward Looking Statements
    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the joint venture and the preclinical development of the SAV technology for COVID-19 and the potential development of products related to COVID-19 and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2019, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Contacts
    Investor Relations Contact:
    Phone: (646) 756-2997
    Email:   
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto, Managing Director
    (212) 896-1254

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/dr-mark-poznansky-co-creator-of--vaxcelerate-appeared-on-msnbc-to-discuss-covid-19-vaccines-301041027.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  50. NEW YORK, April 9, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced initiating the next phase of its study of VNLG-152 novel retinamides (Retinoic acid metabolism blocking agents or RAMBAs) for the treatment of dermatological diseases, at Weill Cornell Medicine. 

    Hoth continues to examine the efficacy of RAMBAs in blocking acne pathogenic gene expression and carcinogenesis in mice.  Solubility and formulation had been established for the drug for use in both human keratinocytes and mouse studies. A human keratinocyte in vitro acne study has been optimized, which uses molecules released by Propionibacterium acnes, or P. acnes, to induce an inflammatory response in these cells. 

    As part…

    NEW YORK, April 9, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced initiating the next phase of its study of VNLG-152 novel retinamides (Retinoic acid metabolism blocking agents or RAMBAs) for the treatment of dermatological diseases, at Weill Cornell Medicine. 

    Hoth continues to examine the efficacy of RAMBAs in blocking acne pathogenic gene expression and carcinogenesis in mice.  Solubility and formulation had been established for the drug for use in both human keratinocytes and mouse studies. A human keratinocyte in vitro acne study has been optimized, which uses molecules released by Propionibacterium acnes, or P. acnes, to induce an inflammatory response in these cells. 

    As part of the next phase of this study, the assay will be tested to explore whether VNLG-152 is capable of blocking this inflammatory response. Immediately after identifying an effective dose of VNLG-152, the researchers will conduct studies on mouse skin to determine if this drug is effective in blocking acne-like inflammation in vivo

    Mr. Robb Knie, Chief Executive Officer of Hoth, commented, "Our management team is honored to collaborate with Weill Cornell Medicine as their researchers continue to explore the treatment benefits of our proprietary dermatological solution. We believe that VNLG-152 has the potential to offer a unique therapeutic benefit to people suffering from acne and psoriasis."

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth recently entered into a Joint Development Agreement to further the development of vaccine prospects to prevent, intercept or treat the Coronavirus (COVID-19) based upon VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH).

    To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements
    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the preclinical development of VNLG-152 and the potential development of products related to VNLG-152 and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2019, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Contacts
    Investor Relations Contact:
    Phone: (646) 756-2997
    Email: 
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto, Managing Director
    (212) 896-1254

    Cision View original content:http://www.prnewswire.com/news-releases/hoth-therapeutics-commences-next-phase-of-vnlg-152-study-301038015.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  51. NEW YORK, April 2, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced its joint venture entity with Voltron Therapeutics, Inc., HaloVax, has entered into a Sponsored Research Agreement with the Vaccine and Immunotherapy Center (VIC) of the Massachusetts General Hospital (MGH). The goal of this partnership is to co-develop a new vaccine designed to protect patients at risk of novel coronavirus (COVID-19) infection, leveraging the Self-Assembling Vaccine (SAV) platform developed by the VIC and licensed exclusively to Voltron Therapeutics, Inc.  Voltron will spearhead the development along with its joint development partner Hoth.

    The vaccine is expected to enter animal testing within the next 30 days. The rapid advancement of this collaboration highlights the partnership between HaloVax and Hoth Therapeutics, to advance this application of VaxCelerate, the SAV platform licensed from the VIC at MGH for vaccine development.

    Dr. Mark Poznansky, Director, Vaccine and Immunotherapy Center, MGH stated, "The self-assembling vaccine has been designed to be highly adaptable, allowing for seamless modifications in the face of potential genetic drifts or future coronaviruses."

    Pursuant to an agreement announced on March 23, 2020, Hoth shall be granted the right to receive single digit royalties from the sale of any products developed, and shall have the right to acquire up to a 30% equity interest in HaloVax, HaloVax, LLC is a special purpose subsidiary of Voltron Therapeutics, Inc.

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth recently entered into a Joint Development Agreement to further the development of vaccine prospects to prevent, intercept or treat the Coronavirus (COVID-19) based upon VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH).
    To learn more, please visit www.hoththerapeutics.com.

    About Voltron Therapeutics, Inc.
    Voltron Therapeutics, Inc., a Delaware corporation, was founded in 2017 to lead and accelerate the development of the Vaccine and Immunotherapy Center (VIC), and the Massachusetts General Hospital's novel Self Assembling Vaccine technology in a variety of indications, including in Oncology and emerging Infectious Diseases. Voltron holds an exclusive worldwide license to this technology. For more information please visit www.voltrontx.com.

    Forward Looking Statements
    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the joint venture and the preclinical development of the SAV technology for COVID-19 and the potential development of products related to COVID-19 and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2019, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Contacts
    Investor Relations Contact:
    Phone: (646) 756-2997
    Email:   
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto, Managing Director
    (212) 896-1254

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-update-on-halovax-partnership-vaccine-to-fight-covid-19-with-sponsored-research-agreement-with-the-vaccine-and-immunotherapy-center-vic-of-the-massachusetts-general-hospital-mgh-301034214.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  52. NEW YORK, March 30, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced it has entered into a non-binding letter of intent ("LOI") with Isoprene Pharmaceuticals, Inc. to acquire the full licensing rights of VNLG-152 novel retinamides (Retinoic acid metabolism blocking agents, or RAMBAs) for the treatment of dermatological diseases. Isoprene is a cancer therapeutic company that is a University of Maryland, Baltimore New Venture Initiative start-up founded by Vincent Njar, the lead scientific inventor, which is developing novel small molecules for the treatment of cancer.

    Hoth had previously announced that pre-clinical work is underway at Weill Cornell Medicine to examine the efficacy of RAMBAs in blocking acne pathogenic gene expression and carcinogenesis in mice, which is currently ongoing.

    The LOI contemplates that the Company and Isoprene would enter into a definitive agreement pursuant to which Hoth will make a $50,000 investment in Isoprene in the form of a convertible promissory note, which shall bear annual interest at a rate of 6%, and shall have a discount upon conversion of 10% from the equity purchase price of the qualified financing into which the promissory note converts. Furthermore, as part of its licensing rights, Hoth will receive royalty payments from Isoprene for any use of its VNLG-152.

    Mr. Robb Knie, Chief Executive Officer of Hoth, commented, "We are excited to expand our relationship with Isoprene and support the work of Dr. Njar and his team.  Hoth looks forward to finalizing this agreement."

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth recently entered into a Joint Development Agreement to further the development of vaccine prospects to prevent, intercept or treat the Coronavirus (COVID-19) based upon VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH).
    To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements
    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements about our expectation to enter into a license agreement, the expected terms of such license agreement, and the potential development of VNLG-152, and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2019, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Contacts
    Investor Relations Contact:
    Phone: (646) 756-2997
    Email:   
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto, Managing Director
    (212) 896-1254

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-enters-into-letter-of-intent-with-isoprene-pharmaceuticals-inc-to-license-vnlg-152-for-treatment-of-dermatological-diseases-301031507.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  53. NEW YORK, March 27, 2020 /PRNewswire/ --  HaloVax, LLC a biopharmaceutical company and special purpose subsidiary of Voltron Therapeutics, Inc., announced they have reached an agreement with Hoth Therapeutics, Inc (NASDAQ:HOTH) (previously released) to advance an application of VaxCelerate, a self-assembling vaccine (SAV) platform licensed from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH), to develop a vaccine designed to protect patients at risk of Coronavirus (COVID-19) infection.  Voltron Therapeutics, Inc. has acquired an exclusive license to this technology.

    HaloVax and Hoth, with the support of MGH, will work jointly on bringing this SAV to patients at risk of being infected with COVID-19. The VaxCelerate…

    NEW YORK, March 27, 2020 /PRNewswire/ --  HaloVax, LLC a biopharmaceutical company and special purpose subsidiary of Voltron Therapeutics, Inc., announced they have reached an agreement with Hoth Therapeutics, Inc (NASDAQ:HOTH) (previously released) to advance an application of VaxCelerate, a self-assembling vaccine (SAV) platform licensed from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH), to develop a vaccine designed to protect patients at risk of Coronavirus (COVID-19) infection.  Voltron Therapeutics, Inc. has acquired an exclusive license to this technology.

    HaloVax and Hoth, with the support of MGH, will work jointly on bringing this SAV to patients at risk of being infected with COVID-19. The VaxCelerate platform was developed to improve patient outcomes by engaging the immune system to identify and remove infectious agents. The technology initially demonstrated proof of concept in Lassa Fever, an emerging infectious disease, with the support of the Department of Defense (DoD). [REF] These same principles are being applied to developing a vaccine against the COVID-19 pandemic.

    VaxCelerate offers two unique elements to combat the Coronavirus - one fixed immune adjuvant and one variable immune targeting.  VaxCelerate offers several potential advantages over other compounds in combination therapy. In infectious applications, it allows rapid development against viruses and other pathogens. The vaccine focuses on both DNA and internal / external mutated proteins providing the immune system with more potential targets to attack.

    Pat Gallagher, Voltron's CEO commented, "Voltron has been fortunate to work the team at the VIC and the Partners Organization for the past two years advancing our Self Assembling Vaccine (SAV) platform (developed at the VIC and licensed by Voltron).  During this time, we have demonstrated the ability to both modulate and stimulate the immune system in a number of disease states.  Data in four animal models in both infectious disease and oncology suggest the SAV's unique flexibility may have a clinically relevant impact in a number of settings.  We believe that this platform can potentially help eradicate new pathogens as they emerge in a timely fashion.  Our novel structural/manufacturing approach to vaccines could reduce development timelines and improve the patient experience.  We are excited to be partnering with Hoth as we believe that that they have a strong SAB which can help Voltron's subsidiary, HaloVax, accelerate it's clinical work at some of the country's top hospitals.  We are delighted to partner with Hoth to advance our COVID-19 vaccine."

    VaxCelerate was created by Drs. Mark Poznansky, MD, PhD, and Jeffrey Gelfand, MD, who will continue to support its research and development, as COVID-19 has reached pandemic status.  Dr. Poznansky is the Director of the Vaccine and Immunotherapy Center (VIC) and Physician at Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical School. Dr. Poznansky will serve as both scientific founder and scientific advisory board member to help advise on the early clinical research and implementation of testing in the hospital setting as well as to help gather additional academic and clinical KOLs to serve on the SAB.

    Dr. Gelfand is an infectious disease specialist in Boston, Massachusetts. He received his medical degree from Tufts University School of Medicine and has been in practice for more than 20 years. Dr. Gelfand specializes in infectious diseases. He is also a Clinical Professor of Medicine, where he has developed a novel approach for targeting (tumor) antigens whose sequence may not be known or structure even identified.

    Dr. Mark Poznansky, Director, Vaccine and Immunotherapy Center, MGH stated, "The team at the Vaccine and Immunology Center at Massachusetts General Hospital is focused on developing a self-assembling vaccine (SAV) for COVID-19 through its existing VaxCelerate platform. The mobilization of T-cells in the eradication of viruses is well documented.   Our experience in proof of concept studies supports the ability of SAV to evoke immune responses to viruses.   Through our partnership with HaloVax, we look forward to collaborating with Hoth to bring this potentially lifesaving vaccine to the clinic and ultimately the population at large and especially individuals who are at risk for the most serious consequences of COVID-19 infection." 

    Dr. Michael Callahan, Chief of Translational Medicine, Vaccine and Immunotherapy Center, MGH said, "This SAV technology developed at the VIC, which has proof of concept data in infectious diseases and oncology in four animal models, has the potential to rapidly address the global COVID-19 pandemic. The customizable cellular immunity generated by the SAV may safely and effectively protect patients worldwide.   Additionally, the SAV platform affords remarkable flexibility to alter or add targets if the Coronavirus begins to drift genetically.  Having worked on many 'emergency' pandemics before, I believe that SAV could offer a number of advantages in treating patients and sparing healthcare workers."

    The SAV program has intellectual property surrounding composition of matter. Incorporating HSP70 more broadly activates the immune system in contrast to prior vaccine efforts, which used classic adjuvants like alum, etc. The vaccine is >90% HSP70 and Aviden. Neoantigens are then incorporated to customize the vaccine.

    About HaloVax, LLC

    Halovax, LLC is a special purpose subsidiary of Voltron Therapeutics, Inc.  The mission of HaloVax is to develop a novel, Self-Assembling Vaccine against COVID-19, utilizing technology licensed by Voltron Therapeutics, Inc. from the Vaccine and Immunotherapeutics Center at the Massachusetts General Hospital.  The vaccine is being designed from a validated platform to provide customized cellular immunity against COVID-19, as well as be able to adapt rapidly to potential genetic drift of the virus.  For more information, please visit www.HaloVax.com.  

    About Voltron Therapeutics, Inc

    Voltron Therapeutics, Inc., a Delaware corporation, was founded in 2017 to lead and accelerate the development of the Vaccine and Immunotherapy Center (VIC), and the Massachusetts General Hospital's novel Self Assembling Vaccine technology in a variety of indications, including in Oncology and emerging Infectious Diseases.  Voltron holds an exclusive worldwide license to this technology.  With the work of our world class team of researchers and physicians, this technology has shown in certain pre-clinical studies initial proof of concept in two infectious diseases (Lassa Fever and Q Fever) as well as two oncology indications (Ovarian and HPV Related).  For more information please visit www.voltrontx.com.

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements
    Voltron Therapeutics, Inc.
    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the VaxCellerate Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Voltron's current expectations and various assumptions. Voltron believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Voltron may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and any Voltron filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Voltron's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Voltron cannot guarantee future results, events, levels of activity, performance or achievements. Voltron does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Hoth Therapeutics, Inc.
    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the BioLexa Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2019, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Investor Contact:
    Pat Gallagher, CEO
    973-216-6014
    , or

    Matt Duffy, Treasurer & Director
    646-335-5923

    Cision View original content:http://www.prnewswire.com/news-releases/halovax-announces-agreement-with-hoth-therapeutics-to-joint-develop-a-self-assembling-vaccine-sav-to-protect-patients-at-risk-of-coronavirus-covid-19-infection-301030709.html

    SOURCE Voltron Therapeutics, Inc.

    View Full Article Hide Full Article
  54. NEW YORK, March 24, 2020 /PRNewswire/ --Hoth Therapeutics, Inc. (NASDAQ:HOTH) ("Hoth" or the "Company"), a biopharmaceutical company, today announced the pricing of its previously announced "best efforts" underwritten public offering of 1,449,275 shares of its common stock at a price to the public of $3.45 per share. Hoth expects to receive aggregate gross proceeds of approximately $5 million from the offering, before deducting the underwriting discount and estimated offering expenses. The offering is expected to close on or about March 26, 2020, subject to customary closing conditions.

    Laidlaw & Company (UK) Ltd. is acting as sole book-running manager for the offering. The Benchmark Company, LLC is serving as Qualified Independent Underwriter for the offering.  Roth Capital Partners is acting as a financial advisor to the Company.

    Hoth intends to use the net proceeds from the offering for general corporate purposes, including the development of products to prevent the COVID-19 virus, working capital, sales and marketing activities, and general and administrative matters.

    A shelf registration statement on Form S-3 (Registration No. 333-236887) relating to the public offering of the shares of common stock described above was previously filed with the Securities and Exchange Commission ("SEC") and declared effective on March 11, 2020. A preliminary prospectus supplement and accompanying prospectus relating to the underwritten public offering was filed with the SEC on March 23, 2020 and is available on the SEC's website at www.sec.gov. Copies of the final prospectus supplement (when available) and accompanying prospectus relating to the offering may be obtained from Laidlaw & Company (UK) Ltd., 521 Fifth Ave., 12th Floor, New York, NY 10175, Attention: Syndicate Dept.; email: .

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of the prospectus supplement and accompanying prospectus forming a part of the effective registration statement.

    About Hoth Therapeutics Incorporated

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements


    Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including statements regarding the proposed offering, timing and the use of proceeds. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this press release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company's filings with the Securities and Exchange Commission. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

    Investor Contact:
    Phone: (646) 756-2997
    Email:  
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto, Managing Director 
    (212) 896-1254

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-announces-pricing-of-5-million-public-offering-of-common-stock-301028797.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  55. NEW YORK, March 23, 2020 /PRNewswire/ -- Hoth Therapeutics Inc. (NASDAQ:HOTH) ("Hoth" or the "Company"), a biopharmaceutical company, today announced that it intends to offer shares of its common stock in a "best efforts"  underwritten public offering. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

    Laidlaw & Company (UK) Ltd. is acting as sole book-running manager for the offering. The Benchmark Company, LLC is serving as Qualified Independent Underwriter for the offering. Hoth intends to use the net proceeds from the offering for general corporate purposes, including the development of products to prevent the COVID-19 virus, working capital, sales and marketing activities, and general and administrative matters.

    A shelf registration statement on Form S-3 (Registration No. 333-236887) relating to the public offering of the shares of common stock described above was previously filed with the Securities and Exchange Commission (SEC) and declared effective on March 4, 2020. A preliminary prospectus supplement and accompanying prospectus relating to the underwritten public offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Copies of the preliminary prospectus supplement (when available) and accompanying prospectus relating to the offering may be obtained from Laidlaw & Company (UK) Ltd., 521 Fifth Ave., 12th Floor, New York, NY 10175, Attention: Syndicate Dept.; email: .

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of the prospectus supplement and accompanying prospectus forming a part of the effective registration statement.

    About Hoth Therapeutics Incorporated

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements
    Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including statements regarding the proposed offering, timing and the use of proceeds. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

    Investor Contact:
    Phone: (646) 756-2997
    Email:  
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto, Managing Director 
    (212) 896-1254

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-inc-announces-proposed-public-offering-of-common-stock-301028529.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  56. NEW YORK, March 23, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced it has reached an agreement with Voltron Therapeutics, Hoth Therapeuticsto form a joint venture entity (to be named HaloVax) to commence preclinical studies for the development of vaccine prospects to prevent, intercept or treat the Coronavirus (COVID-19) based upon VaxCelerate, a self-assembling vaccine (SAV) platform exclusively licensed by Voltron from the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital (MGH). 

    Hoth and Voltron, with the support of MGH, will work jointly on exploring and developing this SAV technology as a means to aid patients at risk of being infected with COVID-19. [The VaxCelerate vaccine platform was developed as a means of rapidly generating and pre-clinically testing a new vaccine against specific pathogen targets. The technology which received Department of Defense (DoD) funding has demonstrated proof of concept in Lassa Fever, an emerging infectious disease.  HaloVax intends to use these same SAV principles to assist in the development of a potential vaccine against the COVID-19 pandemic.

    Hoth believes VaxCelerate offers two unique elements to combat the Coronavirus - one fixed immune adjuvant and one variable immune targeting and offers several potential advantages over other compounds in combination therapy. In infectious applications, it allows rapid development against viruses and other pathogens. The vaccine focuses on both DNA and internal / external mutated proteins providing the immune system with more potential targets to attack.

    VaxCelerate was founded by Dr. Mark Poznansky, MD, PhD, and Dr. Jeffrey Gelfand, MD, who will both continue to support its research and development.  Dr. Poznansky is the Director of the Vaccine and Immunotherapy Center (VIC) and a Physician at Massachusetts General Hospital, as well as an Associate Professor of Medicine at Harvard Medical School. Dr. Poznansky will serve as both scientific founder and scientific advisory board member of Halovax to help advise on the early clinical research and implementation of testing in the hospital setting.

    Dr. Gelfand is an infectious disease specialist in Boston, Massachusetts. He received his medical degree from Tufts University School of Medicine and has been in practice for more than 20 years. Dr. Gelfand's specializes in infectious disease. He is also a Clinical Professor of Medicine at Harvard University, where he has developed a novel approach for targeting (tumor) antigens whose sequence may not be known or structure even identified.

    Dr. Mark Poznansky, Director, Vaccine and Immunotherapy Center, of MGH stated, "The team at the Vaccine and Immunology Center at Massachusetts General Hospital is focused on developing a self-assembling vaccine (SAV) for COVID-19 through its existing VaxCelerate platform. The mobilization of T-cells in the eradication of viruses is well documented.  Our experience in proof of concept studies supports the ability of the SAV to evoke immune responses to viruses.  Through our partnership with Voltron, we look forward to collaborating to bring this technology to the clinic and exploring how it can potentially be used to prevent, intercept or treat the population at large and especially individuals who are at risk for the most serious consequences of COVID-19 infection." 

    Dr. Michael Callahan, Chief of Translational Medicine, Vaccine and Immunotherapy Center, of MGH said, "We believe this SAV technology developed at the VIC, which has proof of concept data in infectious diseases and oncology in four animal models, has the potential to assist in the rapid development and testing of products to prevent, intercept or treat COVID-19. The customizable cellular immunity generated by the SAV may safely and effectively protect patients worldwide."

    Dr. Andrew Herr, PhD, Hoth's Scientific Advisor, will work closely with Dr. Pozansky and Dr. Gelfand. Dr. Herr is an associate professor in the Division of Immunobiology and Center for Systems Immunology, with an affiliate appointment in the Division of Infectious Diseases at Cincinnati Children's Hospital within the UC Department of Pediatrics. Dr. Herr completed his thesis work in molecular biophysics from Washington University in St. Louis, and completed his postdoctoral work in structural immunology at the California Institute of Technology as a Damon Runyon Research Fellow. He was recruited to the University of Cincinnati College of Medicine as an Ohio Eminent Scholar in Structural Biology before moving to Cincinnati Children's Hospital.

    "COVID-19 is global a pandemic. With the support of Andy Herr, Hoth's Scientific Advisor and professor of infectious diseases at the University of Cincinnati, we intend to leverage our resources to develop products designed to prevent, intercept or treat this deadly virus. We believe that the VaxCelerate technology has the potential to provide a differentiated approach to finding a COVID-19 vaccine," said Mr. Robb Knie, Chief Executive Officer of Hoth.

    Pursuant to the agreement, Hoth shall be granted the right to receive single digit royalties from the sale of any products developed, and shall have the right to acquire up to a 30% equity interest in HaloVax.

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements

    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the joint venture and the preclinical development of the SAV technology for COVID-19 and the potential development of products related to COVID-19 and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2019, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Investor Contact:
    Phone: (646) 756-2997
    Email:  
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto, Managing Director 
    (212) 896-1254

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-announces-agreement-to-joint-development-of-a-self-assembling-vaccine-sav-for-the-potential-treatment-of-the-coronavirus-covid-19-301028140.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  57. NEW YORK, March 19, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) (the "Company' or "Hoth"), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis, psoriasis and acne as well as gene therapy treatment for asthmatics, today announced results from a preclinical study demonstrating the potential effectiveness of WEG232, a topical treatment with specific substance P-receptor inhibitor for Erlotinib-induced facial dermatitis and hair loss in cancer patients.

    Erlotinib, an EGFR1-tyrosine kinase inhibitor, is an effective anti-tumorigenesis agent, which combats several cancers including lung, colon, head and neck.  Typically, significant and often severe cutaneous toxicities are serious side effects of Erlotinib, limiting its full potential use to prolong patient survival. Previous studies suggest that neurogenic inflammation plays a serious role in causing EGFR-TKI induced off-target toxicity.  This trial was designed to assess if topical application of WEG232, a specific Substance P-receptor inhibitor, would be protective against erlotinib-induced facial rash and/or hair loss. 

    The research, which took place at the George Washington University and supported by Hoth, suggests the topical application of WEG232 could be very effective in suppressing erlotinib induced-facial rash/hair loss with approximate 71% reduction. It concluded that WEG232 may be used as an effective intervention to prevent EGFR-TKI-induced cutaneous toxicity.

    Mr. Robb Knie, Chief Executive Officer of Hoth, added, "This 12-week study with 25 SD-rats showed overwhelming compelling results of a 71% facial rash and hair loss reduction.   Our next steps will be to further our preclinical work while also preparing for a pre-Investigational New Drug (Pre-IND) meeting request with the U.S. FDA.  We look forward to publishing complete results of the aforementioned study in poster form prior to our pre-IND."

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements
    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the BioLexa Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2019, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Contacts
    Investor Relations Contact:
    Phone: (646) 756-2997
    Email:  
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto, Managing Director 
    (212) 896-1254

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-announces-positive-preclinical-data-of-weg232-treatment-developed-for-cancer-patients-suffering-from-erlotinib-induced-facial-dermatitis-and-hair-loss-301026876.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  58. NEW YORK, March 16, 2020 /PRNewswire/ -- Diamond Equity Research, an equity research firm with a focus on micro capitalization and small capitalization public companies has released a comprehensive update note of Hoth Therapeutics, Inc. (NASDAQ:HOTH). The report includes detailed information on Hoth Therapeutics' business model and recent developments. More detailed information can be found in Diamond Equity Research's September 2019 initiation report.

    The full research report is available by registering here. Highlights from the report include:

    Hoth Therapeutics, Inc. has intensively collaborated with university research labs to develop their drug candidates. Although currently still in early development stages, the company is targeting large markets. HOTH expects to face significant competition from other current treatments and the development pipelines of large pharmaceutical companies and emerging biotechnology companies. It competes in an industry characterized by (1) rapid technological change, (2) evolving industry standards, (3) emerging competition, and (4) new product introductions. Large competitors will likely be equipped to (1) provide broader product lines with greater sales and marketing forces, (2) make larger investments in research and development, and (3) consummate more acquisitions to strengthen their drug portfolio.

    That said, we believe HOTH is well positioned in the industry, with its (1) novel and differentiated potential treatment targeted at preventing the formation of bacterial biofilm and addressing the potential impairment of skin barrier function, (2) patented BioLexa Platform, which combines two existing approved drugs, enabling reliance on existing safety data for those drugs, which could result in faster regulatory approval, (3) strong intellectual property portfolio, including exclusive licenses to patents and trademarks, and (4) additional potential therapies targeting dermatological issues and genetic disorders, including diabetic ulcers, skin aesthetics, psoriasis, and food allergies. However, given the early stage of the company the company is suited for sophisticated institutional investors or high-risk tolerant retail investors.

    • Micro capitalization equities tend to trade more on their fundamentals versus macro issues, in line with Hoth Therapeutics recently stating to investors that Coronaviruses (COVID-19) should have limited impact on its operations. The company is still planning its trial in Australia for its proprietary BioLexa Platform for patients suffering from mild to moderate atopic dermatitis. We note later stage assets in this area have historically commanded high valuations, including the recent $1.1 billion Eli Lilly acquisition of Dermira, which was pursuing a phase three trial in atopic dermatitis. Hoth recently provided updates on its earlier stage pipeline. The company's preclinical study of WEG-232 for the dermatological treatment of side effects caused by cancer medications is nearing its completion with updates to be provided soon. Additionally, the company's preclinical study on VNLG-152 at Weill Cornell is moving forward evaluating possible efficacy of RAMBA in preventing acne pathogenic gene expression and carcinogenesis in mice. Hoth is also proceeding with its recently initiated preclinical gene therapy program with North Carolina State University for the treatment of asthma and allergic inflammation. Any positive developments within these trials could function as a catalyst for the stock in our view. Micro capitalization equities tend to trade more on their individual business developments versus macro issues, compared to mid and large capitalization stocks which are more exposed, as such we view any positive material updates on any of Hoth's pipeline as potential catalysts for shares despite macroeconomic headwinds.
    • BioLexa Platform is a patented drug-compound platform for the treatment of eczema that combines approved antibiotics with FDA-approved zinc chelators and topical formulations to address unchecked episodes of eczema by preventing the formation of infectious biofilms and the resulting blockage of sweat ducts. Unlike other treatments in the market such as topical steroids, OTC moisturizers, oatmeal baths, and soaps that lack efficacy in reducing symptoms, BioLexa's approach is intended to delay and prevent the flare-up of symptoms with topical and localized delivery, and can be used with other drugs to maximize benefits. BioLexa can potentially reach the market faster than traditional drugs if the upcoming clinical studies indicate positive results given the 505 (b)(2) pathway.
    • HOTH operates in the large and growing dermatology market. According to the National Eczema Association, there are approximately 32 million atopic dermatitis (AD) patients in the U.S. AD drug sales are projected to reach $13.6 billion by 2022 according to a recent report by Grandview Research. The U.S. market is projected to grow rapidly due to increasing incidence, new targeted therapies, favorable reimbursement policies, and government initiatives to provide better and more affordable treatments.
    • Valuation model indicates upside potential if trials prove successful. Despite the unique value HOTH offers with its novel and differentiated BioLexa Platform, it currently is valued at only a $40 million market capitalization. Our combined discounted cash flow and technology value analysis model indicate a fair value of $7 per share, which is largely contingent on the company successfully getting BioLexa approved in mild to moderate AD (eczema).

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. To learn more, please visit www.hoththerapeutics.com.

    About Diamond Equity Research
    Diamond Equity Research is a leading equity research and corporate access firm focused on small capitalization companies. Diamond Equity Research is an approved sell-side provider on premiere institutional investor platforms including Factset, Morningstar, and Thomson One. The firm is headquartered in midtown Manhattan. For more information, visit www.diamondequityresearch.com.

    Disclosures: Full disclosures pertaining to this report can be found at the end of the report and on the Diamond Equity Research website disclosure section. Diamond Equity Research LLC is being compensated by Hoth Therapeutics, Inc. for producing research materials regarding Hoth Therapeutics, Inc. and its securities, which is meant to subsidize the high cost of creating the report and monitoring the security, however the views in the report reflect that of Diamond Equity Research. All payments are received upfront and are billed for an annual or semi-annual research engagement. As of 03/16/2020 the issuer had paid us $22,000 for our subscription research services, which commenced 08/09/2019 and is billed annually. Diamond Equity Research LLC may be compensated for non-research related services, including presenting at Diamond Equity Research investment conferences, press releases and other additional services. Diamond Equity Research LLC was also paid a one-time fee of $4,000 for one investment note and corresponding press release.  The issuer has paid us for non-research related services consisting of $3,500 to present at two investment conferences and $550 for a press release as of 03/16/2020. Issuers are not required to engage us for these additional services. Additional fees may have accrued since then.

    Forward Looking Statements
    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the BioLexa Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2018, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Contacts
    Investor Relations Contact:
    Phone: (646) 756-2997
    Email:  
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto, Managing Director 
    (212) 896-1254

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/diamond-equity-research-publishes-report-valuing-hoth-common-stock-at-7-00-per-share-301024686.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  59. NEW YORK, March 9, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis, psoriasis and acne along with gene therapy treatment for asthmatics, announced today that its business operations have not been affected by COVID-19 Coronavirus.

    Mr. Robb Knie, CEO of Hoth Therapeutics, Inc. stated, "Hoth continues its plans for an upcoming trial in Australia later this year for its proprietary BioLexa Platform for those patients suffering with mild to moderate atopic dermatitis.  Our preclinical study of WEG-232 for dermatological treatment relating to the side effects of cancer medication is in its final stages and we look forward to sharing those results later this month.  The VNLG-152 preclinical study at Weill Cornell Medicine to examine the efficacy of RAMBA in blocking acne pathogenic gene expression and carcinogenesis in mice is well underway and continuing to proceed.  Our Gene Therapy program in conjunction with N.C. State has progressed to its next steps with no interruptions.  We at Hoth look forward to further updating our shareholders as we continue to work diligently to further the development of therapeutics within our pipeline."

    While the Company does not anticipate that the virus poses any interruptions to its business or its clinical trial timeline, it did offer a reminder to those patients that are afflicted with Atopic Dermatitis.  The National Eczema Society stated that there is currently no "eczema-friendly" hand sanitizer on the market, as those available products all contain alcohol.  Overuse of the product can cause increased dryness to patients' skin, therefore causing cracks and increasing potential points of entry for viruses.  Hoth stands with the National Eczema Society and would like to provide this reminder in an effort to increase awareness and improve public safety. For more information please visit: http://www.eczema.org/coronavirus.

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements
    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the BioLexa Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2018, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Contacts
    Investor Relations Contact:
    Phone: (646) 756-2997
    Email:  
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto, Managing Director 
    (212) 896-1254

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-inc-states-covid-19-coronavirus-poses-no-negative-effect-on-companys-operations-301019499.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  60. NEW YORK, Feb. 19, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis, psoriasis and acne along with gene therapy treatment for asthmatics, announced today that it has received patents granted for its BioLexa Platform, a proprietary antimicrobial therapy designed for the treatment of atopic dermatitis. The therapeutic offers a non-corticosteroid approach treating atopic dermatitis. 

    (PRNewsfoto/Hoth Therapeutics Inc.)

    "We are very pleased to see the expansion of the Hoth Therapeutics intellectual property portfolio in Europe," said Robb Knie, Chief Executive Officer of Hoth Therapeutics.

    About Hoth Therapeutics, Inc.

    NEW YORK, Feb. 19, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis, psoriasis and acne along with gene therapy treatment for asthmatics, announced today that it has received patents granted for its BioLexa Platform, a proprietary antimicrobial therapy designed for the treatment of atopic dermatitis. The therapeutic offers a non-corticosteroid approach treating atopic dermatitis. 

    (PRNewsfoto/Hoth Therapeutics Inc.)

    "We are very pleased to see the expansion of the Hoth Therapeutics intellectual property portfolio in Europe," said Robb Knie, Chief Executive Officer of Hoth Therapeutics.

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements
    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the BioLexa Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2018, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Contacts
    Investor Relations Contact:
    Phone: (646) 756-2997
    Email:  
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto, Managing Director 
    (212) 896-1254

    Related Links
    https://hoththerapeutics.com

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-receives-notice-of-allowance-from-european-patent-office-301007604.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  61. NEW YORK, Feb. 12, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis, psoriasis and acne along with gene therapy treatment for asthmatics, today announced preliminary, preclinical data for its lupus treatment for patients suffering with Cutaneous Lupus Erythematous (CLE), a chronic autoimmune skin disease.

    "The preliminary data of our study is a positive step toward underlining the transformative potential of AEA-loaded Z-pods™ in patients suffering from CLE," stated Mr. Robb Knie, CEO of Hoth Therapeutics, Inc.  "We are pleased with the results we have made in the development…

    NEW YORK, Feb. 12, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis, psoriasis and acne along with gene therapy treatment for asthmatics, today announced preliminary, preclinical data for its lupus treatment for patients suffering with Cutaneous Lupus Erythematous (CLE), a chronic autoimmune skin disease.

    "The preliminary data of our study is a positive step toward underlining the transformative potential of AEA-loaded Z-pods™ in patients suffering from CLE," stated Mr. Robb Knie, CEO of Hoth Therapeutics, Inc.  "We are pleased with the results we have made in the development of our lupus treatment since announcing our strategy earlier this year with our partner Zylö Therapeutics.  At the conclusion of this study we look forward to the next steps in bringing this treatment to those patients in need."

    Mr. Scott Pancoast, CEO of Zylö, added, "These compelling results, coupled with the data from a preliminary study conducted at Einstein College of Medicine, clearly warrant further investigation of this novel approach to treating cutaneous manifestations of lupus."

    Hoth owns an exclusive license to develop Anandamide-loaded Z-pods™ for the treatment of CLE in North America. Anandamide, generally referred to as AEA, is one of the cannabinoids that the human body makes naturally. The Company also possesses rights related to geographic expansion and to follow-on indications such as psoriasis and rheumatoid arthritis.

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements
    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the BioLexa Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2018, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Contacts
    Investor Relations Contact:
    Phone: (646) 756-2997
    Email:  
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto, Managing Director 
    (212) 896-1254

    Related Links
    https://hoththerapeutics.com

    (PRNewsfoto/Hoth Therapeutics Inc.)

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-announces-positive-preliminary-preclinical-data-on-its-therapeutic-for-cutaneous-lupus-erythematosus-cle-a-chronic-autoimmune-skin-disease-301003478.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  62. NEW YORK, Feb. 11, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis, psoriasis and acne along with gene therapy treatment for asthmatics,  today announced that Robb Knie, Chief Executive Officer, will be presenting at the Noble Capital Markets' Sixteenth Annual Investor Conference on February 18, 2020 at the Hard Rock Hotel & Casino, Hollywood, Florida.

    (PRNewsfoto/Hoth Therapeutics Inc.)

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality…

    NEW YORK, Feb. 11, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis, psoriasis and acne along with gene therapy treatment for asthmatics,  today announced that Robb Knie, Chief Executive Officer, will be presenting at the Noble Capital Markets' Sixteenth Annual Investor Conference on February 18, 2020 at the Hard Rock Hotel & Casino, Hollywood, Florida.

    (PRNewsfoto/Hoth Therapeutics Inc.)

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements
    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the BioLexa Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2018, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Contacts
    Investor Relations Contact:
    Phone: (646) 756-2997
    Email:  
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto
    (212) 896-1254

    Related Links
    https://hoththerapeutics.com

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-inc-to-present-at-2020-noble-capital-markets-sixteenth-annual-small-cap-investor-conference-301002589.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  63. NEW YORK, Feb. 4, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis, psoriasis and acne along with gene therapy treatment for asthmatics,  is pleased to announce the initiation of a preclinical study for the treatment of asthma and allergic inflammation in collaboration with North Carolina State University (NC State).  

    (PRNewsfoto/Hoth Therapeutics Inc.)

    The study has begun the delivery and distribution of nebulized particles which will enable the therapeutic oligonucleotide (oligo), short DNA and RNA molecules that have a wide range of applications in gene testing. Hoth has appointed Dr. Glenn Cruse to its Scientific…

    NEW YORK, Feb. 4, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis, psoriasis and acne along with gene therapy treatment for asthmatics,  is pleased to announce the initiation of a preclinical study for the treatment of asthma and allergic inflammation in collaboration with North Carolina State University (NC State).  

    (PRNewsfoto/Hoth Therapeutics Inc.)

    The study has begun the delivery and distribution of nebulized particles which will enable the therapeutic oligonucleotide (oligo), short DNA and RNA molecules that have a wide range of applications in gene testing. Hoth has appointed Dr. Glenn Cruse to its Scientific Advisory Board and will oversee the Company's gene therapy programs advancements.

    Mr. Robb Knie, Chief Executive Officer of Hoth Therapeutics, Inc. commented, "We are extremely pleased that our gene therapy program with NC State has officially begun and that Dr. Cruse who is overseeing the advancement of experiments has joined our Scientific Advisory Board.  Commencement of this initiative is an important step in the development and growth of our company.  Dr. Cruse's expertise as a leading mast cell biologist in allergic and inflammatory diseases will be invaluable for the preclinical development of Splice-switching oligonucleotides (SSOs) for asthma."

    In November 2019 Hoth entered into a licensing agreement with North Carolina State University (NC State) to study NC State's Exon Skipping Approach for Treating Allergic Diseases. This Exon Skipping Approach was developed by Dr. Glenn Cruse, Principal Investigator and Assistant Professor in the Department of Molecular Biomedical Sciences at the NC State College of Veterinary Medicine. During Dr. Cruse's research, a new approach for the technique of antisense oligonucleotide-mediated exon skipping to specifically target and down-regulate IgE receptor expression in mast cells was identified. These findings set a breakthrough for allergic diseases as they are driven by the activation of mast cells and the release of mediators in response to IgE-directed antigens.

    Glenn Cruse completed his Ph.D.  at Glenfield Hospital, The University of Leicester, UK in 2009. He then moved to the National Institutes of Health in Bethesda, Maryland in January 2010 to start a visiting postdoctoral fellowship in the Laboratory of Allergic Diseases, NIAID, In January 2015, Dr. Cruse was appointed as a Research Fellow in the same laboratory. Dr. Cruse joined the Department of Molecular Biomedical Sciences at NC State in January 2016 as an Assistant Professor. 

    Dr. Cruse is a mast cell biologist that has authored and co-authored over 30 publications including articles in top journals such as the New England Journal of Medicine, Proceedings of the National Academy of Sciences USA and Immunity. The Cruse lab is interested in the role that mast cells play in allergic and inflammatory diseases and identifying novel therapeutics that target mast cells. Since mast cells act as sentinel cells that participate in both innate and acquired immunity, particularly at biological barriers, emphasis on diseases in tissues at the interface with the environment such as the lung, skin, gastrointestinal tract and even the neuro-immune axis are the main focus of the lab.

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements
    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the BioLexa Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2018, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Contacts
    Investor Relations Contact:
    Phone: (646) 756-2997
    Email:  
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto
    (212) 896-1254

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-initiates-preclinical-gene-therapy-program-with-nc-state-for-the-treatment-of-asthma-and-allergic-inflammation-300998521.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  64. NEW YORK, Jan. 29, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company focused on developing new generation therapies for dermatological and immunological disorders such as atopic dermatitis, psoriasis, asthma and acne, announced today that the Company, after further evaluation under its Commercial Evaluation Sublicense and Option Agreement with the University of Maryland, Baltimore (UMB) and Isoprene Pharmaceuticals Inc. will exercise its option for full licensing rights of Dermatology Field to develop and commercialize therapeutic compounds for the treatment of dermatological conditions in humans.

    (PRNewsfoto/Hoth Therapeutics Inc.)

    The licensing agreement stems from results reported by UMB relating to the effect Retinoic acid metabolism…

    NEW YORK, Jan. 29, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company focused on developing new generation therapies for dermatological and immunological disorders such as atopic dermatitis, psoriasis, asthma and acne, announced today that the Company, after further evaluation under its Commercial Evaluation Sublicense and Option Agreement with the University of Maryland, Baltimore (UMB) and Isoprene Pharmaceuticals Inc. will exercise its option for full licensing rights of Dermatology Field to develop and commercialize therapeutic compounds for the treatment of dermatological conditions in humans.

    (PRNewsfoto/Hoth Therapeutics Inc.)

    The licensing agreement stems from results reported by UMB relating to the effect Retinoic acid metabolism blocking agents (RAMBAs) offer in treating cancer and dermatology related issues. To view the published results of the research, please click here.  Furthermore, Hoth has begun its preclinical study program and anticipates sharing these results upon completion of the study.

    Mr. Robb Knie, Chief Executive Officer of Hoth, commented, "We are pleased with our research of VNLG-152 novel retinamides (Retinoic acid metabolism blocking agents or RAMBAs) for the treatment of dermatological diseases over the last several months and believe that this therapeutic brings significant value to Hoth's pipeline.  We look forward to working with UMB, Isoprene and Dr. Vincent Njar, lead inventor of VNLG-152 and Scientific Board Member of Hoth Therapeutics."

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements
    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the BioLexa Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2018, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Contacts
    Investor Relations Contact:
    Phone: (646) 756-2997
    Email:  
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto / Daniela Guerrero
    (212) 896-1254 / (212) 682-6300

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-to-further-its-research-of-vnlg-152-and-plans-exercise-of-its-option-agreement-with-university-of-maryland-baltimore-and-isoprene-pharmaceuticals-inc-300994964.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  65. NEW YORK, Jan. 21, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company focused on developing new generation therapies for dermatological and immunological disorders such as atopic dermatitis, psoriasis, asthma and acne, announced today that the Company has concluded its "In-life 28-day animal study" for their BioLexa Platform. 

    (PRNewsfoto/Hoth Therapeutics Inc.)

    The BioLexa Platform is a proprietary antimicrobial therapy designed for the treatment of atopic dermatitis. The therapeutic offers a non-corticosteroid approach treating atopic dermatitis. 

    The condition of the minipigs was observed and checked for dermal observations, dosing, and bioanalysis sample collection. All animals were in good condition with no test item-related dermal…

    NEW YORK, Jan. 21, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company focused on developing new generation therapies for dermatological and immunological disorders such as atopic dermatitis, psoriasis, asthma and acne, announced today that the Company has concluded its "In-life 28-day animal study" for their BioLexa Platform. 

    (PRNewsfoto/Hoth Therapeutics Inc.)

    The BioLexa Platform is a proprietary antimicrobial therapy designed for the treatment of atopic dermatitis. The therapeutic offers a non-corticosteroid approach treating atopic dermatitis. 

    The condition of the minipigs was observed and checked for dermal observations, dosing, and bioanalysis sample collection. All animals were in good condition with no test item-related dermal observations. Hoth's team also observed the clinical pathology processing and necropsies of the males. There did not appear to be any gross test item-related findings at necropsy and that data will be provided when post testing is concluded.  There were no test item related ophthalmic findings, so those exams will not be needed in the recovery animals. Hoth discussed plans to make the reporting phase of the study as efficient as possible and the Company will review the data and phase reports as they are available. 

    Mr. Robb Knie, Chief Executive Officer of Hoth, commented, "Management is pleased to continue our progress through critical industry testing standards. We await the bioanalytical report and look forward to utilizing this study for our proposed application for clinical trials in humans later this year."

    About Hoth Therapeutics, Inc. 
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, and acne. HOTH has the exclusive worldwide rights to BioLexa, the company's proprietary lead drug candidate topical platform that uniquely combines two FDA approved compounds to fight bacterial infections across multiple indications. HOTH is preparing to launch its clinical trial for the treatment of adolescent subjects, 2-17 years of age, with mild to moderate atopic dermatitis during 2020. To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements 
    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the BioLexa Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2018, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Contacts 
    Investor Relations Contact: 
    Phone: (646) 756-2997 
    Email: 
    www.hoththerapeutics.com

    KCSA Strategic Communications 
    Valter Pinto / Daniela Guerrero 
    (212) 896-1254 / (212) 682-6300 

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-completes-animal-safety-study-of-proprietary-biolexa-platform-for-the-treatment-of-atopic-dermatitis-300989955.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  66. ORLANDO, Fla., Jan. 17, 2020 (GLOBE NEWSWIRE) -- It doesn't take an analyst to suggest that high value merger and acquisition activity in any industry is a bullish sign. And it assuredly doesn't take any research firm at all to suggest that an eczema related company like Hoth Therapeutics, Inc. (NASDAQ:HOTH) would be pleased to see none other than Eli Lilly acquire eczema company Dermira for a whopping $1.1 billion all cash deal.

    Yes, $1.1 billion.

    And while Hoth and Dermira aren't identical companies, it is clear from this and other indicators that the eczema market is rapidly growing. Hoth is well-entrenched in research and development with leading partners in its effort to secure its place in the expanding eczema/atropic dermatitis market…

    ORLANDO, Fla., Jan. 17, 2020 (GLOBE NEWSWIRE) -- It doesn't take an analyst to suggest that high value merger and acquisition activity in any industry is a bullish sign. And it assuredly doesn't take any research firm at all to suggest that an eczema related company like Hoth Therapeutics, Inc. (NASDAQ:HOTH) would be pleased to see none other than Eli Lilly acquire eczema company Dermira for a whopping $1.1 billion all cash deal.

    Yes, $1.1 billion.

    And while Hoth and Dermira aren't identical companies, it is clear from this and other indicators that the eczema market is rapidly growing. Hoth is well-entrenched in research and development with leading partners in its effort to secure its place in the expanding eczema/atropic dermatitis market.

    It is also worth noting that eczema is but one in array of opportunities that Hoth is pursuing. But it is the only one that saw a $1.1 billion acquisition in its industry.

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, and acne. HOTH has the exclusive worldwide rights to BioLexa, the company's proprietary lead drug candidate topical platform that uniquely combines two FDA approved compounds to fight bacterial infections across multiple indications. HOTH is preparing to launch its clinical trial for the treatment of adolescent subjects, 2-17 years of age, with mild to moderate atopic dermatitis during 2020. To learn more, please visit www.hoththerapeutics.com.

    About The Emerging Markets Report:

    The Emerging Markets Report is owned and operated by Emerging Markets Consulting (EMC), a syndicate of investor relations consultants representing years of experience. Our network consists of stock brokers, investment bankers, fund managers, and institutions that actively seek opportunities in the micro and small-cap equity markets.

    For more informative reports such as this, please sign up at http://www.emergingmarketsllc.com/newsletter.php

    Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below.

    We may purchase Securities of the Profiled Company prior to their securities becoming publicly traded, which we may later sell publicly before, during or after our dissemination of the Information, and make profits therefrom. EMC does not verify or endorse any medical claims for any of its client companies.

    EMC has been paid $155,500 by Hoth Therapeutics, Inc. for various marketing services including this report. EMC does not independently verify any of the content linked-to from this editorial. http://emergingmarketsllc.com/disclaimer.php

    Emerging Markets Consulting, LLC
    Florida Office
    15701 State Road 50, Suite #205
    Clermont, FL 34711
    E-mail:
    Web: www.emergingmarketsllc.com

    Primary Logo

    View Full Article Hide Full Article
  67. NEW YORK, Jan. 15, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis, psoriasis and acne along with gene therapy treatment for asthmatics, announced today it has exercised its option to take an exclusive license for patents owned by the George Washington University (GW).  Hoth used the option period to evaluate GW's unique Substance P receptor blocker (Aprepitant) that inhibited cutaneous and other neurogenic inflammation side effects that cancer patients suffer during treatment with anticancer drugs. The exercise of the option agreement allows for Hoth to negotiate an exclusive patent…

    NEW YORK, Jan. 15, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis, psoriasis and acne along with gene therapy treatment for asthmatics, announced today it has exercised its option to take an exclusive license for patents owned by the George Washington University (GW).  Hoth used the option period to evaluate GW's unique Substance P receptor blocker (Aprepitant) that inhibited cutaneous and other neurogenic inflammation side effects that cancer patients suffer during treatment with anticancer drugs. The exercise of the option agreement allows for Hoth to negotiate an exclusive patent license agreement.  The option agreement included pre-negotiated business terms for the exclusive patent license, so Hoth anticipates finalizing the license this month.

    (PRNewsfoto/Hoth Therapeutics Inc.)

    In June of 2019, Hoth entered into a sponsored research agreement with GW to explore the potential use of Aprepitant in different forms.

    Mr. Robb Knie, Chief Executive Officer of Hoth, commented, "Our research collaboration with GW has yielded positive preliminary results.  Our next step will be to plan for the quickest pathway to help patients suffering from adverse events, often so severe that they impair the patient's compliance with the anticancer treatment and even cause its discontinuation.  Management looks forward to sharing the preclinical results of our unique formulation of this topical therapeutic upon its completion later this year."

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, and acne. HOTH has the exclusive worldwide rights to BioLexa, the company's proprietary lead drug candidate topical platform that uniquely combines two FDA approved compounds to fight bacterial infections across multiple indications. HOTH is preparing to launch its clinical trial for the treatment of adolescent subjects, 2-17 years of age, with mild to moderate atopic dermatitis during 2020. To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements
    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the BioLexa Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2018, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Contacts
    Investor Relations Contact:
    Phone: (646) 756-2997
    Email: investorrelat 
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto / Daniela Guerrero
    (212) 896-1254 / (212) 682-6300

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-exercises-patent-licensing-option-with-the-george-washington-university-to-further-develop-a-therapeutic-for-cancer-patients-suffering-cutaneous-changes-like-rash-and-hair-loss-as-well-as-other-neurogenic-inflam-300986933.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  68. ORLANDO, Fla., Jan. 14, 2020 (GLOBE NEWSWIRE) -- The headline of our written offering today probably appears a little different from our regular titles. Typically we don't lead with things that are so widely despised or feared. But when we are discussing biopharmaceutical company Hoth Therapeutics, Inc. (NASDAQ:HOTH) the widespread loathing of the aforementioned maladies is precisely the point.

    Since Hoth is intent on developing remedies for these afflictions the size of these markets is important. And since nearly every reader of today's missive has encountered one of them or surely known someone who has it does directly speak to the market opportunity.

    Let's take them one by one.

    Acne:

    Hoth announced it was entering into a research collaboration

    ORLANDO, Fla., Jan. 14, 2020 (GLOBE NEWSWIRE) -- The headline of our written offering today probably appears a little different from our regular titles. Typically we don't lead with things that are so widely despised or feared. But when we are discussing biopharmaceutical company Hoth Therapeutics, Inc. (NASDAQ:HOTH) the widespread loathing of the aforementioned maladies is precisely the point.

    Since Hoth is intent on developing remedies for these afflictions the size of these markets is important. And since nearly every reader of today's missive has encountered one of them or surely known someone who has it does directly speak to the market opportunity.

    Let's take them one by one.

    Acne:

    Hoth announced it was entering into a research collaboration agreement with Weill Cornell Medicine to examine the ability of retinoic acid metabolism blocking agents (RAMBA) to block acne pathogenic gene expression in human keratinocytes, mouse skin, and carcinogenesis in mice.

    According to Grand View Research, the global acne drug market size is expected to reach USD 5.9 billion by 2025, according to a new report by Grand View Research, Inc., registering a 4.2% CAGR during the forecast period. Several factors such as emergence of biologics, unhealthy lifestyle, and rising disease incidence are anticipated to drive the market.

    Eczema/Dermatitis

    Hoth recently announced that the Company has completed Phase I of their In-Life dose escalation study for atopic dermatitis/eczema. The phase 1 Dosing was done in animals for toxicology purposes in preparation for human trails this year. 

    The Business Research Firm believes the global dermatitis drugs market which was valued at about $17.88 billion in 2018 is expected to grow to $25.52 billion at an annual growth rate of 9.3% through 2022. 

    Asthma:

    Hoth recently announced the initiation of a preclinical study for the treatment of asthma and allergic inflammation in collaboration with North Carolina State University (NC State) beginning on January 1, 2020.

    According to a recent report, the global anti-asthma drugs market was valued at USD 18.9 billion as of 2015 and is projected to reach USD 28.3 billion as of 2022, at a CAGR of 5.94%.

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, and acne. HOTH has the exclusive worldwide rights to BioLexa, the company's proprietary lead drug candidate topical platform that uniquely combines two FDA approved compounds to fight bacterial infections across multiple indications. HOTH is preparing to launch its clinical trial for the treatment of adolescent subjects, 2-17 years of age, with mild to moderate atopic dermatitis during 2020. To learn more, please visit www.hoththerapeutics.com.

    About The Emerging Markets Report:

    The Emerging Markets Report is owned and operated by Emerging Markets Consulting (EMC), a syndicate of investor relations consultants representing years of experience. Our network consists of stock brokers, investment bankers, fund managers, and institutions that actively seek opportunities in the micro and small-cap equity markets.

    For more informative reports such as this, please sign up at http://www.emergingmarketsllc.com/newsletter.php

    Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below.

    We may purchase Securities of the Profiled Company prior to their securities becoming publicly traded, which we may later sell publicly before, during or after our dissemination of the Information, and make profits therefrom. EMC does not verify or endorse any medical claims for any of its client companies.

    EMC has been paid $155,500 on behalf of Hoth Therapeutics, Inc. for various marketing services including this report. EMC does not independently verify any of the content linked-to from this editorial. http://emergingmarketsllc.com/disclaimer.php

    Emerging Markets Consulting, LLC
    Florida Office
    15701 State Road 50, Suite #205
    Clermont, FL 34711
    E-mail:
    Web: www.emergingmarketsllc.com

    Primary Logo

    View Full Article Hide Full Article
  69. NEW YORK, Dec. 23, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological and immunological disorders such as atopic dermatitis, psoriasis, asthma and acne, today issued its 2019 Shareholder Letter.

    Dear Shareholder, 

    Looking back on 2019, our first year as a public company, management is pleased with the significant growth initiatives that we have achieved and the strategic relationships that we have built.  Hoth has made great strides in developing a robust biopharmaceutical platform, focused on developing next generation therapies for dermatological and immunological disorders.  Previously, conventional approaches…

    NEW YORK, Dec. 23, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological and immunological disorders such as atopic dermatitis, psoriasis, asthma and acne, today issued its 2019 Shareholder Letter.

    Dear Shareholder, 

    Looking back on 2019, our first year as a public company, management is pleased with the significant growth initiatives that we have achieved and the strategic relationships that we have built.  Hoth has made great strides in developing a robust biopharmaceutical platform, focused on developing next generation therapies for dermatological and immunological disorders.  Previously, conventional approaches to skin ailments have provided little benefit, typically only offering relief from the symptoms of disease, rather than targeting underlying disease processes. Our belief is that we can provide better treatments for patients who are suffering from these ailments by harnessing the power of our pipeline. Our product pipeline currently includes several treatments, pertaining to diverse dermatological and immunological conditions and encompassing a large addressable market.  In an effort to maintain a transparency and rapport with our investors, we have comprised a summary of Hoth's corporate developments for the current year.

    BioLexa Platform: 
    HOTH's lead drug candidate platform BioLexa, targets millions of patients, suffering from eczema or atopic dermatitis. Early this year we began testing of the BioLexa platform with our partners at Mass General Hospital. Following the initial study, we resynthesized our vehicle and formulation to bring a more robust form of BioLexa to the lab for further toxicology studies. With our partner Particle Sciences, we began production of GLP materials which were sent for our escalating maximum dose study. Upon successful completion of the dose escalation study we undertook a seven-day toxicology study which showed no-ill effects. We are currently in the midst of our 28-day toxicology study, which we will end in early 2020. In addition to possessing exclusive worldwide rights to the BioLexa Platform, we also maintain a licensing deal with the University of Cincinnati to utilize the innovative BioLexa Platform. Our plan is to begin clinical trials in humans in Australia during 2020.

    VNLG-152:
    We have an exclusive Commercial Licensing Agreement with University of Maryland, Baltimore and Isoprene Pharmaceuticals Inc. for the compound VNLG-152 for dermatological use, which has shown strong preclinical results, and we are working to develop for treatment in psoriasis and acne patients. Acne is the result, in part, of Propionibacterium acnes or 'P. acnes' growth in hair follicles, which leads to a defined set of pathogenic gene expression changes. 

    This Fall, Hoth began the synthesis of VNLG -152 and received materials for a proposed animal study. Just last week we announced entering into a research collaboration agreement with Weill Cornell Medicine to examine the ability of retinoic acid metabolism blocking agents (RAMBA) to block acne pathogenic gene expression in human keratinocytes, mouse skin, and carcinogenesis in mice. The research collaboration will be conducted in three phases for a period of one year. Dr. Jonathan Zippin, M.D., Ph.D., FAAD, Associate Professor of Dermatology at Weill Cornell Medicine and Hoth's Senior Scientific Advisor, will be the Principal Investigator for the research collaboration.

    Aprepitant: 
    In July 2019, Hoth and GW announced its working relationship and entering into an exclusive license option agreement pertaining to its intellectual property on the use of Aprepitant in treating skin-related and other side effects from drugs used to treat cancer. This fall, Hoth announced that it has entered into a sponsored research agreement with the George Washington University (GW) and began the SRA to  explore the potential use of Aprepitant for topical and/or systemic therapy to counter the dermatological related side-effects of Erlotinib therapy in cancer patients.  Erlotinib is a drug that is used to combat various cancers and has been known to cause varying degrees of skin rashes, lesions, hair loss and nail changes to patients.  These side-effects can negatively impact the patient's quality of life and even cause usage interruption, jeopardizing the overall success of the treatment.

    The research agreement intends to explore whether other chronic conditions that also display dermatitis may benefit from this novel therapeutic approach. Overseeing this collaboration will be William B. Weglicki, MD, professor of biochemistry and molecular medicine and professor of medicine at the GW School of Medicine and Health Sciences. Dr. William Wegliki recently submitted his manuscript based on his team's findings highlighting the positive dermatological effects of Aprepitant. I'm also pleased to note that just last week, we officially appointed Dr.  Weglicki, M.D. to our Scientific Advisory Board, where we will have even greater access to his expertise.

    Gene Therapy
    In November Hoth announced it entered into a licensing agreement with North Carolina State University (NC State) to study its exon skipping approach for treating allergic diseases. Earlier this month, Hoth announced the initiation of a preclinical study for the treatment of asthma and allergic inflammation in collaboration with North Carolina State University which will begin in early 2020. 

    The study centers around NC State's exon skipping approach for treating allergic Diseases. The exon skipping approach was developed by Dr. Glenn Cruse, Principal Investigator and Assistant Professor in the Department of Molecular Biomedical Sciences at the NC State College of Veterinary Medicine. These findings set a breakthrough for allergic diseases as they are driven by the activation of mast cells and the release of mediators in response to IgE-directed antigens. 

    This collaboration will allow us to leverage this invention from the renowned expertise of Dr. Glenn Cruse and his scientific team at North Carolina State University. We look forward to seeing how their work advances and what this might mean for patients suffering from undesirable steroid side effects who need an alternate treatment for asthma and other allergic diseases.

    Z-Pods:
    The Company is co-developing with Zylö Therapeutics, a patented technology delivery system for drugs treating Cutaneous Lupus Erythematosus (CLE), a chronic autoimmune disease that affects the skin, by using patented xerogel-derived nanoparticles, called Z-pods™. Hoth secured an exclusive license to the Anandamide-loaded Z-pods™ for the treatment of CLE in North America. Anandamide, generally referred to as AEA, is one of the cannabinoids that the human body makes naturally. The topical administration supplies—in a sustained and controlled manner—notoriously hard-to-deliver therapeutic agents, hence improving overall outcome.

    During initial studies, it was reported Z-Pods™ has the capacity to improve drug skin penetration, reduces the expected inflammatory cytokine secretion by keratinocytes when exposed to ultraviolet radiation, prevents the development of CLE skin lesions, improves skin histopathology, prevents inflammation and structural damage on histology and reduces macrophages and C3 accumulation. Zyl has initiated an independent confirmation study to provide a critical point of validation for this proprietary topical solution. In November we announced initiating a confirmatory study and look forward to those results in 2020.

    Genetic Marker:
    The Company secured an exclusive license from the University of Cincinnati using its patented technology to determine a person's propensity to suffer an allergic reaction to certain types of food. We believe this Genetic Marker may lead to the reduction of children undergoing risky food challenge treatments. Hoth looks to leverage this marker in relation to the cause of eczema and food allergy.

    In closing, 2019 served as a monumental first year for us. The Company bolstered its balance sheet and fortified its industry affiliations with some of the most influential and respected leaders in the field of healthcare. I'm confident that the aforementioned updates in this letter will serve as validation that we are well-positioned to leverage the numerous opportunities that lay ahead of us in order to achieve our primary goal of improved shareholder value. 

    I want to thank you all for your interest and commitment in the company and we look forward to continued success into 2020 and beyond.

    Sincerely yours,

    Mr. Robb Knie, Chief Executive Officer

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, and acne. HOTH has the exclusive worldwide rights to BioLexa, the company's proprietary lead drug candidate topical platform that uniquely combines two FDA approved compounds to fight bacterial infections across multiple indications. HOTH is preparing to launch its clinical trial for the treatment of adolescent subjects, 2-17 years of age, with mild to moderate atopic dermatitis during 2020. To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements
    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the BioLexa Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2018, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Contacts
    Investor Relations Contact:
    Phone: (646) 756-2997
    Email:  
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto / Daniela Guerrero
    (212) 896-1254 / (212) 682-6300

    Cision View original content:http://www.prnewswire.com/news-releases/hoth-therapeutics-inc-issues-2019-shareholder-letter-300978805.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  70. NEW YORK, Dec. 19, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, today announced entering into a research collaboration agreement with Weill Cornell Medicine to examine the ability of retinoic acid metabolism blocking agents (RAMBA) to block acne pathogenic gene expression in human keratinocytes, mouse skin, and carcinogenesis in mice.

    (PRNewsfoto/Hoth Therapeutics Inc.)

    Acne is the result, in part, of Propionibacterium acnes or 'P. acnes' growth in hair follicles, which leads to a defined set of pathogenic gene expression changes. The research collaboration will be conducted…

    NEW YORK, Dec. 19, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, today announced entering into a research collaboration agreement with Weill Cornell Medicine to examine the ability of retinoic acid metabolism blocking agents (RAMBA) to block acne pathogenic gene expression in human keratinocytes, mouse skin, and carcinogenesis in mice.

    (PRNewsfoto/Hoth Therapeutics Inc.)

    Acne is the result, in part, of Propionibacterium acnes or 'P. acnes' growth in hair follicles, which leads to a defined set of pathogenic gene expression changes. The research collaboration will be conducted in three phases for a period of one year. Dr. Jonathan Zippin, M.D., Ph.D., FAAD, Associate Professor of Dermatology at Weill Cornell Medicine and HOTH Senior Scientific Advisor, will be the Principal Investigator for the research collaboration.

    Mr. Robb Knie, Chief Executive Officer of Hoth, commented, "Our research collaboration with Weill Cornell Medicine and Dr. Jonathan Zippin falls in line with our mission to research and develop new generation dermatological treatments. At the conclusion of our research together, we will work with the team at Weill Cornell Medicine to evaluate how to translate our findings into new therapies."

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, and acne. HOTH has the exclusive worldwide rights to BioLexa, the company's proprietary lead drug candidate topical platform that uniquely combines two FDA approved compounds to fight bacterial infections across multiple indications. HOTH is preparing to launch its clinical trial for the treatment of adolescent subjects, 2-17 years of age, with mild to moderate atopic dermatitis during 2020. To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements
    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the BioLexa Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2018, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Contacts
    Investor Relations Contact:
    Phone: (646) 756-2997
    Email:  
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto / Daniela Guerrero
    (212) 896-1254 / (212) 682-6300

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-enters-into-research-collaboration-agreement-with-weill-cornell-medicine-to-examine-the-efficacy-of-ramba-in-blocking-acne-pathogenic-gene-expression-300977411.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  71. NEW YORK, Dec. 17, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, today announced the addition of Dr. William Weglicki, M.D. to the Company's Scientific Advisory Board.  While serving on the Board, Dr, Weglicki will oversee Hoth's Aprepitant Program under its Scientific Research Agreement with the George Washington University ("GW").

    (PRNewsfoto/Hoth Therapeutics Inc.)

    Mr. Robb Knie, CEO of Hoth Therapeutics, commented, "I am pleased to welcome Dr. Weglicki to our Scientific Advisory Board. Dr. Weglicki will be instrumental towards the advancement of our Aprepitant program. Hoth…

    NEW YORK, Dec. 17, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, today announced the addition of Dr. William Weglicki, M.D. to the Company's Scientific Advisory Board.  While serving on the Board, Dr, Weglicki will oversee Hoth's Aprepitant Program under its Scientific Research Agreement with the George Washington University ("GW").

    (PRNewsfoto/Hoth Therapeutics Inc.)

    Mr. Robb Knie, CEO of Hoth Therapeutics, commented, "I am pleased to welcome Dr. Weglicki to our Scientific Advisory Board. Dr. Weglicki will be instrumental towards the advancement of our Aprepitant program. Hoth is fortunate to have such well-respected leaders providing their invaluable expertise and insight to each of our significant research and development initiatives."

    Dr. Weglicki is Professor of Biochemistry and Molecular Medicine at the George Washington University School of Medicine. Dr Weglicki is a recipient of the Lifetime Achievement Award in Cardiovascular Science, Medicine and Surgery, The International Academy of Cardiovascular Sciences. After completing a medical residency at Georgetown University Hospital in 1964 he completed a Cardiology fellowship in 1966 at Duke University where he trained in clinical cardiac catheterization and pharmacology basic research. He was then appointed as a research associate at NIH's NICHHD and the McCollum Pratt Institute of the Johns Hopkins University where he studied the cardiac pathobiology of alpha tocopherol deficiency. In 1968 He joined Harvard's Peter Bent Brigham Hospital Department of Medicine's Cardiovascular Research unit, and rose from Instructor to Associate Professor in 1975. There he concentrated his research on the role of phospholipases of the heart in the ischemic perturbation of cardiac membrane phospholipids and organelles, which led to several RO1 NIH grant awards. With his research team he moved to the Medical College of Virginia/VCU in 1975 as chairman of the Department of Biophysics and served as a professor of Medicine (Cardiology); there he was active in teaching medical and mentoring graduate students, while publishing a series of manuscripts on cardiac lysosomal activity in myocardial ischemia and the distribution of phospholipases in cardiac mitochondria and sarcolemmal membranes, and overseeing a new NHLBI Training Grant on molecular mechanisms of cardiovascular injury. At the Oklahoma Medical Research Foundation he led their Cardiovascular Research Program. He joined the George Washington University Department of Medicine in 1985 and formed the Division of Experimental Medicine; in 1987 this core group of investigators was awarded a Program Project grant on Molecular Mechanisms of Cardiovascular Injury from the National Heart, Lung, and Blood Institute. This research included identifying free-radical peroxidative injury during myocardial ischemia and the protective antioxidant properties of cardiac beta blocking drugs such as propranolol and carvedilol. At present he is a Professor of Biochemistry and Molecular Medicine and Medicine (Cardiology). He has been a principal investigator of NIH grants for more than thirty years. His ongoing research focuses on preventing neurogenic inflammation and hyomagnesemia effects associated with some anticancer drugs.

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, and acne. HOTH has the exclusive worldwide rights to BioLexa, the company's proprietary lead drug candidate topical platform that uniquely combines two FDA approved compounds to fight bacterial infections across multiple indications. HOTH is preparing to launch its clinical trial for the treatment of adolescent subjects, 2-17 years of age, with mild to moderate atopic dermatitis during 2020. To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements
    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the BioLexa Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2018, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Contacts
    Investor Relations Contact:
    Phone: (646) 756-2997
    Email:  
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto / Daniela Guerrero
    (212) 896-1254 / (212) 682-6300

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-announces-the-appointment-of-dr-william-weglicki-md-to-scientific-advisory-board-300976186.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  72. ORLANDO, Fla., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Nearly every person suffering from atopic dermatitis, more popularly known as "eczema," knows just how difficult it can be to find effective remedies for his or her condition. Many prescription and over-the-counter treatments are not always consistent in providing relief, making new revolutionary improved topical medications a welcome addition to the narrow range of dermatological products dedicated to treating this difficult-to-cure ailment. Hoth Therapeutics, Inc. (NASDAQ:HOTH), is one such pharmaceutical company focused on providing eczema patients with a non corticosteriod therapeutic that actually helps treat eczema rather than just stop the itch.

    BioLexa - A Competitive Advantage Among

    ORLANDO, Fla., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Nearly every person suffering from atopic dermatitis, more popularly known as "eczema," knows just how difficult it can be to find effective remedies for his or her condition. Many prescription and over-the-counter treatments are not always consistent in providing relief, making new revolutionary improved topical medications a welcome addition to the narrow range of dermatological products dedicated to treating this difficult-to-cure ailment. Hoth Therapeutics, Inc. (NASDAQ:HOTH), is one such pharmaceutical company focused on providing eczema patients with a non corticosteriod therapeutic that actually helps treat eczema rather than just stop the itch.

    BioLexa - A Competitive Advantage Among Its Industry Peers
    Despite the relatively narrow regime of therapies for atopic dermatitis, solutions do abound, and any patient (as with any investor) would wonder what might make one solution better than another. HOTH's answer to that question would point to its proprietary flagship product--the BioLexa Platform--a patented antimicrobial therapy based on cutting-edge scientific research from the University of Cincinnati.

    So, what is it about BioLexa that differentiates it from other treatments? It's one of the first and few drugs aimed at preventing rather than merely responding to eczema symptoms. Prevention versus response--two different approaches whose values can differ like night and day from the viewpoint of a patient.

    How does it work? BioLexa combines an FDA-approved zinc chelator with antibiotics to prevent infectious "biofilms" from forming. By preventing the formation of biofilms, bacteria is rendered vulnerable to elimination by antibiotics. In addition to HOTH's preventive approach, its BioLexa solution also has the unique capacity to target bacteria, differentiating it yet again from most other therapeutic products on the market, as the majority of treatments available are designed to address general factors--e.g. inflammation and immune-related conditions--in order to treat a condition that BioLexa targets directly.

    Considering the aims toward preventive treatment and direct bacterial targeting, BioLexa-based therapies may prove a competitive advantage in a field where most products are by and large responsive and whose scope may be less direct. This potentially places HOTH in a unique industry position in a market that is projected to reach $28 billion in global spending by the end of 2019, according to SNS Research.

    The Road to FDA Approval
    HOTH may seek FDA approval via the 505(B)(2) application process in order to reduce its products' time-to-market. There are three regulatory pathways toward FDA approval. The 505(B)(1) pathway for new drug testing has a time frame ranging from 8-10 years. 505(j) for generic drugs takes between 1-2 years. The third, 505(B)(2), the pathway that HOTH may pursue, is a modified version of the 505(B)(1) that will enable HOTH to complete the regulatory process much faster, typically 3 years. HOTH plans on launching its clinical trials in humans in 2020.

    New Developments and Licensing for Gene Therapy
    As reported last September, HOTH had begun working with George Washington University to provide solutions countering the dermatological side effects that Erlotinib therapy may have on cancer patients. Recently, HOTH's research and product capacity has been tapped for exploration into yet another field concerning dermatological ailments: gene therapy. 

    On November 26, 2019, HOTH announced a new licensing agreement with North Carolina State University to study the university's "Exon Skipping Approach" for the treatment of allergic diseases. The Exon approach, developed by NC State professor Dr. Glenn Cruse, is a potential treatment approach based on RNA splicing. If executed according to design, this approach causes cells to "skip" the problematic sections of genetic code contributing to a patient's allergic ailment. Though currently in development, this approach represents a potential breakthrough in the field of allergic diseases. 

    "This new collaboration will allow us to leverage this invention from the renowned expertise of Dr. Glenn Cruse and his scientific team at North Carolina State University. We look forward to seeing how their work advances and what this might mean for patients suffering from undesirable steroid side effects who need an alternate treatment for asthma and other allergic diseases," said Robb Knie, HOTH's Chief Executive Officer.

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. (NASDAQ:HOTH), ("HOTH" or the "Company"), is a biopharmaceutical company focused on developing new generation therapies for dermatological disorders including atopic dermatitis, chronic wounds, psoriasis and acne. For more information on their areas of research and product development, visit their website at www.hoththerapeutics.com.

    For more informative reports such as this, please sign up at http://www.emergingmarketsllc.com/newsletter.php

    Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below.

    We may purchase Securities of the Profiled Company prior to their securities becoming publicly traded, which we may later sell publicly before, during or after our dissemination of the Information, and make profits therefrom. EMC does not verify or endorse any medical claims for any of its client companies.

    EMC has been paid $92,500 on behalf of Hoth Therapeutics, Inc. for various marketing services including this report. EMC does not independently verify any of the content linked-to from this editorial. http://emergingmarketsllc.com/disclaimer.php

    Emerging Markets Consulting, LLC
    Florida Office
    15701 State Road 50, Suite #205
    Clermont, FL 34711
    E-mail:
    Web: www.emergingmarketsllc.com

     

    Primary Logo

    View Full Article Hide Full Article
  73. PHILADELPHIA, PA / ACCESSWIRE / December 11, 2019 / Hoth Therapeutics, Inc. (NASDAQ:HOTH), will be presenting at this year's Investor Summit on December 17th in Philadelphia.

    The Investor Summit will take place at Hotel Monaco, featuring 30 companies and over 200 institutional and retail investors.

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics is a development-stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema.

    The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.

    To register as a presenting company please email

    PHILADELPHIA, PA / ACCESSWIRE / December 11, 2019 / Hoth Therapeutics, Inc. (NASDAQ:HOTH), will be presenting at this year's Investor Summit on December 17th in Philadelphia.

    The Investor Summit will take place at Hotel Monaco, featuring 30 companies and over 200 institutional and retail investors.

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics is a development-stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema.

    The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.

    To register as a presenting company please email .

    To request complimentary investor registration: please visit our website at www.microcapconf.com.

    News Compliments of ACCESSWIRE

    FOR MORE INFORMATION

    Please visit: www.microcapconf.com

    Or, contact Ashley Allard at

    SOURCE: Hoth Therapeutics

    View source version on accesswire.com:
    https://www.accesswire.com/569873/Hoth-Therapeutics-Inc-to-Present-at-the-Investor-Summit-on-December-17th-in-Philadelphia

    View Full Article Hide Full Article
  74. NEW YORK, Dec. 9, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, is pleased to announce the initiation of a preclinical study for the treatment of asthma and allergic inflammation in collaboration with North Carolina State University (NC State) beginning on January 1, 2020.

    (PRNewsfoto/Hoth Therapeutics Inc.)

    The goal of the study is to determine the best approach for targeting allergic inflammation in the airways with Splice-switching oligonucleotides (SSOs) and establish proof of principle by providing preclinical mouse data to inform consequent toxicology, ADME (absorption…

    NEW YORK, Dec. 9, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, is pleased to announce the initiation of a preclinical study for the treatment of asthma and allergic inflammation in collaboration with North Carolina State University (NC State) beginning on January 1, 2020.

    (PRNewsfoto/Hoth Therapeutics Inc.)

    The goal of the study is to determine the best approach for targeting allergic inflammation in the airways with Splice-switching oligonucleotides (SSOs) and establish proof of principle by providing preclinical mouse data to inform consequent toxicology, ADME (absorption, distribution, metabolism and excretion), and Pharmacokinetics (PK) study or how an organism affects the drug.

    The initial set of experiments look to establish the delivery of SSOs targeting the gene encoding the FcεRIβ protein in the lungs of mice by using an ultrasonic nebulizer and assessing its distribution and function in mast cells throughout for a period of one year by using RNA (Ribonucleic acid) scope technology. Once effective delivery of SSOs to the lungs has been established and determined that delivery of a target gene SSO reduces allergic airway inflammation in a standard asthma mouse model, HOTH and NC State plan to move on to the second phase of the study.

    During the second phase, the aim will be to determine the efficacy of SSO combinations that target FcεRIβ and other genes that function in the IgE receptor pathway, in airway inflammation using humanized mouse models to establish which target gene(s) to move forward with. The study will determine the efficacy, in vivo, by administering SSOs for the target gene(s) and establishing whether targeting FcεRIβ alone or in combination with other genes provides the best therapeutic approach.

    Mr. Robb Knie, Chief Executive Officer of Hoth Therapeutics, Inc. commented, "After signing our license agreement with NC State in November 2019, we are pleased to quickly move forward with the design of our preclinical study for asthma. This study will not only allow us to identify and advance drug candidates for asthma and other allergic diseases, but it will also play a key role in reversing the progression of allergic reactions in patients."

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, and acne. HOTH has the exclusive worldwide rights to BioLexa, the company's proprietary lead drug candidate topical platform that uniquely combines two FDA approved compounds to fight bacterial infections across multiple indications. HOTH is preparing to launch its clinical trial for the treatment of adolescent subjects, 2-17 years of age, with mild to moderate atopic dermatitis during 2020. To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements
    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the BioLexa Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2018, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Contacts
    Investor Relations Contact:
    Phone: (646) 756-2997
    Email:
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto / Daniela Guerrero
    (212) 896-1254 / (212) 682-6300

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-and-north-carolina-state-university-initiate-preclinical-gene-therapy-study-for-the-treatment-of-asthma-300971038.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  75. NEW YORK, NY / ACCESSWIRE / December 2, 2019 / Hoth Therapeutics, Inc. (NASDAQ:HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, today announced that it will be presenting at the 12th annual LD Micro Main Event on Tuesday, December 10th at 3:00 PM PST / 6:00 PM EST. Mr. Robb Knie, Chief Executive Officer, will be presenting and meeting with investors.

    The LD Micro Main Event will take place on December 10th-12th in Los Angeles, at the Luxe Sunset Bel Air Hotel, which will feature 275 companies, and will be attended by over 1,400 individuals.

    View Hoth Therapeutics's profile here: http://www.ldmicro.com/profile/HOTH

    NEW YORK, NY / ACCESSWIRE / December 2, 2019 / Hoth Therapeutics, Inc. (NASDAQ:HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, today announced that it will be presenting at the 12th annual LD Micro Main Event on Tuesday, December 10th at 3:00 PM PST / 6:00 PM EST. Mr. Robb Knie, Chief Executive Officer, will be presenting and meeting with investors.

    The LD Micro Main Event will take place on December 10th-12th in Los Angeles, at the Luxe Sunset Bel Air Hotel, which will feature 275 companies, and will be attended by over 1,400 individuals.

    View Hoth Therapeutics's profile here: http://www.ldmicro.com/profile/HOTH.

    About Hoth Therapeutics, Inc.

    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, and acne. HOTH has the exclusive worldwide rights to BioLexa, the company's proprietary lead drug candidate topical platform that uniquely combines two FDA approved compounds to fight bacterial infections across multiple indications. HOTH is preparing to launch its clinical trial for the treatment of adolescent subjects, 2-17 years of age, with mild to moderate atopic dermatitis during 2020. To learn more, please visit www.hoththerapeutics.com.

    About LD Micro

    LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space.

    What started out as a newsletter highlighting unique companies has transformed into several influential events annually (Invitational, Summit, and Main Event).

    In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe.

    For those interested in attending, please contact KCSA at or David Scher at or visit www.ldmicro.com for more information.

    Contacts
    Investor Relations Contact:
    Phone: (646) 756-2997
    Email:
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto / Daniela Guerrero
    (212) 896-1254 / (212) 682-6300

    SOURCE: Hoth Therapeutics via LD Micro

    View source version on accesswire.com:
    https://www.accesswire.com/568160/Hoth-Therapeutics-to-Present-at-the-LD-Micro-Main-Event-XII

    View Full Article Hide Full Article
  76. NEW YORK, Nov. 26, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, today announced it has entered  into a licensing agreement with North Carolina State University (NC State) to study NC State's Exon Skipping Approach for Treating Allergic Diseases.

    (PRNewsfoto/Hoth Therapeutics Inc.)

    This Exon Skipping Approach was developed by Dr. Glenn Cruse, Principal Investigator and Assistant Professor in the Department of Molecular Biomedical Sciences at the NC State College of Veterinary Medicine. During Dr. Cruse's research, a new approach for the technique of antisense oligonucleotide-mediated…

    NEW YORK, Nov. 26, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, today announced it has entered  into a licensing agreement with North Carolina State University (NC State) to study NC State's Exon Skipping Approach for Treating Allergic Diseases.

    (PRNewsfoto/Hoth Therapeutics Inc.)

    This Exon Skipping Approach was developed by Dr. Glenn Cruse, Principal Investigator and Assistant Professor in the Department of Molecular Biomedical Sciences at the NC State College of Veterinary Medicine. During Dr. Cruse's research, a new approach for the technique of antisense oligonucleotide-mediated exon skipping to specifically target and down-regulate IgE receptor expression in mast cells was identified. These findings set a breakthrough for allergic diseases as they are driven by the activation of mast cells and the release of mediators in response to IgE-directed antigens. 

    Mr. Robb Knie, Chief Executive Officer of Hoth, commented, "This new collaboration will allow us to leverage this invention from the renowned expertise of Dr. Glenn Cruse and his scientific team at North Carolina State University.  We look forward to seeing how their work advances and what this might mean for patients suffering from undesirable steroid side effects who need an alternate treatment for asthma and other allergic diseases."

    The high-affinity IgE receptor (FcεRI) plays a central role in the initiation of allergic responses. The research project looks to target novel genes, which are critical for surface IgE receptor expression. The project will utilize splice-switching oligonucleotides (SSOs) to force expression of a truncated isoform of the target genes to reduce expression of FcεRI in mouse asthma models.

    Through this collaborative project, NCSU looks to establish the most effective approach for targeting genes that regulate surface expression of FcεRI in mast cells that mediate allergic airway inflammation. The study will be administering SSOs for the target genes, to optimize delivery and examine the best therapeutic approach.

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, and acne. HOTH has the exclusive worldwide rights to BioLexa, the company's proprietary lead drug candidate topical platform that uniquely combines two FDA approved compounds to fight bacterial infections across multiple indications. HOTH is preparing to launch its clinical trial for the treatment of adolescent subjects, 2-17 years of age, with mild to moderate atopic dermatitis during 2020. To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements
    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the BioLexa Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in Hoth's Form 10K for the period ending December 31, 2018, and Hoth's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Contacts
    Investor Relations Contact:
    Phone: (646) 756-2997
    Email:  
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto / Daniela Guerrero
    (212) 896-1254 / (212) 682-6300

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-and-north-carolina-state-university-enter-license-agreement-for-gene-therapy-300965178.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  77. NEW YORK, Nov. 18, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, today announced that its CEO and President, Robb Knie will be attending Benchmark's 8thAnnual Discovery 1x1 Conference. The conference will be held in New York City on December 4, 2019. For more information about the conference or to schedule a one-on-one meeting, please contact the conference coordinator.

    (PRNewsfoto/Hoth Therapeutics Inc.)

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders…

    NEW YORK, Nov. 18, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, today announced that its CEO and President, Robb Knie will be attending Benchmark's 8thAnnual Discovery 1x1 Conference. The conference will be held in New York City on December 4, 2019. For more information about the conference or to schedule a one-on-one meeting, please contact the conference coordinator.

    (PRNewsfoto/Hoth Therapeutics Inc.)

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, and acne. HOTH has the exclusive worldwide rights to BioLexa, the company's proprietary lead drug candidate topical platform that uniquely combines two FDA approved compounds to fight bacterial infections across multiple indications. HOTH is preparing to launch its clinical trial for the treatment of adolescent subjects, 2-17 years of age, with mild to moderate atopic dermatitis during 2020. To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements
    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the BioLexa Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon HOTH's current expectations and various assumptions. HOTH believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. HOTH may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in HOTH's Form 10K for the period ending December 31, 2018, and HOTH's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as HOTH's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. HOTH cannot guarantee future results, events, levels of activity, performance or achievements. HOTH does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Contacts
    Investor Relations Contact:
    Phone: (646) 756-2997
    Email:  
    www.hoththerapeutics.com

    KCSA Strategic Communications
    Valter Pinto / Daniela Guerrero
    (212) 896-1254 / (212) 682-6300

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-to-attend-benchmarks-8th-annual-discovery-1x1-conference-300959678.html

    SOURCE Hoth Therapeutics, Inc.

    View Full Article Hide Full Article
  78. NEW YORK, Nov. 14, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, today announced, in partnership with the George Washington University (GW), the initiation of  a preclinical study of Aprepitant for dermatological treatment relating to the side effects of cancer medication.

    (PRNewsfoto/Hoth Therapeutics Inc.)

    In July 2019, HOTH and GW announced its working relationship and entering into an exclusive license option agreement pertaining to its intellectual property on the use of Aprepitant in treating skin-related and other side effects from drugs used to treat cancer. Traditionally…

    NEW YORK, Nov. 14, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH) ("HOTH" or the "Company"), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, today announced, in partnership with the George Washington University (GW), the initiation of  a preclinical study of Aprepitant for dermatological treatment relating to the side effects of cancer medication.

    (PRNewsfoto/Hoth Therapeutics Inc.)

    In July 2019, HOTH and GW announced its working relationship and entering into an exclusive license option agreement pertaining to its intellectual property on the use of Aprepitant in treating skin-related and other side effects from drugs used to treat cancer. Traditionally, Aprepitant is utilized along with other medications to help prevent nausea and vomiting caused by cancer drug treatment chemotherapy by blocking the cause and one of the body's natural substances, neurokinin-1.

    Mr. Robb Knie, CEO of Hoth Therapeutics, commented, "Initial findings by our team and GW on the positive dermatological effects of Aprepitant in cancer patients have been fascinating. We are pleased today to launch this study to continue our exploration of this possible treatment. Hoth looks forward to our initial data read-out and further testing with our partners at the George Washington University."

    Under the terms of the agreement, HOTH has the option to exclusively license two U.S. patents covering methods of using Aprepitant and other drugs that inhibit this neurokinin-1 function. Based on early data findings from HOTH and GW, this preclinical study is being initiated to continue exploring the dermatological benefits of Aprepitant in cancer patients who receive chemotherapy.

    About Hoth Therapeutics, Inc.
    Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. HOTH's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, and acne. HOTH has the exclusive worldwide rights to BioLexa, the company's proprietary lead drug candidate topical platform that uniquely combines two FDA approved compounds to fight bacterial infections across multiple indications. HOTH is preparing to launch its clinical trial for the treatment of adolescent subjects, 2-17 years of age, with mild to moderate atopic dermatitis during 2020. To learn more, please visit www.hoththerapeutics.com.

    Forward Looking Statements
    This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the BioLexa Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as "anticipate", "being", "will", "plan", "may", "continue", and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon HOTH's current expectations and various assumptions. HOTH believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. HOTH may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption "Risk Factors" in HOTH's Form 10K for the period ending December 31, 2018, and HOTH's other filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as HOTH's current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. HOTH cannot guarantee future results, events, levels of activity, performance or achievements. HOTH does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

    Contacts
    Investor Relations Contact:
    Phone: (646) 756-2997
    Email:  
    www.hoththerapeutics.com

    KCSA Strat